The safety, efficacy and neuromotor effects of the neurosteroid anaesthetic alfaxalone in rats by Lau, Cora
 1 
 
 
 
 
The Safety, Efficacy and Neuromotor Effects of the Neurosteroid Anaesthetic 
Alfaxalone in Rats 
Cora Lau 
BVSc (Hons) 
 
 
 
 
 
 
 
 
 
A thesis submitted for the degree of Doctor of Philosophy at 
The University of Queensland in 2013 
School of Biomedical Sciences 
 2 
 
Abstract 
 
Rodents are routinely anaesthetised for husbandry and biomedical research purposes.  All anaesthetics 
carry a degree of risk, complications and side effects. An ideal anaesthetic for rodents is safe, 
predictable, alleviates pain and distress and can be performed without specialist training. A survey 
was created to identify anaesthetic agents frequently administered to rodents currently utilised by the 
research community.  Findings indicated injectable anaesthetics were very commonly used and 
complications were often associated with use, highlighting the lack of a safe, predictable laboratory 
rodent anaesthetic protocol.   
Alfaxalone is a neuroactive steroid injectable anaesthetic agent with a high margin of safety, and is 
commonly used in veterinary anaesthesia as the Alfaxan® formulation.  I sought to establish whether 
alfaxalone could be used as an injectable anaesthetic agent for laboratory rodents.  A plasma 
pharmacokinetics study was performed using IV and IP Alfaxan® in adult female Wistar rats (7-10 
weeks).  Mean T1/2elim for 2 and 5 mg.kg
-1
 IV was short (~17 minutes), but could not be estimated for 
IP dosing due to sustained plasma levels for up to 60 minutes after injection.  Clp for IV injection was 
calculated at 24.5% and 23% of cardiac output respectively.  The observed Cmax was 2.99 mg.L
-1
 for 
IP administration, and 2.2 ± 0.9 and 5.2 ± 1.3 mg.L
-1
 for 2 and 5 mg.kg
-1
 IV administration 
respectively.  AUC0-60 was 96 min.mg.L
-1
 for IP dosing.  The relative bioavailability for IP dosing was 
26% and 28%, compared to IV doses of 2 and 5mg.kg
-1
  respectively.  Alfaxalone given IP caused 
longer sleep times than IV dosing, although anaesthesia was not induced in 30% of rats. 
Importantly, all rats exhibited muscle twitching after alfaxalone administration.  I then sought to test 
whether combining IP injection of Alfaxalone with common premedication agents could improve 
anaesthetic induction rates and reduce muscle twitching, to provide a viable anaesthetic regimen for 
rats. Medetomidine (0.5 mg.kg
-1
), medetomidine-butorphanol (0.35 mg.kg
-1
-0.2 mg.kg
-1
), 
Acetylpromazine (ACP) -methadone (3 mg.kg
-1
-0.7 mg.kg
-1
) and ACP-xylazine (3 mg.kg
-1
-3 mg.kg
-1
) 
were administered IP 10 minutes prior to IP alfaxalone (20 mg.kg
-1
).  ACP-xylazine, medetomidine 
and medetomidine-butorphanol all significantly reduced twitching.  Medetomidine-butorphanol 
provided surgical anaesthesia without prolonged recovery and provided an adequate plane of 
anaesthesia for short painful surgical procedures.   
However, none of these premedication agents fully eliminated alfaxalone-induced muscle twitching.  I 
therefore carried out electrophysiological studies of motor neurons (MN), to determine the mechanism 
causing neuromotor excitation in response to alfaxalone.  Previous data has shown that alfaxalone can 
modulate strychnine-sensitive glycinergic receptors, which may, in part, contribute to the adverse 
neuromotor excitatory responses manifested as muscle twitching during alfaxalone anaesthesia.  The 
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effects of alfaxalone on inhibitory synaptic transmission to hypoglossal motor neurones (HMNs) were 
investigated.   
Whole cell patch clamp recordings were performed on HMNs in transverse brainstem slices (300 µm 
thickness) prepared from 10-12 day old Wistar rats anaesthetised with sodium pentobarbitone (100 
mg.kg
-1
 IP).  Spontaneous and evoked glycinergic inhibitory post-synaptic currents (IPSCs) were 
recorded at a holding potential of –60mV, using a CsCl-based internal solution, in the presence of the 
non-NMDA and NMDA glutamate receptor blockers NBQX (10µM) and APV (50µM) and the 
GABAA receptor blocker bicuculline (5µM).  An alfaxalone dose response study was performed with 
bath-applied alfaxalone at increasing concentrations of 10nM, 30nM, 100nM, 300nM, 1µM, 3µM and 
10µM (n=7).  Both spontaneous and paired evoked IPSCs (at 150 ms inter-stimulus interval) were 
recorded.  A reduction in evoked IPSC peak amplitude, rise time and decay time without paired pulse 
ratio changes was consistent with alfaxalone altering postsynaptic glycine receptors, causing 
prolongation of both channel opening and closure.  A decrease in spontaneous IPSC frequency at 
higher doses was suggestive of presynaptic modulation by alfaxalone, decreasing glycine release from 
the presynaptic terminal.  At high doses, alfaxalone induced an inward current in HMNs, without 
significant change in input resistance.   
Cannabinoid receptors (CBR) can directly modulate both glycine release and GlyR function in 
HMNs.  I postulated that alfaxalone exerted its effects on glycinergic transmission by increasing 
postsynaptic endocannabinoid synthesis and activation of cannabinoid 1 receptors (CB1Rs). The 
CB1R inverse agonist-antagonist AM251 (1µM; n= 6) or the CB1R competitive antagonist NESS0327 
(100pM; n=5) both blocked spontaneous IPSC frequency depression, evoked IPSC amplitude 
reduction, decay time prolongation and baseline inward current produced by alfaxalone at micromolar 
concentrations. Application of the CB1R competitive agonist WIN55,212-2 (n=7) alone caused a 
dose-dependent evoked IPSC peak amplitude depression, starting at nanomolar concentrations. 
WIN55,212-2 (300nM; n=5) partially blocked IPSC amplitude reduction by co-application of 
alfaxalone, but did not alter increases in IPSC decay time or induction of an inward current.  These 
findings indicate that alfaxalone induced endocannabinoid signalling to indirectly activate CB1Rs, 
which resulted in reduced postsynaptic glycine receptor activity at low alfaxalone doses, and reduced 
presynaptic release of glycine and induction of an inward current at higher alfaxalone doses. These 
responses to alfaxalone are likely to make HMNs more excitable, and may therefore underlie 
neuromotor excitation during alfaxalone anaesthesia.  Combination of alfaxalone with CB1R 
antagonists or negative modulators of endocannabinoid signalling may therefore provide an optimal 
anaesthetic regime for laboratory rodents. 
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INTRODUCTION 
 
Anaesthesia is frequently used in laboratory animals so that routine husbandry and experimental 
procedures can be performed.  There is a strong need for anaesthetic agents that are easy to 
administer, provide immobilisation, analgesia and muscle relaxation with an adequate margin of 
safety.  Laboratory animal anaesthesia is often performed by researchers that do not have adequate 
anaesthetic training or expertise.  In many cases, lack of equipment to deliver inhalation anaesthesia 
and lack of experience in the use of these agents, dictate the use of injectable agents to both induce 
and maintain unconsciousness. Anaesthesia is an integral part of biomedical research and the extent of 
surgical intervention dictates the anaesthetic plane and time frame necessary.  Procedures range from 
brief immobilisation for relatively non-painful procedures to prolonged surgical anaesthesia for 
complex surgery.  With rapid advancements in biomedical sciences there have still been no major 
improvements in rodent anaesthetic protocols.  Anaesthetic combinations such as ketamine-xylazine 
were reportedly used 30 years ago and remain a widely used anaesthetic combination today (Green et 
al., 1981, Stickrod, 1979, Saha et al., 2007).   
 
Intravenous (IV) access can be easily obtained in larger animals due to visible superficial vessels. 
However, this route of access is not as straight forward in small rodents.  It is technically difficult to 
perform IV injections in rodents and is often replaced by a simpler injection technique (Flecknell, 
1993a).  The intraperitoneal (IP) route of anaesthetic delivery is more commonly used in laboratory 
rats and mice.  IP injections are simple and only require a needle, syringe and minimal expert ise 
(Flecknell, 1993b).  In addition, IP injections cause less tissue damage than the intramuscular (IM) 
route (Smiler et al., 1990) and a larger injection volume can be delivered in a particular site causing 
minimal discomfort.  But no matter how simple it is to deliver an anaesthetic, there is always a degree 
of risk for developing anaesthetic-associated complications and side effects.  Anaesthetics that are 
delivered in a single bolus injection could lead to variable anaesthetic depth and do not allow for 
immediate adjustment of dose.  This large variation in anaesthetic response can mean that a dose of 
drug that would produce anaesthesia in one animal could be ineffective in another at worst lethal 
(Flecknell, 1993b).  This highlights the need for an injectable anaesthetic agent that is consistent in 
effect and has a high margin of safety. 
 
Alfaxalone is a neurosteroid with anaesthetic properties that is commercially available as Alfaxan® 
CD-RTU (Jurox Pty Ltd, Rutherford).  Alfaxalone reportedly has a high margin of safety in a range of 
species including dogs and horses (Ferre et al., 2006, Muir et al., 2008, Goodwin et al., 2012). This 
anaesthetic quality would be highly desirable for rodents.  In this thesis we aim to determine whether 
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alfaxalone is a safe and effective anaesthetic agent for use in laboratory rats as a commonly used 
species in biomedical research.   
 
History of alfaxalone 
Hans Selye first documented the existence of steroids that possessed anaesthetic properties in 1941 
(Sutton, 1972).  It was at this early stage that steroid anaesthetics showed several advantages over 
barbiturate anaesthetics.  An increased therapeutic ratio and progressive liver metabolism with no 
redistribution into the body tissues meant an increased anaesthetic safety margin (Sutton, 1972).  It 
was also determined at this time that the steroid required an oxygen atom at either end of the steroid 
molecule to produce anaesthetic effects. In contrast, an increased number of double bonds in A and B 
rings decreased the steroid-induced anaesthetic activity (Sutton, 1972).  In 1965, an anaesthetic 
steroid 3α-hydroxy-5α-pregnane-11, 20-dione (alfaxalone) was developed and shown to be the most 
potent steroid molecule  tested in an early steroid screening program, when injected intravenously in 
mice (Davis and Pearce, 1972).  Low doses of 1-27mg.kg
-1 
 IV were sufficient to cause a loss of 
righting reflex in the mouse within a few seconds of the injection, and doses as high as 507mg.kg
-1 
 IV 
were administered before death occurred (Davis and Pearce, 1972), demonstrating a wide margin of 
safety.  The IV anaesthetic dose (AD50) in 50% of mice was 1.87mg.kg
-1 
 with a lethal dose (LD50) in 
50% of mice at 54.7mg.kg
-1 
indicating a therapeutic index of 30.4 (Davis and Pearce, 1972).   
 
 
3α-hydroxy-5α-pregnane-11, 20-dione (Alfaxalone) chemical structure 
 
Due to the lipophilic nature of alfaxalone, it was initially solubilised in a non-ionic detergent 
polyoxyethylenated castor oil, Cremaphor EL (Brewster et al., 1989).  This product was commercially 
available as Althesin®, or Saffan® (the veterinary version), and contained alphadolone acetate to 
increase the solubility of alfaxalone in Cremaphor EL (Davis and Pearce, 1972).  Althesin® showed 
greater antinociceptive potency than chloralose-urethane, urethane and pentobarbital in Sprague 
Dawley rats, as well as producing minimal to no suppression of core body temperature and mean 
arterial blood pressure (Ching, 1984).  This alfaxalone-alfadalone formulation had promising 
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anaesthetic potential, but the availability and use of this preparation was discontinued due to the 
allergic side effects associated with the Cremaphor EL excipient (Brewster et al., 1989, Lorenz et al., 
1977).  However, in the time of its availability as Althesin®, a number of studies were performed 
using this formulation of alfaxalone/alfadalone in rats and mice.  Tissue distribution studies of 
Althesin® and metabolism and excretion studies in rats were performed along with AD50 and LD50 of 
mice (Davis and Pearce, 1972, Card et al., 1972, Child et al., 1972).  Studies were also conducted on 
the effect of Althesin on reproduction in mice and rats (Child et al., 1972) 
 
Cyclodextrins have an amphiphatic property that can form soluble and reversible inclusion complexes 
with water-insoluble compounds (Brewster et al., 1989).  This has led to the formulation of alfaxalone 
that is available today.  Using 2-hydroxypropyl-β-cyclodextrin (HPCD) has improved the solubility of 
alfaxalone by 375 times, therefore removing the need for the addition of alfadalone (Estes et al., 1990, 
Muir et al., 2008).  An HPCD-alfaxalone formulation, Alfaxan®-CD RTU was developed by Jurox 
Pty Ltd, and is commercially available in Australia for dogs and cats.   
 
Alfaxalone administration, distribution, metabolism and elimination (ADME) 
Plasma pharmacokinetics of the HPCD preparation of alfaxalone has been performed in cats, dogs and 
horses.  The pharmacokinetics of alfaxalone show non-linear pharmacokinetic parameters after IV 
administration of Alfaxan® in cats (Whittem et al., 2008), dogs (Ferre et al., 2006), horses (Goodwin 
et al., 2011).  A rebound effect of plasma levels was observed in some cats and dogs and majority of 
horses, where an intermittent elevation in plasma level was evident and followed by a return of 
plasma levels to the presumed slope of the pharmacokinetic time profile (Whittem et al., 2008, Ferre 
et al., 2006, Goodwin et al., 2011).  Alfaxalone clearance (Clp) at clinically relevant doses was 
approximately 5-10% of cardiac output for cats compared with 50-60% in the beagle dog and 46% in 
horses (Ferre et al., 2006, Whittem et al., 2008, Goodwin et al., 2011).  These results show 
considerably similar pharmacokinetic profiles between species administered Alfaxan®. 
 
Alfaxalone pharmacokinetic studies in rats have been performed using various solvents, including 
Cremaphor EL, dimethyl sulfoxide (DMSO), acetonitrile and HPCD, as it is well known that 
formulation variations could affect the pharmacokinetic parameters of anaesthetic drugs (Whittem et 
al., 2008).  Althesin® alfaxalone plasma half-life was approximately 7 minutes in rats using gas liquid 
chromatography (GLC) extraction methods (Child et al., 1972).  The distribution half-life of 0.8 ± 0.1 
min and elimination half-life of 14 ± 0.7 minutes was reported in male Wistar rats using high-
performance liquid chromatography (HPLC) extraction method, where it was also shown that HPCD 
did not alter alfaxalone pharmacokinetic parameters when compared to DMSO vehicle (Visser et al., 
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2002).  The Alfaxalone clearance rate reportedly almost equalled the rat liver blood flow, which 
indicated that body weight was important for alfaxalone clearance (Visser et al., 2002). 
Radio-active labelled 
14
C-alfaxalone showed that alfaxalone became widely distributed throughout 
body tissues following a single intravenous injection in Sprague Dawley rats and became localised in 
the central nervous system (CNS) within one minute (Card et al., 1972).  At three minutes post 
injection, the highest level of 
14
C-alfaxalone was found in the liver and by ten minutes, alfaxalone 
isotopes had reached the renal medulla (Card et al., 1972).  Alfaxalone was almost completely cleared 
from body tissues within an hour following IV administration (Card et al., 1972).  Furthermore, the 
majority of radio-labelled alfaxalone was retrieved from faeces and urine within the first 48 hours 
with 97.9% recovered within a period of five days post intravenous injection (Child et al., 1972).  
However, to date, there has been no pharmacokinetic study of alfaxalone administered in the 
commercially available formulation to rats. 
 
Intraperitoneal administration of alfaxalone 
It is technically difficult to acquire intravenous access in a rat or mouse, and therefore the 
intraperitoneal (IP) route of administration of substances to rodents is most frequently used.  Adult 
female Wistar rats displayed periods of electroencephalographic silence from 6-8 minutes after 0.5mL 
per 100g body weight IP Althesin® injection (Fink et al., 1982).  Alfaxalone appears to show an age 
dependent increase in dosage required to induce anaesthesia.  An elevated dose requirement of IP 
Althesin® was necessary to maintain surgical anaesthesia for 30 day old compared with 17 day old 
female Wistar rats (Fink et al., 1982).  17 day old male and female rats of comparable weight required 
a similar dose, but at 90 days of age, male rats required four times the dose of female rats to maintain 
surgical anaesthesia (Fink et al., 1982).  No clinically significant pharmacokinetic differences between 
sexes have been reported (Ferre et al., 2006). 
 
Neurosteroids and their neuronal actions  
Neurosteroids are a class of steroids that do not interact with hormone steroid receptors (Visser et al., 
2000).  They are synthesised in response to several physiological states, including stress and 
pregnancy (Hosie et al., 2006).  Endogenous neurosteroids are synthesised in the central and 
peripheral nervous systems from cholesterol, with one of the earliest observations being their 
anaesthetic properties (Sutton, 1972, Shiraishi et al., 2003, Compagnone and Mellon, 2000, Belelli 
and Lambert, 2005).  It is the function that neurosteroids have on producing anaesthesia that we are 
most interested.   
The anaesthetic potency of many anaesthetic compounds follow the Meyer-Overton rule which states 
that the action of general anaesthetics is proportional to their lipid membrane partition coefficient 
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(Heimburg and Jackson, 2007, Thompson and Wafford, 2001).  But also, he anaesthetic potency 
correlates well with their activity at the -aminobutyric acid A receptor (GABAAR) (Thompson and 
Wafford, 2001). The GABAAR complex is a multimeric structure made up of five subunits and it is 
well known that the majority of the fast inhibitory synaptic transmission in the mammalian brain is 
mediated by the neurotransmitter -aminobutyric acid (GABA), which is the endogenous ligand for 
the GABAAR (Lambert et al., 1995, Paul and Purdy, 1992).  Activation of the, GABAAR by GABA or 
other ligands, rapidly decreases CNS excitability and it is thought that neurosteroids induce 
anaesthesia by this mechanism (Cottrell et al., 1987, Lambert et al., 1995, Paul and Purdy, 1992, Hill-
Venning et al., 1996).   Both endogenous and synthetic neurosteroids are well established positive 
allosteric modulators of the GABAAR (Lambert et al., 1995, Harrison and Simmonds, 1984, 
Compagnone and Mellon, 2000, Weir et al., 2004, Hill-Venning et al., 1996, Belelli and Lambert, 
2005).  More specifically, endogenous neurosteroids act as potent modulators of all major GABAAR 
isoforms and regulates GABAAR through two distinct binding sites in the transmembrane domains by 
potentiation or direct activation of GABAAR (Hosie et al., 2006, Belelli and Lambert, 2005). The 
presence of a β subunit has been shown to play an important role in the allosteric modulatory effects 
of IV anaesthetics on the GABAA R (Carlson et al., 2000).  More specifically, alfaxalone also directly 
activates GABAA Rs containing  αγ subunits, therefore demonstrating the importance of the γ2 
subunit for allosteric GABAAR modulation by alfaxalone (Carlson et al., 2000).  A dual mechanism 
of action was reported for alfaxalone in isolated bovine chromaffin cells under voltage clamp 
conditions (Cottrell et al., 1987).  Low alfaxalone concentrations (>30nM) potentiated GABA-
induced ion current amplitude and increased mean open time of GABAAR chloride channels (Cottrell 
et al., 1987, Nolan et al., 1997).  At higher concentrations (>1μM), alfaxalone also directly activated 
GABAARs, causing an increase in chloride channel conductance (Cottrell et al., 1987, Nolan et al., 
1997, Visser et al., 2002).  The GABAAR effects of neurosteroids are well established and the 
resultant effects of GABAAR activation by alfaxalone is the induction of anaesthesia.   
 
It has been suggested that alfaxalone may possess antinociceptive effects and potential antinociceptive 
properties of neurosteroids have been investigated at several receptor sites (Shiraishi et al., 2003, 
Horishita et al., 2002, Nadeson and Goodchild, 2000, Nadeson and Goodchild, 2001, Winter et al., 
2003, Britton et al., 1991). However there is conflicting evidence of antinociceptive activity for 
alfaxalone.  Spinal muscarinic acetylcholine receptors are involved in antinociception, and inhibition 
of muscarinic receptor function has been demonstrated for IV anaesthetics and analgesic agents 
(Shiraishi et al., 2003).  Alfaxalone at clinically relevant doses was shown to inhibit M1 and M3 
muscarinic receptors expressed in Xenopus laevis oocytes (Shiraishi et al., 2003).  An alternative 
antinociceptive pathway has been suggested, in which noradrenergic neurotransmission is enhanced 
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by noradrenaline transporter inhibition (Horishita et al., 2002).  Alfaxalone competitively suppressed 
noradrenaline uptake by interfering with desipramine binding and noradrenaline recognition in 
cultured bovine adrenal medullary cells (Horishita et al., 2002).  Antinociceptive actions were also 
reported for neurosteroids, in which alfadalone-alfaxalone combination reportedly produced 
antinociceptive effects by positive modulation of spinal cord GABAARs (Nadeson and Goodchild, 
2000).  However, the antinociceptive properties were attributed to the neurosteroid alfadalone and not 
to alfaxalone (Nadeson and Goodchild, 2001).  Similar reports support the lack of antinociceptive 
effects of alfaxalone.  Clinical studies involving the tail flick latency test for antinociception reported 
pain suppressive properties for alfadalone, but not alfaxalone, at a non-sedative dose, 10mg.kg
-1
 
alfaxalone IP (Winter et al., 2003).  Similarly, no antinociceptive benefits were apparent in adult 
Wistar rats administered 8mg.kg
-1
of alfaxalone in which no significant change in tail-flick latency 
was observed compared with control (Britton et al., 1991).  This data suggests that an ideal 
anaesthetic regimen based on alfaxalone would incorporate an antinociceptive agent. 
 
Like GABAAR, glycine receptors (GlyR) also play a role in mediating fast inhibitory 
neurotransmission in the CNS, particularly in brainstem and spinal cord circuits.  GlyRs are ligand-
gated chloride ion channels activated by the synaptically release amino acid glycine, composed of 
pentamers of α and β subunits.  Glycinergic neurotransmission is involved in the coordination of 
reflex responses, sensory signal processing and nociception in the adult CNS (Mukhtarov et al., 
2005).  Strychnine-sensitive GlyRs are involved in the modulation of spinal sensory input, nociceptive 
signals and pain processing, and enhancement of inhibitory GlyR activity could lead to suppression of 
nociceptive signals (Ahrens et al., 2008, Laube et al., 2002, Betz and Laube, 2006).   
Along with GABAAR modulation, alfaxalone has also been shown to potentiate the actions of glycine 
on the GlyR. Alfaxalone and the neurosteroids ORG20599 and minaxolone did not elicit a detectable 
current response on α1 GlyRs expressed in Xenopus laevis oocytes when applied in the absence of 
glycine, but produced a dose-dependent increase in inward current responses elicited by glycine (Weir 
et al., 2004).  The potentiation of α1 GlyRs was much less pronounced for alfaxalone than that of 
ORG20599 and minaxolone, suggesting that GlyR modulation does not play a critical role for the 
anaesthetic action of neurosteroids (Weir et al., 2004).  Similarly, the concentration of alfaxalone 
necessary to potentiate the α1 GlyR subunits, transiently transfected into transformed human 
embryonic kidney (HEK 293) cells, was much higher than that required for GABAAR modulation, 
suggesting that GlyR potentiation by neurosteroids would fall outside a clinically relevant range 
(Ahrens et al., 2008).   
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Clinical use of alfaxalone 
Alfaxan® has been widely used for anaesthetic induction in cats and dogs since its introduction into 
the veterinary anaesthetic market (Ferre et al., 2006).  The removal of the Cremaphor EL solvent 
abolished many of the side effects associated with the Althesin® preparation.  Several studies have 
been carried out to determine the efficacy of this new formulation, and all results were promising, 
with alfaxalone showing a large margin of safety. IV alfaxalone produced a smooth and uneventful 
anaesthetic induction in premedicated horses and was rapidly cleared from plasma (Goodwin et al., 
2011).  Additionally, alfaxalone use in neonatal foals showed good quality of induction and recovery 
from anaesthesia (Goodwin et al., 2012).  Alfaxalone provided a smooth and rapid induction of 
anaesthesia in beagle dogs at clinical (2mg.kg
-1
) and supra-clinical (10mgkg
-1
) IV doses, 
demonstrating its safety at five times the effective dose (Ferre et al., 2006).  Similarly, mixed-breed 
dogs showed rapid induction, good muscle relaxation and uneventful anaesthetic recovery with 
6mg.kg
-1
 and 20mg.kg
-1
 IV doses (Muir et al., 2008).  A fast and stable anaesthetic induction was 
obtained with alfaxalone anaesthesia in cats at 5mg.kg
-1
 IV (Whittem et al., 2008, Muir et al., 2009).  
Young healthy cats aged between 3 to 12 months showed smooth and rapid anaesthetic induction 
followed by rapid and unremarkable recovery after a titrated dose of IV alfaxalone (Zaki et al., 2009).   
 
However, one common observation with alfaxalone anaesthesia was the presence of neuro-excitation 
during anaesthetic induction and recovery.  This was manifested as muscle twitching and limb 
paddling, and was observed in 7 of 47 and 10 of 47 cats given IV alfaxalone anaesthetic respectively 
(Mathis et al., 2012). Twitching was also reported in pigs; 20 of 60 pigs anaesthetised with alfaxalone 
displayed muscle and jaw twitching after anaesthetic induction, and 6 pigs shook during the 
anaesthetic recovery period (Keates, 2003).  Dogs showed less pronounced neuro-excitatory signs, 
such as agitation and noise hypersensitivity when stimulated, during alfaxalone anaesthetic recovery 
(Ferre et al., 2006).   This neuro-excitatory effect of alfaxalone has also been reported with other 
neurosteroids, where pro-convulsant properties have been described in at least twenty neurosteroid 
compounds causing seizures following IV administration in mice (Paul and Purdy, 1992).   
 
Alfaxalone for rodent anaesthesia 
Alfaxalone anaesthesia is widely used in veterinary medicine for its ease of administration, wide 
margin of safety, and its titratable nature when given IV.  Current studies indicate rapid and smooth 
anaesthetic induction and recovery in most veterinary species, and it is believed that these favourable 
characteristics of alfaxalone anaesthesia could be translated for use in laboratory rodents.  Initially, 
this thesis identified currently utilised anaesthetic regimens from a rodent anaesthetic survey aimed at 
researchers.  In this survey, several anaesthetic-related complications were identified with commonly 
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used injectable anaesthetic combinations, highlighting the need for a safer and more reliable injectable 
anaesthetic combination for laboratory rodents.   
My initial hypothesis provided some evidence that alfaxalone could fill these criteria and potentially 
improve on current rodent anaesthetic protocols.  In rats, the IV route is not possible without invasive 
intervention and is technically difficult to perform.  In this case, the IP route of drug administration is 
common place for laboratory rodents.  A pharmacokinetic investigation in rats was performed to 
determine whether alfaxalone was suitable for IP administration.  Results were promising, as 
sustained plasma levels were seen up to 60 minutes post IP administration of 20mg.kg
-1
alfaxalone.  
This was a major benefit, as it provided a simple route of anaesthetic delivery as well as longer sleep 
times than IV dosing.  Following this, an alfaxalone clinical trial was performed in adult Wistar rats 
using IP, IM and SC administration of alfaxalone.  Pilot studies revealed that neuro-excitation was 
prominent via all routes of alfaxalone delivery. So a plan was devised to incorporate various 
premedication agents into an alfaxalone anaesthetic regimen to see if neuroexcitation could be 
eliminated.  Findings showed, however, that neuro-excitation was reduced by some premedication 
agents, but not abolished.  As the neuro-excitatory effects appeared to be one of the major limitations 
in providing an effective alfaxalone anaesthetic protocol for rats, it was prudent to find the mechanism 
for alfaxalone neuro-excitation using electrophysiological studies.   
 
The effects of alfaxalone on inhibitory synaptic transmission to motor neurons (MN) was investigated 
using whole cell patch clamp technique in hypoglossal motor neurons (HMNs) in brainstem slices 
from Wistar rats.  A reduction in evoked inhibitory postsynaptic current (IPSC) peak amplitude, rise 
time and decay time without paired pulse ratio changes, was consistent with alfaxalone altering the 
activity of postsynaptic glycine receptors, causing prolongation of both channel opening and closure.  
A decrease in spontaneous IPSC frequency at higher doses of alfaxalone was suggestive of 
presynaptic modulation by alfaxalone, decreasing glycine release from the presynaptic terminal.  At 
high doses, alfaxalone also induced an inward current in HMNs, without significant change in input 
resistance.  We then postulated that alfaxalone exerted its effects on glycinergic transmission by 
increasing postsynaptic endocannabinoid synthesis and activation of cannabinoid 1 receptors (CB1Rs) 
through transient receptor potential (TRP) channel activation.  Our results were supportive of these 
mechanisms possibly underlying increased HMN excitability and neuromotor excitation.  Ultimately, 
addressing the neuro-excitation will not just improve anaesthesia for laboratory rodents, but improve 
anaesthesia for all veterinary species.  
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CHAPTER ONE 
Rodent Anaesthetic Survey 
 
Abstract 
It is commonly accepted that pain and distress should be minimised in animals undergoing any 
surgical procedure.  This view has superseded previous ideas where anaesthesia was available merely 
to facilitate the researcher, and the animals’ welfare was overlooked.  Fortunately, this outdated 
attitude is no longer the norm.  An ideal anaesthetic protocol for research animals would be safe, 
predictable, alleviates pain and distress and could be performed by scientists untrained in anaesthetic 
practice.  A survey of rodent anaesthetic techniques was conducted to identify commonly used 
anaesthetic protocols currently being utilised by the research community in Australasia.  30 survey 
responses were received from various research Institutions around Australia and New Zealand 
detailing their anaesthetic and analgesic protocols in rats and mice.  Results identified ketamine-
xylazine anaesthetic combination and isoflurane as the most common injectable and inhalation 
anaesthetic respectively.  The predominant anaesthetic delivery method was by injection.  61.5% 
respondents used injectable anaesthetic agents for rats as compared with 38.5% gaseous anaesthesia.  
Buprenorphine was the predominant analgesic chosen for both rats and mice and non-steroidal anti-
inflammatory medications were not favoured for use in mice.  Anaesthetic associated complications 
most frequently encountered were inadequate depth of anaesthesia, hypothermia, long recovery time, 
apnoea and unexpected wake up from anaesthesia.  Anaesthetic related rodent mortality was not 
uncommon ranging markedly between researchers up to 100% deaths.  The rodent anaesthetic survey 
identified several commonly chosen anaesthetic combinations and analgesic agents and with them 
their associated anaesthetic complications.  Results highlighted a need for increased anaesthetic 
training for research scientists and technicians.  Regardless of the time consuming nature of training, 
ultimately this would be more cost and time effective given the high complication rate faced by 
researchers. At present, only a limited number of anaesthetic agents are utilised and they are still 
accompanied by a number of complications. Therefore it is prudent to find a simple and safe 
anaesthetic protocol for rats and mice that provides a wide margin of safety to ultimately reduce 
anaesthetic related complications and death.  Alfaxalone could potentially provide a safer and easy 
alternative laboratory rodent anaesthetic to currently available anaesthetic agents. 
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Introduction 
 
Laboratory rats and mice are frequently anaesthetised for husbandry and biomedical research 
purposes.   Historically anaesthesia was merely required to provide immobilisation and no emphasis 
was placed on the physiological and metabolic effects caused by the anaesthetic agents on the animals 
themselves (Wixson et al., 1987c).  A good anaesthetic protocol needs to be safe, predictable and 
ensure that the mouse or rat cannot experience any pain or distress during the procedure (Flecknell, 
1993b).  Unfortunately, all anaesthetic agents carry with them a degree of risk for complications and 
side effects.  Importantly, poor peri-operative care could result in complications such as prolonged 
recovery, unnecessary stress on the animal and potential mortality (Flecknell, 1993b).   
 
Regardless of the anaesthetic regimen chosen, anaesthetic maintenance is difficult in rodents due to 
their small size and requirement for specialised rodent-specific monitoring equipment (Flecknell, 
1993a).  This is compounded by the lack of veterinary anaesthetic expertise where anaesthetic 
monitoring is performed by researchers and not by trained veterinary anaesthetists. As an additional 
complicating factor, researchers must take into account the possible differences in anaesthetic 
tolerance between species, and also the possible differences between the growing number of 
genetically modified rodent strains (Avsaroglu et al., 2007).   
 
Over the last few decades, some investigators have tried to identify the most commonly administered 
anaesthetic and analgesic agents used in biomedical research for laboratory rodents (Richardson and 
Flecknell, 2005, Stokes et al., 2009).  These studies involved the use of a structured literature review 
from published peer reviewed articles.  The results from these literature searches gave us an insight 
into drug progression for rodent anaesthesia. 
 
Between 1990 and 2000, there was a marked reduction in the use of ether.  This was a convenient 
anaesthetic agent, however it was not only irritant to rodents, but also posed an occupational risk as it 
was potentially explosive when combined with oxygen and air (Richardson and Flecknell, 2005).   As 
a potential replacement for ether, many other gaseous agents including isoflurane and halothane were 
employed but appropriate delivery apparatus is necessary along with equipment for the removal of 
waste gases (Richardson and Flecknell, 2005).  As a consequence of the considerably expensive 
gaseous anaesthetic delivery systems, the use of injectable agents became a common alternative 
anaesthetic route.  A shift towards using combination anaesthetic agents was seen within the early 
2000s as an attempt to minimise adverse effects attributed to using sole agents (Stokes et al., 2009).  
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This was also followed by a noticeable increase in the use of analgesic agents, which were given in 
addition to an anaesthetic regimen to provide analgesia (Stokes et al., 2009).   
 
These surveys focused only on results from peer reviewed journals and the anaesthetic protocols used 
for that particular study.  We believe that many rodent anaesthetics are performed not only by 
researchers, but also animal technicians that routinely perform rodent anaesthesia for husbandry 
procedures.  Therefore we designed a rodent anaesthetic survey to help us identify the most 
commonly used anaesthetic regimens for researchers and animal technicians.  This survey focused 
directly on typical anaesthetic practices used within laboratories and animal facilities.  Survey data 
was collected between 2009 and 2012, approximately five years after the last survey report.  The 
results of this survey would help determine which anaesthetic regimen are currently most utilised and 
also whether there is a market for a new anaesthetic agent such as alfaxalone to enter the laboratory 
rodent industry. 
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Materials and Methods 
The rodent anaesthetic survey was limited to three A4 pages to encourage participation (Appendix 1).  
Wording of the survey was chosen carefully so that respondents felt comfortable answering sensitive 
questions pertaining to mortality rates and complications encountered.  A list of anaesthetic related 
complications was supplied to help prompt a response from survey participants. 
Key information requested from this survey was sorted into sections. Section 1 of the survey 
ascertained the animals’ signalment, number of animals and anaesthetic regimen used for that 
particular protocol.  Section 2 asked specific questions associated with anaesthetic experience and 
participants’ thoughts on the quality of that anaesthetic regimen (Appendix 1).   
 
Anaesthetic survey distribution 
The anaesthetic survey was emailed to a variety of rodent users in the research industry ranging from 
rodent breeding and housing facilities to biomedical research Institutes around Australia and New 
Zealand.  The rodent anaesthetic survey was uploaded to the Australia and New Zealand Laboratory 
Animal Association (ANZLAA) member’s website.  ANZLAA members are largely employed within 
the rodent breeding and housing industry in Australasia.  Surveys were also circulated around more 
local research facilities including the Pharmacy Australia Centre of Excellence, Mater Medical 
Research Institute and Queensland Institute of Medical Research.  Within The University of 
Queensland, surveys were distributed to The University of Queensland Veterinary Teaching Hospital, 
The University of Queensland Biological Resources and The University of Queensland School of 
Biomedical Sciences.  Research Institutes within the University of Queensland campus, Australian 
Institute for Bioengineering and NanoTechnology, Institute for Molecular Biosciences and 
Queensland Brain Institute members were also invited to take part in this rodent anaesthetic survey.   
Printed copies of the anaesthetic survey with a postage paid envelope, were made available to 
participants preferring a hard copy of the document.  During an annual ANZLAA meeting held in 
Sydney in 2010, surveys were promoted and distributed via self addressed and postage paid 
envelopes.   
 
Anaesthetic survey data compilation 
Survey replies were received from all around Australia and New Zealand.  In the interest of 
confidentiality, survey participants and facility names were not disclosed and instead a survey 
number, from 1 to 30, was allocated.  All data collected were collated and tabulated identifying 
anaesthetic regimen, procedural impact, analgesic use, anaesthetic complications and mortality rate 
for rats and mice.  Anaesthetic agent combinations were categorised as injectable or inhalation 
anaesthesia.  The procedural impact on the rodents was categorised into non-invasive, moderate and 
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invasive interventions.  Non-invasive intervention was defined as a procedure that required minimal 
physical contact where the anaesthesia was merely performed to provide immobilisation.  Moderate 
intervention was defined as any procedures requiring administration or removal of substances such as 
injections or blood collection.  Invasive intervention was defined as any procedures involving surgical 
intervention requiring surgical site incision and wound closure.  Analgesic agents were defined as 
analgesic agents used in addition to that used for anaesthesia, therefore not inclusive of anaesthetic 
agents that possessed analgesic properties.  All data were presented in a table with data presented as 
total numbers, mean, range and percentages.   
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Results 
Approximately 300 survey forms were distributed around Australia between July of 2009 and 2012 
and a total of thirty anaesthetic survey replies were collected.  Investigators were not contacted for 
additional information due to the sensitive nature of some of the survey questions and the confidential 
manner in which the survey information was treated.  Contact details were not requested and therefore 
survey responses received by mail were anonymous.  In total, thirty survey responses were received 
over the allocated period resulting in an approximate response rate of 10%.   
 
The majority of anaesthetics were delivered by injection 
The predominant anaesthetic delivery method described in the anaesthetic survey was by injection.  
61.5% of respondents used injectable anaesthetic agents for rats (Table 1.1).  This bias towards the 
use of injectable agents was more so in mice than for rats.  75% of mouse anaesthetics were 
administered by injection.  Ketamine-xylazine combination was the most popular injectable 
anaesthetic agent for both rats and mice.  Tiletamine-zolazepam (Zoletil®) - xylazine combination 
anaesthesia was the next most popular injectable anaesthetic combination for rats and mice.  Almost 
all anaesthetics here were delivered by intraperitoneal injection.  Only one survey respondent 
administered anaesthesia via the intramuscular injection.   
 
Inhalation agents were more common for rats 
38.5% of respondents used inhalation agents in rats compared with 25% for mice.  Isoflurane was the 
only inhalation agent administered to rats.  Both isoflurane and methoxyflurane anaesthesia was 
utilised for mouse anaesthesia. 
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ANAESTHETIC AGENTS 
Rats 
N  
(%) 
Mouse 
N  
(%) 
  Total survey responses 26  
(100) 
12  
(100) 
  Injectable Anaesthetic Agents 
  Ketamine & Xylazine 
9  
(34.6) 
6  
(50) 
  Tiletamine-Zolazepam & Xylazine 
6  
(23.1) 
2  
(16.7) 
  Pentobarbital 
1 
(3.8)  
  Tribromoethanol 
 
1  
(8.3) 
  Inhalation Anaesthetic Agents 
  Isoflurane 
10  
(38.5) 
1  
(8.3) 
  Methoxyflurane 
 
2  
(16.7) 
 
Table 1.1. Anaesthetic agent combinations used in rats and mice. 
Lists survey response data for injectable and inhalation anaesthetic agent combinations as described 
by rodent anaesthetic survey respondents.  The responses were separated into rat and mouse 
anaesthesia and displayed as the number of responses in total number (N) and as a percentage (%). 
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Analgesic use in laboratory rodents 
Of the 30 surveys collected, 28 investigators responded to the analgesic question.  From these 
responses, additional analgesics were administered to 47.8% of rats and 40% of mice.  Additional 
analgesia was not administered to all rodents where the procedures were categorised as moderately 
invasive and invasive (Table 1.2).  The most commonly administered analgesic agent for both rats and 
mice was the opioid drug buprenorphine.  Non-steroidal anti-inflammatory agents, meloxicam, 
carprofen and paracetamol were reported.  One local anaesthetic agent, bupivacaine was reportedly 
used for rat analgesia (Table 1.2). 
 
Drug restrictions did not limit anaesthetic and analgesic choice 
Drug restrictions did not limit the use of ketamine or opioid analgesic agents.  Only 3 of 30 
respondents chose tiletamine-zolazepam over ketamine based on the difficulties with handling a 
schedule 8 drug restricted agent.  Rather, 14 respondents stated their choice of anaesthetic was not 
affected by drug restrictions, but based on its familiarity, convenience and anaesthetic qualities.   
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a) 
 Procedural impact Analgesia No Analgesia No Response 
Rat 
  Non-invasive 1 3 0 
  Moderate  2 5 0 
  Invasive 8 2 2 
  Total  
   (%) 
11 
(47.8) 
10 
(43.5) 
2 
(8.7) 
Mouse 
  Non-invasive 0 1 0 
  Moderate 1 4 0 
  Invasive 3 1 0 
  Total 
   (%) 
4 
(40) 
6 
(60) 
0 
(0) 
 
 
b) 
Analgesia Rat Mouse 
 
Buprenorphine 5 4 
Meloxicam 3 0 
Carprofen 2 0 
Paracetamol 1 1 
Bupivicaine 1 0 
Total 12 5 
 
Table 1.2.  Analgesic agent use in correlation with procedural impact for rats and mice. 
a) Analgesic usage for non-invasive, moderate and invasive procedures in both rats and mice 
b) Analgesic agents most commonly reported for use in rats and mice 
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Reported anaesthetic related complications 
Investigators reported a range of anaesthetic related complications but two survey respondents 
mentioned no complications were observed in their rat anaesthetics and three survey respondents 
noted no complications with mouse anaesthesia.  Additionally, no complications were observed with 
inhalation anaesthesia in mice. 
 
The most common anaesthetic complication reported was inadequate depth of anaesthesia after a 
single dose of an injectable agent (Table 1.3).  66.6% of survey participants experienced this 
complication in mice and 56% in rats during injectable anaesthesia.  One investigator reported 50% of 
their mouse ketamine-xylazine anaesthetics were inadequate (Table 1.5).  
 
Unexpected anaesthetic wake-up was observed in rats following both injectable and inhalation 
anaesthesia where it affected 25% of injectable anaesthesia and 30% of inhalation anaesthesia (Table 
1.4).  This complication was not observed during mouse anaesthesia. 
 
37.5% of rats appeared cold during injectable anaesthesia in rats and similarly 33.3% for mice (Table 
1.4 & Table 1.5).   Four survey participants specifically mentioned that the animals appeared cold 
even when a supplementary heat pad was provided.   
 
Apnoea was observed with both injectable and inhalation anaesthetics.  25% of rats showed periods of 
apnoea when given an injectable anaesthetic (Table 1.2).  One Investigator reported an 83% incidence 
of apnoea as a consequence of administering ketamine-xylazine.  Apnoea was observed by three of 
twelve investigators performing mouse anaesthesia (Table 1.5). 
 
Prolonged anaesthetic recovery was predominantly seen with injectable anaesthesia with 37.5% of 
(Table 1.3).  One Investigator mentioned prolonged recovery from anaesthesia in 50% of the rats 
anaesthetised with pentobarbital (Table 1.4).  Additionally, another investigator observed a 10% 
prevalence of prolonged recoveries following ketamine-xylazine anaesthesia in mice (Table 1.5). 
 
Only 50% of survey participants reported their anaesthetic related mortality rates.   Mortality rates 
identified in this rodent anaesthetic survey ranged from no deaths to 100% mortality (Table 1.7).   
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 rat mouse 
 injectable inhalation injectable inhalation 
 N % N % N % N % 
No complications 1 6.3 1 10 1 11.1 2 66.7 
No response to this question 0 0 3 30 1 11.1 1 33.3 
Inadequate depth after initial administration 9 56 1 10 6 66.6 0 0 
Unexpected wakeup 4 25.0 3 30 0 0 0 0 
Cold 6 37.5 1 10 3 33.3 0 0 
Apnoea 4 25.0 2 20 3 33.3 0 0 
Long recovery 6 37.5 1 10 3 33.3 0 0 
Total Survey Responses 16 10 9 3 
 
 
Table 1.3. Survey findings for anaesthetic complications associated with injectable and 
inhalation anaesthetic agents for rats and mice. 
Complications as experienced by survey respondents are represented as a percentage of responses 
compared with total survey responses.  Where N = total number of survey respondents experiencing 
the complication 
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Survey number 
Inadequate 
Cold Apnoea 
Unexpected Prolonged 
Anaesthesia Wakeup Recovery 
1           
2   12.5       
3 10         
4 10 10     50 
5 20   1 1 20 
6 5   83.3 16.7   
8         % not specified 
9   33.3   1   
10 2 % not specified     % not specified 
11           
12     % not specified     
13         1 
14 0.05     2.5 1 
15 1       % not specified 
16 0.025         
17 % not specified % not specified 7.1 7.1   
18     5 30   
20           
21   10       
22       50   
23           
24 10 % not specified       
25           
27           
Range 0.025 to 20% 10 to 33.3% 1 to 83.3% 1 to 50% 1 to 50% 
 
Table 1.4. Survey findings representing the most commonly experienced anaesthetic-related 
complications in rats. 
The frequency each anaesthetic-related complication was experienced by survey respondents as a 
percentage of their total anaesthetics performed in rats.  
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Survey number Inadequate Cold Apnoea Prolonged 
  Anaesthesia     Recovery 
4 2   1   
7 1 1     
10     % not specified 1 
13         
14 5       
16       1 
17 10   % not specified   
19 50       
26 % not specified % not specified   10 
28         
29         
30         
Range 5 to 50%  1%  1% 1 to 10% 
  
Table 1.5. Survey findings representing the most commonly experienced anaesthetic-related 
complications in mice. 
The frequency each anaesthetic-related complication was experienced by survey respondents as a 
percentage of their total anaesthetics performed in mice. 
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 Rat Mouse 
Survey number Mortality (%) Anaesthetic regimen Mortality (%) Anaesthetic regimen 
1 15.6 Tiletamine-Zolazepam & Xylazine     
2 0.4 Tiletamine-Zolazepam & Xylazine     
3 1 Tiletamine-Zolazepam & Xylazine     
4 No response Pentobarbitone 2 Tiletamine-Zolazepam & Xylazine 
5 10 Ketamine & Xylazine     
6 1 Ketamine & Xylazine     
7     1 Tribromoethanol 
8 100 Ketamine & Xylazine     
9 No response Ketamine & Xylazine     
10 No response Ketamine & Xylazine No response Ketamine & Xylazine 
11 No response Isoflurane     
12 No response Isoflurane     
13 0.6 Ketamine & Xylazine No response Ketamine & Xylazine 
14 1 Ketamine & Xylazine 1 Ketamine & Xylazine 
15 No response Tiletamine-Zolazepam & Xylazine     
16 No response Ketamine & Xylazine No response Methoxyflurane 
17 0 Ketamine & Xylazine 0 Ketamine & Xylazine 
18 No response Isoflurane     
19     15 Ketamine & Xylazine 
20 5 Isoflurane     
21 2.9 Tiletamine-Zolazepam & Xylazine     
22 0 Isoflurane     
23 No response Isoflurane     
24 No response Isoflurane     
25 No response Isoflurane     
26     1.3 Ketamine & Xylazine 
27 No response Isoflurane     
28     No response Tiletamine-Zolazepam & Xylazine 
29     0 Isoflurane 
30     No response Methoxyflurane 
Total 
Responses  
12 of 24 
(50%) 
 
5 of 12 
(41.7%) 
 
 
Table 1.6.  Anaesthetic associated mortality rates as experienced by survey respondents 
Reported anaesthetic mortality rates defined by each survey respondent for rats and mice.  
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 Survey Rat Mouse 
Anaesthetic regimen Number  Mortality (%) Average Mortality (%) Average 
Tiletamine-Zolazepam  
& Xylazine 
 
1 15.6   2   
2 0.4       
3 1       
15 No response       
21 2.9 5.0   2 
Ketamine & Xylazine 
 
5 10   1   
6 1   No response   
8 100   No response   
9 No response   0   
10 No response   15   
13 0.6       
14 1       
16 No response       
17 0 18.76   5.33 
Isoflurane 
11 No response   0   
12 No response       
18 No response       
20 5       
22 0       
23 No response       
24 No response       
25 No response       
27 No response 2.5   0 
Methoxyflurane 16  N/a N/a  No response N/a 
Tribromoethanol 7  N/a  N/a 1 1 
 
Table 1.7. Comparison of mortality rates associated with various anaesthetic agent 
combinations. 
Reported anaesthetic percentages associated with the anaesthetic regimen for rats and mice 
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Discussion 
A survey response of 30 replies was lower than anticipated from the large number circulated. The low 
response could be in part due to the busy nature of staff and researchers, unwillingness to disclose 
confidential information, or that they just did not know the answers to the questions.  Because of the 
reduced number of survey responses, the results may not be representative of the Australasian 
research community.  In spite of this, the rodent anaesthetic survey findings were still invaluable in 
providing us with first hand information about rodent anaesthesia within the research community.    
 
Ketamine-xylazine is still the most commonly used injectable anaesthetic regimen 
Ketamine-xylazine anaesthetic combination was identified as the most commonly used injectable 
regimen in mice and rats.  This result is consistent with previously published survey findings from 
2000-2001 and 2005-2006 that showed an increasing trend towards its use and a decrease in use of 
pentobarbital (Stokes et al., 2009).  A veterinary survey established ketamine combinations as the 
most widely used anaesthetic agent for almost every species including laboratory rodents due to its 
perceived safety, minimal cardiovascular and respiratory depressive effects (Wagner and Hellyer, 
2000, Saha et al., 2007).  However, the safety aspect of this combination did not translate from the 
veterinary to the research field.  One investigator mentioned they experienced an inadequate depth of 
anaesthesia in 50% of the ketamine-xylazine anaesthetics in mice.  Another investigator reported a 
83% incidence of apnoea following ketamine-xylazine injection in rats.  Additionally, significant 
mortality rates were reported in the survey findings that were consistent with other published 
literature (Wixson et al., 1987c, Smith, 1993, Wixson et al., 1987a, Arras et al., 2001).  Xylazine itself 
has been implicated in several anaesthetic-related adverse issues.  Twenty-five percent of 
complications in one study involved the use of xylazine in the veterinary anaesthetic protocol (Dyson 
et al., 1998).  And an increased anaesthetic related mortality rate was observed in cats and dogs given 
xylazine (Clarke and Hall, 1990).  But even with these side effects, ketamine-xylazine combination, 
first reported for used in rats over 30 years ago, is still the most commonly used rodent anaesthetic 
today (Stickrod, 1979, Green et al., 1981, Saha et al., 2007).   
 
Zolazepam-tiletamine-xylazine is the alternative injectable anaesthetic  
The zolazepam-tiletamine combination anaesthetic, marketed as zoletil® (Virbac Australia, Pty Ltd, 
Milperra NSW, Australia) is a commonly used veterinary anaesthetic (de la Pena et al., 2012).  This 
combination provides rapid induction, immobilisation, good muscle relaxation, and smooth recovery 
from anaesthesia (Ferrari et al., 2005).  And these features could account for zolazepam-tiletamine 
and xylazine anaesthetic mixture being the second most chosen injectable anaesthetic protocol in this 
study.  There are many similarities between zolazepam-tiletamine-xylazine and ketamine-xylazine 
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combinations.  Both these anaesthetic regimen incorporate a muscle relaxant, xylazine and a 
dissociative agent, ketamine or tiletamine.  The inclusion of zolazepam provides additional relaxant 
effects.  Zolazepam is a benzodiazepine tranquilizer and tiletamine is an arylaminoalkalone, non-
narcotic dissociative anaesthetic agent. They work in combination to provide these anaesthetic 
qualities (Ferrari et al., 2005, Saha et al., 2007).  As with any anaesthetic regimen, there are still some 
associated side effects.  Sprague Dawley rats anaesthetised with zolazepam-tiletamine developed dose 
and time dependent hypertension similar to known cardio-stimulatory effects of other dissociative 
anaesthetic agents (Wilson et al., 1993).  However, cardiovascular depression, consisting of persistent 
hypotension and bradycardia, was observed when zolazepam-tiletamine was administered in 
combination with xylazine (Wilson et al., 1993).  Zolazepam-tiletamine-xylazine combination in 
horses demonstrated that respiratory depression was associated with both CNS sedative effects of 
xylazine and the dose dependent respiratory depression of tiletamine (Wilson et al., 1993, Hubbell et 
al., 1989). 
 
The use of pentobarbital as an injectable rodent anaesthetic has been superseded 
Previously, pentobarbital was the most commonly used laboratory rodent anaesthetic.  However its 
use has dropped from 33% of the total reported anaesthetic use in 2000-2001, to 16% in 2005-2006 
with an increase in isoflurane use from 2% to 16% and ketamine-xylazine combination from 15% to 
31% in this time (Stokes et al., 2009).  This drop in pentobarbital use is consistent with our findings, 
with only one in thirty survey respondents picking pentobarbital as their anaesthetic of choice.  This 
investigator also noted they experience a 10% of rats were inadequately anaesthetised, 10% were 
appeared cold, and 50% of rats experienced prolonged recovery (Table 1.4).  When used a sole 
anaesthetic agent, pentobarbital is considered a poor analgesic and is associated with many 
complications including severe cardiovascular and respiratory depression and a low safety margin 
(Ferrari et al., 2005, Flecknell, 1993b, Field et al., 1993, Danneman and Mandrell, 1997). With safety 
concerns such as these, and an abundance of more reliable anaesthetic combinations available, the 
shift away from pentobarbital use was inevitable. 
 
Tribromoethanol anaesthesia causes gastrointestinal side effects 
Tribromoethanol and its combinations can provide rapid and deep anaesthesia followed by rapid 
recovery in mice and rats (Weiss and Zimmermann, 1999, Cho et al., 2011, Gopalan et al., 2007, 
Gopalan et al., 2005).  One survey respondent used tribromoethanol frequently in mice and from their 
experience however, observed approximately 1% mortality rate.  Tribromoethanol has also been 
associated with increased post-operative mortality and intestinal complications such as abdominal 
adhesions, peritonitis and ileus (Tarin and Sturdee, 1972, Arras et al., 2001, Zeller et al., 1998, Cho et 
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al., 2011).   Contrasting reports state that tribromoethanol has a very low mortality rate when used 
correctly and has few complications (Weiss and Zimmermann, 1999).  But in line with increasing 
animal welfare concerns, there must be good justification in choosing this anaesthetic over currently 
available anaesthetic combinations that bring with them fewer post-anaesthetic complications.  
Additionally, the development of anaesthetic-related intestinal complications could compromise the 
biomedical research data.  
 
A shift towards the use of inhalation anaesthesia 
The shift towards the use of inhalation anaesthesia could likely be driven by the moral and ethical 
considerations associated with the use of animals in research (Flecknell, 1993a).  Inhalation agents are 
delivered in combination with 100% oxygen and this in itself would improve anaesthetic recovery 
times and would alone increase its safety.  Regardless of the increase in inhalation anaesthetic use, 
there is still an increased anaesthetic risk to rodents due to their small size.  It is technically difficult to 
intubate rodents so therefore the majority of inhalation anaesthetics are delivered via a face mask and 
relying on the animal breathing spontaneously (Flecknell, 1993a).  Along with risks to rodents, 
handlers could also potentially be exposed to waste gases where isoflurane exposure has been linked 
to a higher incidence of infertility and spontaneous abortion in women (Mazze, 1985).   
 
Isoflurane is fast becoming an anaesthetic of choice for rats 
Isoflurane gaseous anaesthesia was the most frequently used inhalation anaesthetic agent in this study.  
This high proportion of gaseous anaesthetic use reflects a shift from older perceptions where 
anaesthetics merely provided immobilisation to animals, to reducing anaesthetic recovery time and 
ultimately improving animal welfare (Wixson et al., 1987c).  Stokes (2009) reported an increase in 
isoflurane use from 2.6% to 17.4% within five years for rats (Stokes et al., 2009).  This progressive 
move towards inhalation anaesthesia appears to be continuing with 38.5% of survey respondents 
within this study choosing isoflurane as their anaesthetic of choice for rats.   In general, delivery of 
gaseous anaesthesia is costly due to the expense of the anaesthetic delivery systems in comparison to 
the use of a simple needle and syringe for injectable anaesthetic delivery (Flecknell, 1993b).   
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Methoxyflurane is the inhalation anaesthetic of choice of mice 
In mice, the anaesthetic survey identified methoxyflurane as the inhalation anaesthetic of choice.  This 
is likely due to methoxyflurane being relatively safe use in simple anaesthetic chambers (Flecknell, 
1993b, Tarin and Sturdee, 1972, Itah et al., 2004, Saul and Fisher, 1974).  It is frequently used for 
short procedures and has been reported to possess analgesic properties (Arras et al., 2007).   
 
Inadequate anaesthetic depth is the most commonly reported anaesthetic complication 
An inadequate depth of anaesthesia following an initial dose of an injectable anaesthetic agent was 
listed as the most frequently encountered anaesthetic complication.  Multiple confounding issues 
could influence this finding, such as the length of time post injection that the respondent allowed 
before deeming the anaesthetic inadequate and a possible lack of knowledge of correct anaesthetic 
dosages. Several survey respondents were unable to supply accurate anaesthetic dose rates but instead 
provided a recipe for their anaesthetic mixture or a volume administered to each animal without 
obtaining body weights.  This could indicate that many survey respondents were unaware of the exact 
dosage of an anaesthetic agent each rodent received.  Other complicating issues could be associated 
with differences in anaesthetic requirements for varying strains of rats and mice where protocols may 
not have been tailored to that particular strain.   
 
Temperature control is difficult in rodents 
Maintenance of core temperature is of utmost importance as hypothermia is possibly the most 
important cause of anaesthetic-related mortality in mice (Flecknell, 1993b).  The high surface-to-mass 
ratio in rodents can lead to rapid heat loss of 4 to10
 o
C in core body temperature over 15 to 20 minutes 
during anaesthesia (Taylor, 2007).  Pentobarbital was found to cause profound hypothermia in rats 
and ketamine-xylazine combinations caused a dose dependent depression in core and surface body 
temperatures (Wixson et al., 1987c).  This is consistent with one investigator’s observations that 50% 
of their rats appeared cold during pentobarbital anaesthesia.  Volatile anaesthetics such as isoflurane 
and methoxyflurane also cause a decrease in body temperature (Hitt et al., 1977).  Therefore external 
heating would be recommended to aid in maintenance of core body temperature.  Heat pads or heat 
blankets with a surface temperature of 37.2-38.9
o
C provided rats and mice with an effective heat 
source that could help maintain core body temperature during anaesthesia (Taylor, 2007). In contrast, 
4 survey respondents specifically noted that their animals appeared cold regardless of the presence of 
a heat pad and in this case, these rodents may be experiencing peripheral vasoconstriction rather than 
actual hypothermia.  It must also be mentioned that a heat pad usually only provides a small contact 
area in which case, would provide little thermoregulatory support to the rat or mouse.  In this study, 
the temperature of the external heating provided by the survey respondent and the body temperature 
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readings were not ascertained.  The respondents were also not asked to define at what point they 
determined a rodent was cold.  So it could only be postulated that if in fact the rodents were 
hypothermic and the delivery of external heating was inadequate. 
 
Respiratory compromise is frequently associated with rodent anaesthesia 
Apnoea was one of the most frequently observed anaesthetic complications in this study.  There is a 
multitude of possible problems that can lead to the development of apnoea.  Respiratory depressive 
drugs, increased anaesthetic depth, and also lack of oxygen supplementation are only a few possible 
preceding factors leading to apnoea.  It is always recommended however, that 100% oxygen 
supplementation is administered during anaesthesia especially if a respiratory depressive agent.   
 
Unexpected wake up from anaesthesia is not uncommon 
Unexpected wake up from anaesthesia was observed during both inhalation and injectable 
anaesthesia.  It is expected that the cause of anaesthetic “wake up” is due to inadequate depth of 
anaesthesia.  This could reflect the lack of training prior to performing anaesthesia with particular 
anaesthetic agents.  Also a lack of expertise in using equipment, such as an inhalation anaesthetic 
circuit, could in itself be detrimental to the rat or mouse.  Additionally, inadequate anaesthesia for 
injectable agents could likely be due to the IP route of administration as this route is slow to absorb 
into circulation and is subjected to a high degree of liver metabolism (Lukas et al., 1971) (Flecknell, 
1993b).  This resultant clinical effect is variability in depth of anaesthesia.  Frequently, survey 
respondents mentioned that their reason for choosing an anaesthetic protocol was due to their 
familiarity with it and the importance of previous experience with an anaesthetic regimen must not be 
overlooked. 
 
Research concerns over providing additional analgesia 
It is widely accepted that pain and distress should be minimised when performing experimental 
procedures (Flecknell, 1984, Liles and Flecknell, 1992b, Liles and Flecknell, 1993, Hawkins, 2002).  
In this survey, 48% of respondents provided analgesia to their rats and 40% for mice.  2 of 12 rats and 
1 of 4 mice survey respondents did not provide analgesia for invasive procedures.  One common 
argument against the use of analgesia is that although an analgesic agent could improve the analgesic 
properties of an anaesthetic regimen, this addition could lead to marked alterations in the 
physiological effects of an anaesthetic (Wilson et al., 1993).  There are some concerns that analgesic 
agents could potentially affect experimental outcomes, but it is usually possible for an investigator to 
be able to administer one of several classes of analgesic agents including opioids, non-steroidal anti-
inflammatory (NSAID) medications and local anaesthetics.  Also pain assessment in rodents can be 
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subjective and many behavioural markers for pain can be missed (Hawkins, 2002, Roughan and 
Flecknell, 2003b).  This variability in pain assessment methods could ultimately contribute to the lack 
of pain relief used for particular studies.   
 
Buprenorphine is the most commonly used rodent analgesic agent 
Survey results identified buprenorphine as the most frequently used analgesic agent for rats and mice, 
which is consistent with published data (Richardson and Flecknell, 2005).  Buprenorphine is an opioid 
partial agonist that has a high affinity for the μ receptor, and morphine-like agonist effects at low 
doses and minimal agonist effects at higher doses (Dum and Herz, 1981, Bishop, 2005, Bourque et al., 
2010).  This opioid possesses a ceiling effect for respiratory depression but not for its analgesic 
properties (Guarnieri et al., 2012).  Bupenorphine can be administered subcutaneously or orally in rats 
and mice (Liles and Flecknell, 1992a, Volker et al., 2000, Abelson et al., 2012) and has shown to be 
effective in treating multiple pain conditions including neuropathic pain (Guarnieri et al., 2012).  Pre-
anaesthetic subcutaneous (SC) administration of buprenorphine, during ketamine-medetomidine 
injectable anaesthesia, was associated with respiratory arrest and mortality in rats (Hedenqvist et al., 
2000).  In contrast, pre-anaesthetic or peri-anaesthetic buprenorphine followed by halothane 
anaesthesia improved food and water intake post surgically compared with that of control rats (Liles 
and Flecknell, 1993, Liles and Flecknell, 1994).  There is also evidence that opioid medication itself 
could potentially reduce the stress response associated with surgery and therefore there is a possibility 
that the effects of buprenorphine could be unrelated to pain (Liles and Flecknell, 1994).  Even though 
buprenorphine administration has associated complications, it appears to have become a prominent 
analgesic agent for laboratory rodents regardless of the varying opinions on its safety.   
 
NSAIDS provides an alternative analgesic agent to opioid drugs 
As a means of reducing opioid associated side effects, alternative analgesics such as the NSAID 
agents have been employed (Bourque et al., 2010, Roughan and Flecknell, 2003a).  The NSAID 
medications used by survey respondents were meloxicam and carprofen for rats but not mice.  
Meloxicam and carprofen are cyclo-oxygenase inhibitors that reduce inflammatory pain by reducing 
or stopping prostaglandin, prostacyclin and thromboxane production (Liles and Flecknell, 1992b).  
NSAID are sometimes considered weaker analgesic agents than opioid analgesic agents, but due to 
their anti-inflammatory actions, can suppress pain by reducing pain associated with an inflammatory 
reaction to surgery (Liles and Flecknell, 1992b, Liles and Flecknell, 1994).  In an analgesic study, 
meloxicam treated rats showed fewer signs of behavioural and physiological changes than 
buprenorphine treated rats following implantation of radiotelemetery devices (Bourque et al., 2010).  
There are however potential side effects to the use of NSAID, such as gastric ulceration and other 
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gastrointestinal complications (Engelhardt et al., 1995a, Engelhardt et al., 1995b, van der Vijver et al., 
2012), and these factors should be taken into account when determining the most effective analgesic 
agent for a particular surgical procedure.  
Paracetamol has no anti-inflammatory properties but at the correct doses can provide good analgesia 
(Liles and Flecknell, 1992b). 
 
Anaesthetic related mortality rates in laboratory rodents are not usually recorded 
Mortality rates for laboratory animal anaesthesia are frequently unpublished (Whelan and Flecknell, 
1992).  In contrast, anaesthetic mortality rates are frequently published in the veterinary and medical 
professions.  In veterinary practice, one study reported a 1 in 679 mortality rate in dogs and cats 
undergoing anaesthesia and another study recorded 48 in 3546 mortality due to anaesthetic related 
complications equating to approximately 1.4% (Whelan and Flecknell, 1992, Clarke and Hall, 1990, 
Bille et al., 2012).  Mortality rates as low as 1 in 10,000 was recorded in the medical field (Dyson et 
al., 1998).  In comparison, the Researchers’ attitude towards acceptable losses varies from 1.4% as 
unacceptable to 9% being considered low (Whelan and Flecknell, 1992).   Previously published data 
indicate that mice anaesthetised with ketamine-xylazine or ketamine-diazepam showed the higher 
mortality rate than pentobarbital and fentanyl in combination with droperidol (Wixson et al., 1987c).  
High doses of ketamine-xylazine combination given IP to mice above 99/13.2mg.kg
-1
 and rats above 
80/12mg.kg
-1
 caused significant mortality (Smith, 1993).  This high mortality rate is consistent with 
findings from other investigators where significant mortalities were noticed with the ketamine-
xylazine drug combination (Arras et al., 2001, Wixson et al., 1987a).  
 
In contrast to laboratory mice, the inclusion of ketamine for use in dog and cat anaesthesia was 
associated with lower than expected complication rates and possibly due to the sympathetic 
stimulation by ketamine (Dyson et al., 1998).  50% of rat and 41.7% of mice survey respondents did 
not respond to the question regarding their experience with anaesthetic-related mortality rate.  This 
low response rate could be interpreted in several ways.  It is possible that the survey respondents did 
not experience any mortality with their anaesthetic protocol or they were unwilling to respond to this 
question.  The majority of participants that did not respond used inhalation anaesthesia, which is has 
been shown to have fewer complications and possibly considered the safer route of anaesthetic 
delivery.  Poor peri-operative care due to inadequately trained anaesthetic administrators could be a 
major contributor to mortality rates indicated in this survey (Flecknell, 1993b).  Hypothermia due to 
rapid temperature loss could contribute to high mortality rates (Wixson et al., 1987c). 
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Drug restrictions do not determine anaesthetic regimen 
The Health (Drugs and Poisons) Regulation 1996 tightly controls the use of schedule 8 (controlled 
drugs) drugs of addiction in Australia, therefore increasing the difficulty in obtaining pain relief 
medication such as buprenorphine as well as anaesthetic agents like ketamine.  Even with these 
restrictions, only 10% of survey respondents chose an alternative anaesthetic protocol because of 
these restrictions. This could be in part due to the increase in animal welfare requirements for 
analgesic agents such as opioids.  It is likely that many larger research institutions would have access 
to an authorised person legally able to obtain, store and dispense restricted medications to research 
staff.  With these findings, it would seem that researchers have more freedom for choice of 
anaesthesia and analgesia protocols than previously speculated. 
 
The rodent anaesthetic survey identified several commonly chosen anaesthetic combinations, 
analgesic agents and with them their associated anaesthetic complications.  The results from the 
survey show that there is a need for increased anaesthetic training for investigators.  At present, only a 
limited number of anaesthetic agents are being utilised and it appears that these few anaesthetic 
protocols are still accompanied by a relatively high number of complications. Therefore it is prudent 
to find a simple and safe anaesthetic protocol for rats and mice that provides a wide margin of safety 
to ultimately reduce anaesthetic related complications and death.  We believe that alfaxalone 
anaesthesia could possibly fill this gap and provide a safer and easy alternative laboratory rodent 
anaesthetic to currently available anaesthetic agents. 
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CHAPTER TWO 
 
 
INTRODUCTION TO PUBLISHED PAPER 
Pilot Study – Determination of alfaxalone concentration 
In laboratory rodents, it is not routine to perform anaesthesia via the intravenous route.  This is 
technically difficult in rats and can only be performed by highly trained individuals.  Therefore it is 
important to determine whether other routes of alfaxalone anaesthetic administration are feasible. 
Results from the rodent anaesthetic survey showed that the most commonly used route of injection in 
laboratory rodents is by intraperitoneal injection.  This route offers ease of administration requiring 
only simple equipment and minimal handling expertise (Flecknell, 1993b).  A pilot experiment was 
constructed to compare the intraperitoneal, intramuscular and subcutaneous dosing regimen for 
alfaxalone.   
 
Alfaxalone pilot study - 10 mg.kg
-1
 IM, SC & IP 
Personal communication with Jurox Pty Ltd, the manufacturer of Alfaxan®, identified anecdotally 
that premedication with 2-3 mg.kg
-1
 xylazine followed by 10-11 mg.kg
-1
 Alfaxan® provided adequate 
anaesthesia for rats.  Therefore the starting dose for used in this study was 10 mg.kg
-1
 alfaxalone to 
provide baseline data.  Five adult female Wistar rats weighing 135-157g were each given an IM, SC 
and IP dose of 10 mg.kg
-1
 alfaxalone (Appendix 2.1).  A period of at least 48 hours was allowed 
between anaesthetic routes to ensure alfaxalone was washed out from previous administration.  IM 
injections were performed in the right quadriceps femoris muscle (Chellman et al., 1994), SC 
injections were administered into the loose skin on the right dorsal flank and IP injections were given 
in the left lower quadrant of the ventral abdominal cavity (Smiler et al., 1990).  The induction time 
was recorded as the time from anaesthetic administration to when rats lost their ability to maintain 
sternal recumbency.  Immobilisation time was calculated as the total time from induction to return of 
sternal recumbency.  The twitching score was developed in an attempt to quantitatively assess the 
degree of twitching observed with each anaesthetic (Table 2.0).   
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Twitch Score 
   Description 
None  
(- or 0) 
   Relaxed body position 
   No spasmodic movements 
  
Mild  
(+ or 1) 
   Short-lived minor muscle contractions 
   Relaxed body position 
   Localised to the facial region or extremities 
Moderate  
(++ or 2) 
   Short-lived minor muscle contractions 
   Multiple regions affected at one time 
   Increased muscle tone 
Severe  
(+++ or 3) 
   Full body pronounced muscle contractions 
   Increased muscle tone 
   Marked startle response to auditory or physical stimulus 
 
Table 2.0.  A descriptive and quantitative measurement for twitching 
Twitching was categorised into three categories, where each category shows increasing levels of 
neuro-excitation  
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Alfaxalone administration – 10 mg.kg-1 IM 
The IM route showed the most consistency in inducing anaesthesia, with all five rats injected with 
alfaxalone showing an induction time of 2-4 minutes.  Four of the five rats attained immobilisation for 
7-13 minutes, and these same four rats twitched during this time.  The twitch was seen as either a full 
body or facial twitch and all were allocated a twitch score of 2 (Table 2.0).    
 
Alfaxalone administration – 10 mg.kg-1 SC 
Three out of five rats showed an induction time of four minutes after the SC injection of alfaxalone.  
Immobilisation time, however, was very short for these rats and only lasted 1-4 minutes.  The 
remaining two rats were not anaesthetised and did not lose their righting reflex.  A twitch score of 1 
was observed in two rats, one of which was not anaesthetised.   
 
Alfaxalone administration – 10 mg.kg-1 IP  
Only one of the five rats achieved anaesthetic induction, and the time to induction was long at 10 
minutes.  This rat was immobilised for two minutes, in which only lateral recumbency was allowed.  
The remaining 4 rats were not anaesthetised.  They appeared sedated and remained responsive to 
physical and auditory stimulation.  Twitching was not observed in any rats receiving IP dosing. 
 
10 mg.kg
-1
 alfaxalone IM, SC or IP  
IM appeared to be the most effect route of alfaxalone administration.  This was the only route that 
achieved anaesthetic immobilisation in all rats dosed, albeit short.  SC alfaxalone was able to induce 
three of the five rats for anaesthesia, but immobilisation time was too short to allow for any 
procedures to be performed.  IP alfaxalone at10 mg.kg
-1
 could not be considered an anaesthetic agent, 
as merely sedation was achieved.  This could be attributed to the first pass elimination of alfaxalone 
through hepatic metabolism after IP dosing (Lukas et al., 1971).  Twitching was most apparent with 
IM alfaxalone and was not observed with IP alfaxalone.   
 
It was obvious that 10 mg.kg
-1 
alfaxalone did not produce adequate anaesthesia via any route.  IM 
alfaxalone appeared promising, however the immobilisation times achieved were short.  We therefore 
decided to increase the alfaxalone dose to 20 mg.kg
-1
.  IP administration at 20 mg.kg
-1
 was shown in 
our pharmacokinetic data to produce sustained plasma alfaxalone levels up to 60 minutes.  The IM 
route was discontinued at this dose, due to the increased injection volume.  Large volumes 
administered IM is difficult in practice and appears to cause more pain than injections at other sites; it 
has even been suggested that this route not be used in smaller mammals, including rodents (Morton et 
al., 2001).  Therefore only IP and SC routes were investigated further at 20 mg.kg
-1
 alfaxalone.   
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Alfaxalone pilot study – 20 mg.kg-1 SC & IP 
For the SC study, female Wistar rats weighing 156-195g (n=8), were given a single 20 mg.kg
-1
 SC 
dose of alfaxalone.  For the IP study, female Wistar rats at a starting weight of 155-205g (n=4), were 
given 20 mg.kg
-1
 IP once weekly for 2-4 consecutive weeks.   
 
Alfaxalone administration – 20 mg.kg-1 SC 
Induction times were variable and ranged between 4-21 minutes.  Two of eight rats were not 
anaesthetised and therefore did not achieve anaesthetic induction or immobilisation.  Immobilisation 
times also varied and ranged from 2-40 minutes (Appendix 2.3.).  Twitching occurred in three of eight 
rats with twitch scores ranging from 1-3.   
 
Alfaxalone administration – 20 mg.kg-1 IP 
Anaesthetised rats produced induction and immobilisation times ranging from 2-6 minutes and 31-58 
minutes respectively. However, on three occasions and in three different rats, anaesthesia was not 
achieved.  These data therefore showed that 75% of rats achieved immobilisation and the remaining 
25% were not anaesthetically induced (Appendix 2.2).   In addition, moderate to severe twitching was 
apparent in all rats that were immobilised.   
 
Overall, it appeared that the increased alfaxalone dose was more promising.  20 mg.kg
-1
 alfaxalone 
was much more effective as an anaesthetic than 10 mg.kg
-1
 alfaxalone.  However, as anaesthesia was 
not achieved in all rats, and the variation in anaesthetic time for the SC route was prevalent, an 
increase in alfaxalone dose to 30 mg.kg
-1
 was investigated. 
 
Alfaxalone pilot study – 30 mg.kg-1 SC & IP 
Female Wistar rats (n=3) weighing 182-195g were giving a single dose of alfaxalone SC at  
30 mg.kg
-1
.  30 mg.kg
-1
 IP was administered to male Sprague Dawley rats, weighing 160-220g 
(n=14).   
 
Alfaxalone administration – 30 mg.kg-1 SC 
Two out of three rats achieved anaesthetic induction within 3-5 minutes.  The last rat however took 20 
minutes before the righting reflex was lost.  These animals showed a range of 3-20 minutes for 
induction.  Immobilisation times ranged from 39-83 minutes.  Twitching occurred in all three rats, 
with two rats twitching severely (Appendix 2.3).   
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Alfaxalone administration – 30 mg.kg-1 IP 
Eleven of fourteen rats achieved anaesthetic induction within 2-4 minutes of alfaxalone 
administration.  Three of fourteen rats did not lose their righting reflex and therefore were not induced 
for anaesthesia.  Of the anaesthetised rats, immobilisation time ranged from 7-33 minutes.  The 
incidence in twitching appeared markedly reduced, and were observed in five of fourteen rats been 
rated as mild in the majority of these (Appendix 2.4).  
 
Alfaxalone administration – IM route  
A starting dose of 10 mg.kg
-1
 alfaxalone was administered.  Of the three routes examined, IM 
appeared the most promising with all five rats immobilised by this route.  Unfortunately, increased IM 
dose rates were not practical, as the injection volume necessary was prohibitive.  Increased injection 
volume following an IM dose could lead to acute pain-on-injection as well as delayed pain associated 
with deep tissue trauma (Chellman et al., 1994).  Rats given an injection volume of 0.16-0.47mL 
ketamine-xylazine developed gross and microscopic lesions following IM injection, likely causing 
post-anaesthetic pain and discomfort for at least two weeks (Smiler et al., 1990).  Alfaxan® 
preparation is within a physiological pH of 6.5-7.0 and therefore should be less irritating for IM 
injections.  However, it was shown that a large injection volume will physically distend the muscle, 
leading to swelling at the injection site and, ultimately, muscle damage and pain (Morton et al., 2001).  
Also, isotonic solutions of saline administered IM to Sprague Dawley rats at 0.04mL caused myocyte 
degeneration in the right hind leg musculature and necrosis with histiocytic infiltration from one day 
post injection (Barrueto et al., 2002).  In this study, post-anaesthetic discomfort cannot be ruled out as 
histopathological examination of the lateral femoral muscles were not examined. It is recommended 
that the IM route for injections be used only if an alternative route of administration is not possible 
(Morton et al., 2001).   
 
Alfaxalone administration – SC route 
The SC route of anaesthesia showed vast variability in induction times at all doses examined.  
Through our pilot study trials, the induction times appeared more consistent at 10 mg.kg
-1
, with three 
of five rats achieving anaesthetic induction within four minutes, however at the higher doses, an 
induction time variation of 4-21 minutes was seen with 20 mg.kg
-1
 and 3-20 minutes at 30 mg.kg
-1
.  
Due to this variability, the SC route was ruled out as a viable alternative option to IV alfaxalone 
administration. 
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Alfaxalone administration – IP route 
The administration of 10 mg.kg
-1
 alfaxalone IP was not effective at providing anaesthesia, as several 
rats were not even induced for anaesthesia.  Only one in five rats even developed recumbency and the 
period to which they were immobilised was short.  Following 20 mg.kg
-1
 IP alfaxalone, rats displayed 
more consistent induction and immobilisation times than that produced from the lower dose, but still 
25% rats were not anaesthetised.  Additionally an appreciably high frequency of twitching was 
observed with this dose of alfaxalone (Appendix 2.2).  11 of 14 rats were anaesthetised with 30 
mg.kg
-1
 IP alfaxalone, producing short immobilisation times of between seven and 33 minutes.  The 
increase in dosing rate to 30 mg.kg
-1
 was performed with male Sprague Dawley rats (due to 
availability),  in contrast to the other studies, which were performed in female Wistar rats   Therefore, 
a direct comparison between IP doses of alfaxalone at 20 mg.kg
-1
 and 30 mg.kg
-1
 was not made due to 
the strain and sex differences in rats.  However, Wistar and Sprague Dawley rats are outbred rat 
strains, both more variable than isogenic inbred rats (Festing, 1993).  Additionally no published sex 
differences have been reported in other species with the use of Alfaxan® (Ferre et al., 2006, Goodwin 
et al., 2011).   
 
The increase in alfaxalone dose to 30 mg.kg
-1
 SC did not appear to improve induction times however 
immobilisation time was increased.  Twitching was severe in two of the three rats administered this 
dose of alfaxalone SC.  As for IP alfaxalone, induction times were consistent, but immobilisation 
times were shorter.  Twitching was severe in one rat given IP alfaxalone.   We observed no 
detrimental effects from a three fold increase in alfaxalone dose from 10 mg.kg
-1
 to 30 mg.kg
-1
 to rats 
other than twitching, highlighting the large safety margin alfaxalone possesses.  The preliminary data 
showed the IP dose of 20mg.kg
-1
 was most effective at producing immobilisation and therefore was 
chosen for pharmacokinetic investigation.  
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Abstract 
Alfaxalone (3α-hydroxy-5α-pregnane-11, 20-dione) is a neuroactive steroid with anaesthetic 
properties and a wide margin of safety. The pharmacokinetic properties of alfaxalone administered 
intravenously and intraperitoneally in rats (n=28) were investigated.  Mean T1/2elim for 2 and 5 mg.kg
-1
 
IV was 16.2 and 17.6 min respectively, but could not be estimated for IP dosing, due to sustained 
plasma levels for up to 60 minutes after injection.   Clp for IV injection was calculated at 57.8  23.6 
and 54.3   6.8 mL.min-1.kg-1 , which were 24.5% and 23% of cardiac output respectively.  The 
observed Cmax was 3.0 mg.L
-1
 for IP administration, and 2.2 ± 0.9 and 5.2 ± 1.3 mg.L
-1
 for 2 and 5 
mg.kg
-1
 IV administration respectively.  AUC0-60  was 96.2 min.mg.L
-1
 for IP dosing.  The relative 
bioavailability for IP dosing was 26% and 28% compared to IV dosing.  Differences in t1/2elim and Clp 
from previous pharmacokinetic studies in rats are likely due to variations in alfaxalone formulation 
rather than sex differences.  Alfaxan® given IP caused sustained levels of alfaxalone, no apnoea and 
longer sleep times than IV dosing, although immobilization was not induced in 30% of rats given 
Alfaxan® IP.  A pharmacodynamic study of the effects of combining IP injection of Alfaxan® with 
other premedication agents is worthwhile, to determine whether improved anaesthesia induction could 
ultimately provide an alternative anaesthetic regimen for rats.   
 
Keywords 
Alfaxalone, rat, pharmacokinetics, intraperitoneal, anaesthesia
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Alfaxalone (3α-hydroxy-5α-pregnane-11, 20-dione) is a neuroactive steroid with anaesthetic 
properties due to its positive allosteric modulation of the gamma aminobutyric acid type A (GABAA) 
receptor (Visser et al., 2000). Alfaxalone solubilised with the exipient 2-hydroxypropyl-β-
cyclodextrin (HPCD) is available as Alfaxan® (Jurox Pty Ltd, Rutherford, NSW, Australia), which is 
registered for the induction and maintenance of anaesthetic in both dogs and cats in multiple 
countries. Studies have shown that intravenous Alfaxan® provides satisfactory induction of 
anaesthesia in dogs (Ferre et al., 2006), cats (Zaki et al., 2009), horses and pigs (Keates, 2003, 
Goodwin et al., 2011, Goodwin et al., 2012, Whittem et al., 2008), with a five-fold margin of safety at 
supraclinical doses in dogs (Ferre et al., 2006, Muir et al., 2008) and cats (Whittem et al., 2008). The 
pharmacokinetic parameters of alfaxalone have been defined in cats (single/multiple doses), dogs 
(single dose) and horses (single dose) (Ferre et al., 2006, Goodwin et al., 2011, Pasloske et al., 2009, 
Goodwin et al., 2012, Whittem et al., 2008).   
 
Rodents are commonly anaesthetised for veterinary and biomedical research purposes with  a single 
intraperitoneal (IP) injection.  While IP injection is technically simple and requires minimal animal 
restraint, a single dose of anaesthetic can lead to highly variable anaesthetic effects (Flecknell, 1993a).  
Therefore it is important for an injectable agent to have a wide margin of safety to account for 
variation in anaesthetic responses between individuals. Alfaxalone has been investigated in rats in 
varying formulations including acetonitrile (Visser et al., 2000) and the alfaxalone/alfadalone 
combination for humans (Althesin®) and animals (Saffan®), equivalent to 9 mg.mL
-1
 alfaxalone in 
the solvent Cremaphor EL (Child et al., 1972).  As yet no work has been performed in rodents with 
the commercially available formulation Alfaxan®, which is devoid of alfadolone and Cremophor EL.  
In this study, we investigated the single dose pharmacokinetics of alfaxalone, administered 
intravenously or intraperitoneally as Alfaxan® in rats.   
 
All experiments were performed after approval by the University of Queensland Animal Ethics 
Committee (Approval number: 301/10). Adult female Wistar rats (7-10 weeks, 244.2  39.4 g, n = 28) 
housed in a barrier maintained animal facility with a 12/12 hr light/dark cycle and fed standard rat 
pellets and water ad libitum were used.  For IP dosing, a single injection (20 mg.kg
-1
, n=18) of 
Alfaxan® (Batch # 60091) was administered intraperitoneally into the right lower quadrant of the 
ventral abdomen. Serial blood samples collected from a cut on the tail tip were taken from 10 rats at 4, 
6, 10, 15, 20, 30, 45 and 60 minutes post-injection; samples were not collected from all 10 rats at all 
times, due to variability in time to recovery from immobilization (Table 2.1) or failure to collect a 
sufficient volume of blood at different time points.  A single intracardiac blood sample was collected 
at one of these times post-injection in another 8 rats following termination.  This sampling 
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collectively gave sample times of 4, 6, 10, 15, 20, 30, 45 and 60 minutes with varying numbers of 
animals sampled per time point for IP injection (see Figure 2.1 for number of animals sampled per 
time point).  
For IV dosing, an indwelling IV catheter (polyethylene tubing 50 mm length, 0.50 mm OD, 0.20 mm 
ID) was introduced into the femoral vein, following anaesthesia with isoflurane gas using a Tec 3 
isoflurane vapouriser attached to a rodent circuit and size 1, 6.0cm anaesthetic face mask (all from 
Vetquip, Castle Hill, NSW, Australia). The catheter was fixed to the skin with cyanoacrylate 
adhesive.  Rats recovered from isoflurane anaesthesia for 30 – 60 minutes post-implantation prior to 
IV dosing.  Alfaxan® (Batch # 60091), diluted to 1 mg.mL
-1
 with sterile water for injection 
(Norbrook®, Tullamarine, Vic, Australia) was administered by slow, continuous IV infusion over 60 
seconds (2 mg.kg
-1
, n=5; 5 mg.kg
-1
, n=5).   
For all animals, the time from injection to immobilization (failure of the rat to right itself from lateral 
or dorsal recumbency) and to recovery (the time at which sternal recumbency was restored) were 
recorded as induction and recovery times respectively, and the difference between these times was 
calculated as sleep time.  Tail tip blood samples (maximum volume 200 μL, maximum total volume 
1.6 mL) were collected from each rat at 2, 4, 6, 10, 15, 20, 30, 45 and 60 minutes, and immediately 
placed onto wet ice, then centrifuged (4000g, 10 min) within an hour of collection.  The minimum 
effective concentration (MEC) for immobilization was empirically determined by interpolation 
between plasma concentration before and after the time of recovery from immobilization.  Plasma 
samples were kept frozen at -80 ±10˚C during storage and transport to the Jurox Chemistry 
Laboratory until analysis. All plasma samples were analysed individually (Ferre et al., 2006, Pasloske 
et al., 2009, Whittem et al., 2008).   
Alfaxalone Analysis 
Plasma samples underwent solid phase extraction (25-50 μL sample volume), followed by liquid 
chromatography-mass spectrometry (10 μL sample volume) over a 24 hour period in the same 
analytical run using previously described methods (Goodwin et al., 2012).  A calibration curve was 
generated using a standard sample set prepared by spiking known amounts of 11-
hydroxyprogesterone as the internal standard and alfaxalone (2 linear standard curves covering 0.02 – 
0.5 mg.L
-1
 and 0.5 – 5 mg.L-1, r2 > 0.99 for both segments)/ into extracted blank rat plasma. Sample 
alfaxalone concentration was determined by the alfaxalone;11-hydroxyprogesterone peak area ratio.  
The assay lower limit of quantification (LLOQ) was 0.02 mg.L
-1
 in extracted plasma.  
The intra-assay coefficient of variation at LLOQ was <18.5% and <11.0% for other concentration 
levels. The limit of detection (LOD) was 0.002 mg.L
-1
.  Sample extraction recoveries were >86 % for 
all concentration levels.  Both accuracy and precision were acceptable if residual standard deviation 
(RSD) was ±<20% at LLOQ and ±<15% for other concentrations.  Due to variations in the number of 
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samples per sample time obtained from rats receiving IP injection, data analysis was performed on 
pooled data for each time point following IP injection, while data from rats receiving IV injections 
was analysed for each animal individually (Whittem et al., 2008, Ferre et al., 2006, Pasloske et al., 
2009).   
Pharmacokinetic analysis was carried out using non-compartmental methods in Phoenix® 
WinNonLin® v 6.3 (Pharsight Products, Sunnyvale CA, USA) as previously described (Goodwin et 
al., 2012).  The area under the curve (AUC) from time of administration to the last blood sample 
(AUC0-last) was calculated with the linear trapezoidal rule (Gibaldi, 1982).  The terminal slope of the 
curve (λz), estimated by linear regression of ≥ 3 data points using the best fit function, was 
extrapolated to calculate the total AUC from administration time to infinity (AUC0-inf)  as AUC0-last + 
the extrapolated AUC.  The % AUC extrapolated from the last sample time (AUCextrap%) was 
calculated as the the extrapolated AUC ÷ AUC0-inf × 100%. The plasma clearance (Clp), volume of 
distribution (VD) and elimination half-life (t1/2elim) were calculated using standard non-compartmental 
formulae.  For concentration parameters, a best-fit approach was utilised where repeated non-linear 
regressions were used for a series of terminal points. For each regression, an adjusted R
2
 was 
computed with: 
Adjusted R
2 
= 1 – ( 1 - R2 ) x ( n  -1 ) 
         ( n – 2 ) 
where n are the number of data points in the regression and R
2 
 is the square of the correlation 
coefficient. The relative bioavailability (F%) for IP dosing compared to IV dosing was calculated 
with: 
F% =  AUC (IP route)     x Dose (IV)   x  100  
 AUC (IV route) Dose (IP)  
 
(Toutain and Bousquet-Melou, 2004a).  All data are expressed as mean ± SD.   
 
The level of anaesthesia achieved by alfaxalone was not tested by evaluating reflex responses or 
making serial cardiorespiratory measurements. However, a brief description of the immobilization 
achieved is useful; in particular to note that anaesthesia was sufficient to allow repeated blood 
sampling from a tail tip cut, which involved manual massage of the tail to expel blood from the 
wound.  Apnoea, lasting 95-170 sec, occurred in 2 of 5 rats at 2 mg.kg
-1
 IV and 4 of 5 rats at 5 mg.kg 
-
1
 IV dosing, followed by recovery of spontaneous breathing. The mean sleep times for rats given 2 
and 5 mg.kg
-1
 IV were 10.4 ± 6.6 and 12.6 ± 3.3 min, respectively, which were not significantly 
different (P = 0.52, unpaired two tailed t test).  In contrast, after IP dosing, immobilization was not 
induced in 3 of 10 rats, but no apnoea was observed (Table 2.1). The mean sleep time for all rats 
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given 20 mg.kg
-1
 IP was 29.6 ± 21.4 min, which was not significantly longer than for either IV dose 
(P > 0.05, unpaired two tailed t test); excluding rats in which no immobilization was induced, mean 
sleep time was 42.3  7.8 min, which was significantly longer than for either IV dose (P < 0.0001, 
unpaired two tailed t test).   
Animals which did not become immobilized had plasma concentrations of alfaxalone in the lower end 
of the range (0.58-0.78 mg.L
-1
) at 4 minutes after injection; animals which did show immobilization 
had similar or higher plasma alfaxalone levels at 4 minutes (range 0.47-3.78 mg.L
-1
).  As all animals 
given alfaxalone IV showed immobilization, we suggest that variable absorption from the site of IP 
injection are the most likely cause for lack of immobilization. The mean MEC for immobilization of 
rats receiving 2 or 5 mg.kg
-1
 IV was 1.5  0.8 and 2.1  0.4 mg.L-1, respectively (Figure 2.1); and was 
estimated from pooled data to be 1.9 mg.L
-1
 for IP dosing.  IP injection caused muscular twitching in 
8 rats during induction and 7 rats on recovery, with 6 rats twitching during both induction and 
recovery. Mild facial twitching occurred in 2 rats with 2 mg.kg
-1
 IV alfaxalone.  Mean t1/2elim for 2 and 
5 mg.kg
-1
 IV were similar (16.2  9.2 and 17.6  3.2 min respectively) as was the mean Clp (57.8  
23.6 and 54.3   6.8 mL.min-1.kg-1 respectively; Table 2.2).    
To facilitate comparison of Clp between species, Clp was calculated at 24.5% and 23% of cardiac 
output respectively (Toutain and Bousquet-Melou, 2004b).  The mean Clp in rats following IV 
injection was similar to that reported for the dog (53 and 59. mL.kg
-
1.min
-1
 for 2 and 10 mg.kg
-1
 
(Ferre et al., 2006)), but was larger than the mean Clp reported for cats, horses and foals with (25, 37 
and 20 mL.min
-
1.kg
-1
, for 5, 1 and 3 mg.kg
-1
 IV respectively (Goodwin et al., 2011, Goodwin et al., 
2012, Whittem et al., 2008)  In contrast to the high Clp  of alfaxalone following IV injection, sampling 
times of ≤60 min were not adequate to reliably determine alfaxalone Clp  following IP dosing (Figure 
2.1).   
We observed a Cmax of 2.99 mg.L
-1
 at 10 minutes after IP administration, a value between the Cmax  of 
2.2 ± 0.9 and 5.2 ± 1.3 mg.L
-1
 for 2 and 5 mg.kg
-1
 IV respectively; by comparison, the Cmax seen in 
dogs following 2 mg.kg-1 IV was similar (Ferre et al., 2006).  In contrast, IP dosing led to sustained 
alfaxalone plasma levels, with an AUC0-last of 96.2 min.mg.L
-1
, in comparison to AUC0-last of 36.9 and 
86.7 for 2 and 5 mg.kg
-1
 IV respectively.  Sustained plasma alfaxalone levels are the most likely cause 
of longer sleep times following IP injection (Fink et al., 1982), compared with IV administration.  The 
relative bioavailability for 20 mg.kg
-1
 alfaxalone given IP was 26% and 28%, compared to the 2 and 5 
mg.kg
-1
 doses given IV respectively.  This low bioavailability via the IP route is consistent with high 
first pass elimination of alfaxalone through hepatic metabolism (Sear and McGivan, 1981, Novelli et 
al., 1975, Child et al., 1972) after IP injection, which predominantly enters the portal circulation 
(Lukas et al., 1971).  The t1/2elim of 16-17 minutes for the IV doses in our study using adult female 
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Wistar rats is longer than for male Charles River rats (Child et al., 1972) or for male Wistar rats 
(Visser et al., 2000) (7 minutes for ≈ 9 mg.kg-1 alfaxalone as Althesin® IV and 13 minutes for 5 
mg.kg
-1
 alfaxalone in acetonitrile IV respectively).  The longer t1/2elim observed in our study is 
consistent with the lower Clp we observed, in comparison to a Clp of 71mL.min
-
1.kg
-1 
(Visser et al., 
2000).  While sex could account for differences in t1/2elim and Clp in our and other pharmacokinetic 
studies in rat, and female Wistar rats had a 64% higher Cmax than males after IP administration of 
Althesin® (Fink et al., 1982), the pharmacokinetics of alfaxalone given IV are reported to be similar 
in male and female dogs (Ferre et al., 2006) and cats (Whittem et al., 2008). Methodological 
differences in analysis of plasma alfaxalone between older (Child et al., 1972, Fink et al., 1982) and 
more recent (Visser et al., 2000) studies could contribute to the differences between our observations 
and previous reports; however, both methodologies produce t1/2elim values lower than our 
observations.   
Variation in alfaxalone formulation is therefore the more likely cause of differences in the 
pharmacokinetics of alfaxalone in rats.  Alfaxan® given IP produced some attractive anaesthetic 
qualities, including sustained plasma levels of alfaxalone, absence of apnoea and longer sleep times, 
compared to IV dosing. However, immobilization was not induced in 30%  of rats given Alfaxan® IP, 
possibly related to the lower initial plasma concentrations observed in these animals,  and muscle 
twitching was frequently observed.  A pharmacodynamic study of the effects of combining IP 
injection of Alfaxan® with other premedication agents would be useful, to determine whether this 
would reliably improve anaesthesia induction rates and reduce muscle twitching, and thus provide an 
alternative anaesthetic regimen for rats with a wide margin of safety.   
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Observed Cmax: the peak plasma drug concentration for each IV dosing and mean peak plasma 
concentration for IP dosing.   
MEC: Minimum effective concentration, the minimum plasma concentration to maintain 
immobilization.  
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Table 2.1.  Various pharmacodynamic parameters for Individual adult Wistar rats 
administered an injection of Alfaxan® (Jurox Pty Ltd, Australia) at 2mg.kg
-1
 and 5mg.kg
-1
 IV, 
and  20mg.kg
-1
 IP. 
Rat ID Induction time sleep time apnoea twitch on induction  twitch on recovery 
2 mg*kg-1IV (sec) (min) (sec) (y/n) (y/n) 
Rat 4.3 20 22 100 n n 
Rat 5.3 10 7 170 n n 
Rat 6.3 60 8 0 n n 
Rat 7.3 40 6 0 n y 
Rat 12.3 60 9 0 n y 
mean 38 10.4 54     
SD 22.8 6.6 78.0     
Range 10 to 60 6 to 22 0-170 no twitching 1 of 5 twitched 
      
Rat ID Induction time sleep time apnoea twitch on induction  twitch on recovery 
5 mg*kg-1IV (sec) (min) (sec) (y/n) (y/n) 
Rat 8.3 60 9 95 n n 
Rat 9.3 27 18 108 n n 
Rat 10.3 20 12 100 n n 
Rat 11.3 12 12 113 n n 
Rat 13.3 60 12 0 n n 
mean 35.8 12.6 83.2     
SD 22.7 3.3 47.0     
Range 12 to 60 9 to 12 0 to 113 no twitching no twitching 
      
Rat ID Induction time sleep time apnoea twitch on induction  twitch on recovery 
20 mg*kg-1IP (min) (min) (sec) (y/n) (y/n) 
Rat 1 5 35 0 y n 
Rat 2 2 58 0 y y 
Rat 3 3 40 0 y y 
Rat 4 4 35 0 n y 
Rat 5 3 41 0 y n 
Rat 6 4 45 0 y y 
Rat 7 not induced 0 0 y y 
Rat 8 not induced 0 0 n n 
Rat 9 6 42 0 y y 
Rat 10 not induced 0 0 y y 
mean 3.9 29.6 0     
SD 1.3 21.4 0     
Range 3 to 6  0 to 58 0 8 of 10 twitched 7 of 10 twitched 
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Table 2.2. Pharmacokinetic parameters for ten adult Wistar rats after administration of a 60 
sec ‘bolus’ injection of Alfaxan® (Jurox Pty Ltd, Australia) at 2mg.kg-1 and 5mg.kg-1. 
Rat ID t 1/2elim Cl  VZ  AUC0-last  AUC 0-inf  AUC %  Cmax observed Cmax0extrap 
2 mg*kg-1IV (min) (mL*min-1*kg-1) (L*kg-1) (min*mg*L-1) (min*mg*L-1) extrap (mg*L-1) (mg*L-1) 
Rat 4.3 10.4 68.8 1.0 28.2 29.1 3.0 2.491 3.148 
Rat 5.3 11.9 38.9 0.7 50.1 51.4 2.5 2.562 2.676 
Rat 6.3 14.6 90.3 1.9 20.2 22.1 8.8 1.402 2.236 
Rat 7.3 32.5 59.2 2.8 25.2 33.8 25.3 1.216 1.342 
Rat 12.3 11.8 31.7 0.5 60.9 63.1 3.4 3.366 3.679 
mean 16.2 57.8 1.4 36.9 39.9 8.6 2.207 2.616 
SD 9.2 23.6 0.9 17.6 16.9 9.7 0.892 0.892 
Range 10.4-32.5 31.7-90.3 0.5-2.8 20.2-60.9 22.1-63.1 2.5-25.3 1.2-3.4 1.3-3.7 
         
Rat ID t 1/2elim Cl  VZ  AUC0-last  AUC 0-inf  AUC %  Cmax observed Cmax0extrap 
5 mg*kg-1IV (min) (mL*min-1*kg-1) (L*kg-1) (min*mg*L-1) (min*mg*L-1) extrap (mg*L-1) (mg*L-1) 
Rat 8.3 17.8 53.9 1.4 86.3 92.8 7.0 5.578 6.940 
Rat 9.3 15.0 48.8 1.1 98.3 102.5 4.2 6.607 7.380 
Rat 10.3 15.8 47.2 1.1 100.9 105.9 4.7 6.224 5.730 
Rat 11.3 16.7 63.9 1.5 72.9 78.3 6.9 4.207 5.404 
Rat 13.3 23.0 57.6 1.9 75.3 86.8 13.2 3.528 3.427 
mean 17.6 54.3 1.4 86.7 93.3 7.2 5.229 5.776 
SD 3.2 6.8 0.4 12.8 11.3 3.6 1.318 1.548 
Range 15.0-23.0 47.2-63.9 1.1-1.9 72.9-100.9 78.3-105.9 4.2-13.2 3.5-6.6 3.4-7.4 
         
Rat ID t 1/2elim Cl  VZ  AUC0-last  AUC 0-inf  AUC %  Cmax observed  Cmax0extrap 
20 mg*kg-1IP (min) (mL*min-1*kg-1) (L*kg-1) (min*mg*L-1) (min*mg*L-1) extrap (mg*L-1) (mg*L-1) 
Pooled NA NA NA 96.195 NA NA 2.99 NA 
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Figure 2.1.  Plasma alfaxalone concentration over time in rats administered Alfaxan® at 2 
mg.kg
-1
 IV, 5 mg.kg
-1
 IV and 20 mg.kg
-1
 IP doses.  Data are mean ± SD.  As data for IP injection is 
derived from different subsets of animals at different sample times (number of animals contributing to 
each sample time are indicated in parentheses next to the sample time), the symbols are not 
connected.  The mean MEC for each IV dose, defined as the mean minimum plasma alfaxalone 
concentration required to maintain immobilisation, was calculated by extrapolating the plasma 
concentrations at the time of recovery from immobilization from individual plasma concentrations, 
and is presented as a mean, indicated by the dashed lines on the graph. 
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CHAPTER THREE 
 
The use of premedication agents with alfaxalone anaesthesia for laboratory rats 
 
Abstract 
The rodent anaesthetic survey showed that the availability of a safe and reliable injectable anaesthetic 
is limited for laboratory rats.  Although there is an increase in inhalation anaesthetic use, injectable 
anaesthesia is still a common anaesthetic delivery method.  Currently available injectable anaesthetic 
agents such as ketamine-xylazine were associated with respiratory depression, hypotension, diuresis 
and prolonged recoveries (Green et al., 1981, Flecknell, 1993b).  Alfaxalone has been successfully 
used in cats and dogs in veterinary medicine and this success could potentially be translated for 
laboratory rodent use.  Intravenous (IV) and intraperitoneal (IP) alfaxalone pharmacokinetic data 
showed that alfaxalone could potentially be a viable anaesthetic alternative.  Pilot data showed that 
administration of alfaxalone alone produced neuro-excitation, commonly termed twitching, in many 
rats.   
The main study assessed the IP administration of alfaxalone in conjunction with four premedication 
combinations to abolish the incidence and severity of twitching.  Medetomidine (0.5mg.kg
-1
), 
medetomidine-butorphanol (0.35mg.kg
-1 
-0.2mg.kg
-1
), ACP-methadone (3mg.kg
-1 
-0.7mg.kg
-1
) and 
ACP-xylazine (3mg.kg
-1 
-3mg.kg
-1
) was injected IP at T = -10 minutes, followed by IP alfaxalone 
(20mg.kg
-1
, T = 0).  Not all rats were induced by the ACP-methadone and ACP-xylazine regimen.  
Immobilisation times were significantly increased with medetomidine and medetomidine-butorphanol 
premedication. Surgical anaesthesia was not achieved in un-premedicated rats, and was unreliable in 
rats premedicated with ACP-methadone and ACP-xylazine.  Medetomidine and medetomidine-
butorphanol premedication achieved surgical anaesthesia in 14 of 16 rat anaesthetics; however, 
unexpected mortalities occurred in two rats administered medetomidine premedication.   
Twitching severity was significantly reduced with the addition of the premedication agents ACP-
xylazine, medetomidine or medetomidine-butorphanol.  Mean oxygen saturation was significantly 
decreased with the addition of medetomidine and medetomidine-butorphanol premedication.  ACP-
xylazine and, more prominently, medetomidine and medetomidine-butorphanol significantly reduced 
the respiratory rate of rats undergoing alfaxalone anaesthesia.  Medetomidine and medetomidine-
butorphanol protocols showed significantly lower skin temperatures than that observed for control 
rats, whereas ACP-methadone and ACP-xylazine anaesthesia did not show significant mean skin 
temperature differences from control rats.  Medetomidine could not be recommended as a 
premedication at the current sedation doses, due to anaesthetic-related mortalities.  Medetomidine-
butorphanol provided surgical anaesthesia without prolonged recovery.  Medetomidine-butorphanol 
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premedication was sufficient to provide an adequate plane of anaesthesia for short painful surgical 
procedures.  The limiting factor for alfaxalone anaesthesia was the presence of twitching.  
Determining the cause of this neuro-excitation would significantly improve the anaesthetic protocol. 
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Introduction 
The rodent anaesthetic survey provided some insight into what researchers considered important when 
choosing their anaesthetic regimen.  Surprisingly, the regulatory requirements of the schedule 8 
restricted drugs were not a major factor influencing their anaesthetic choice.  Only a few survey 
respondents mentioned that their choice of anaesthetic protocol was based on the regulatory 
limitations of using opioid and dissociative agents.  The survey findings indicated that injectable 
anaesthetics were still commonly used and many complications were still associated with the 
induction, maintenance and recovery from anaesthesia from these agents.  Anaesthetic related 
mortality rates for rats and mice undergoing recovery surgery were much higher than mortality rates 
published for veterinary patients and people (Clarke and Hall, 1990, Bille et al., 2012).  These survey 
findings clearly indicate the need for improved anaesthetic protocols that will provide both ease of 
use, minimal training and predictability of anaesthetic outcomes.   
 
Laboratory rodent anaesthesia has stagnated 
Improvements to rodent anaesthetic protocols seem to have stagnated.  Agents that were used decades 
ago are still used today.  Ketamine-xylazine anaesthesia was identified as the most commonly used 
anaesthetic agent for laboratory rodents in rodent anaesthetic.  This combination anaesthetic has 
definitely stood the test of time, as there are publications on its use dating back to the late 1970s.  The 
fact that such agents have been used in rodents for over 30 years, suggests that there are no better 
anaesthetic combinations available and also highlights the need for a review of current anaesthetic 
practices (Green et al., 1981).  Ketamine is a cyclohexylamine analogue that produces 
unconsciousness and analgesia, but no muscle relaxation (Green, 1975, Green et al., 1981).  Ketamine 
alone at different drug dose ranges resulted in inconsistent levels of analgesia and xylazine on its own 
appeared completely ineffective at doses up to 40mg.kg
-1 
(Green, 1975, Green et al., 1981).  The 
addition of xylazine provided muscle relaxation as part of the response to administration of the drug 
combination, and improved the overall quality of anaesthesia of the two agents alone.    However, 
regardless of the improved sedation and muscle relaxation, many undesirable side effects are 
apparent, including inconsistent analgesia, respiratory depression, hypotension, diuresis and 
prolonged anaesthetic recovery (Flecknell, 1993b, Green et al., 1981).  Several of these complications 
were observed by rodent anaesthetic survey respondents.  Looking at this drug combination alone 
highlights the need for improved laboratory rodent protocols. 
 
Alfaxalone as an alternative rodent anaesthetic agent 
Alfaxalone is a neuroactive anaesthetic steroid that has been shown to have a high margin of safety in 
dogs and cats and is currently used extensively in veterinary practice (Ferre et al., 2006, Muir et al., 
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2008, Whittem et al., 2008).  The formulation of alfaxalone in a lipophilic cyclodextrin excipient is 
available on the Australian market as Alfaxan® (Jurox Pty Ltd, Rutherford NSW).  Limited published 
data is available for Alfaxan® anaesthesia in rats.  In Chapter 2, I undertook a pharmacokinetic study, 
and established that alfaxalone could be administered IV and IP and that sustained plasma levels are 
reached with IP administration.   
 
Premedication agents could improve alfaxalone anaesthesia 
However, there was a large variation in alfaxalone anaesthetic immobilisation times when alfaxalone 
was used as a sole agent.  In veterinary medicine, anaesthetic drug combinations are commonly 
utilised to reduce the doses of each medication necessary and reduce potential side effects of each 
drug (Alves et al.).  The addition of premedication agents here would hopefully provide a more 
predictable anaesthetic.  Neuroleptanalgesia was the term coined by human clinical anaesthetists to 
describe the central nervous depression produced by a combination of a potent sedative analgesic and 
a tranquilliser (Green, 1975).  Neuroleptanalgesia was adapted for use for animals to provide levels of 
immobilisation, with combinations of phenothiazine, α2- adrenergic receptor agonists and opioid 
analgesic agents being the most common (Monteiro et al., 2009, Green, 1975).   
 
Premedication agent combinations that provided neuroleptanalgesia were chosen.  Premedication 
combinations include the opioids methadone and butorphanol, α2- agonists xylazine and 
medetomidine, and the phenothiazone acetylpromazine (ACP).   Phenothiazines such as ACP have 
sedative effects with no analgesic actions and are frequently combined with opioids to improve 
sedation and analgesia (Monteiro et al., 2009, Monteiro et al., 2008, Flecknell, 1993b).  Methadone is 
an opioid analgesic agent commonly administered in combination with ACP in dogs (Flecknell, 1984, 
Abreu et al., 2012).  Methadone analgesia results from its agonist effect on the mu opioid receptor and 
its N-methyl-D-aspartate (NMDA) glutamate receptor antagonism (Monteiro et al., 2008, Monteiro et 
al., 2009).  Butorphanol is an opioid analgesic agent, which is a kappa opioid receptor agonist and 
mild mu opioid receptor antagonist (Abreu et al., 2012).  Butorphanol enhances the effects of α2-
adrenoreceptor agonists, and therefore is often administered in combination with medetomidine 
(Hayashi et al., 1994).  It has been reported that a synergistic analgesic effect is present when co-
administering α2- agonists with an opioid drug, increasing the potency and efficacy of the opioid 
analgesia (Valverde, 2012).  Medetomidine is a more potent α2- agonist than xylazine, and is 
associated with a lower incidence of side effects (Ferrari et al., 2005, Valverde, 2012).  Medetomidine 
has both the sedative and analgesic properties required for a premedication agent.  ACP-xylazine 
combines two sedative agents commonly used in equine anaesthesia (Watney et al., 1988, Nilsfors et 
al., 1988).   
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We aim to address some of the current problems associated with rodent anaesthesia by 
 producing an anaesthetic regimen that would allow for a smooth induction, maintenance and recovery 
from anaesthesia.  Medetomidine and ACP-xylazine premedication combinations were included for 
this purpose.  Alongside medetomidine-butorphanol and ACP-methadone, these four combinations of 
neuroleptanalgesics made up the premedication agents used in combination with IP alfaxalone.  
Preliminary investigations determined whether alfaxalone anaesthesia is effective when administered 
IP, IM and SC at varying doses.  This was followed by the main study where conjunctive therapies 
were utilised in an attempt to improve overall alfaxalone anaesthesia.  Premedication combinations 
chosen for this study possess sedation and analgesic properties that work synergistically with 
alfaxalone to provide a predictable and safe anaesthetic alternative to current injectable anaesthetics 
available.  
 
From our preliminary investigations, we showed that immobilisation was not always achieved and 
unfortunately, we could not recommend alfaxalone as a sole agent to reliably induce anaesthesia in 
rats.  The incidence of twitching was observed consistently, and creates a significant drawback to the 
use of alfaxalone.  On the positive side, we observed that a three fold increase in alfaxalone dose from 
10 mg.kg
-1
 to 30 mg.kg
-1
 did not cause any adverse effects to rats other than twitching, highlighting 
the large safety margin alfaxalone possesses.  As we cannot use alfaxalone alone, our next step was to 
consider the addition of premedication agents.  It is common practice in veterinary medicine to use 
combination anaesthesia to reduce the doses of each drug and reduce potential side effects of each 
drug (Alves et al.).  Here we investigated the use of premedication agents with alfaxalone anaesthesia 
in rats. 
 
The aim of this study was to determine whether premedication agents would help improve alfaxalone 
anaesthesia by improving overall anaesthetic predictability and reducing twitching in rats.  Alfaxalone 
at 20 mg.kg
-1
 IP was chosen, as this dose induced 75% of rats and the immobilisation time for IP 
dosing was more consistent than with SC dosing.  Also, we noticed that all rats anaesthetised at this 
dose range via the IP route developed some degree of twitching, and will therefore allow us to see 
whether alfaxalone reduces this. 
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Materials and Methods 
Female Wistar rats (6-10 weeks old, n = 18) were housed in a barrier maintained animal house 
(Animal Ethics Approval SBS/115/07/ARC) with a 12-hour/12-hour light and dark cycle.  Standard 
rat pellets and water were available ad libitum.  Experiments were performed once weekly for four 
consecutive weeks.  Each week rats were given a different premedication agent combination in 
conjunction with 20 mg.kg
-1
 alfaxalone IP (Table 3.2).  Premedication agents investigated were 
medetomidine (0.5 mg.kg
-1
), medetomidine-butorphanol (0.35 mg.kg
-1
-0.2 mg.kg
-1
), 
Acetylpromazine-methadone (3 mg.kg
-1
-0.7 mg.kg
-1
) and ACP-xylazine combinations (3 mg.kg
-1
-3 
mg.kg
-1
).  Doses for these combinations were determined from prior pilot investigations so that the 
premedication combinations would provide sedation without causing anaesthesia.  Throughout the 
study, the anaesthetic protocols were referred to by their premedication agents.  Control rats received 
sham premedications with injectable 0.9% saline solution. All premedication agent volumes were 
standardised and mixed with injectable saline to give a total injection volume of 0.6mL.  
 
Rats were premedicated IP ten minutes before (T = -10 min) administration of 20 mg.kg
-1
 alfaxalone 
IP (T = 0 min).  All IP injections were administered into the right lower abdominal quadrant, with the 
rat upper body tilted downwards to avoid major organs during injection (Smiler et al., 1990).  Rats 
were then placed onto a heat mat and allowed to breathe room air to simulate the usual laboratory 
setting for rodent anaesthesia.  Rats were monitored every minute for five minutes from T = 0 min.  
The level of sedation achieved from the premedication combination was recorded prior to alfaxalone 
administration.   
 
Sedation levels were categorised in to light, moderate and deep.  Light sedation was recorded when 
rats showed reduced activity but still ambulatory.  Rats displaying moderate sedation were quiet, 
stationary but responded by moving when provoked.  Deep or heavy sedation was achieved when rats 
were stationary, had reduced muscle tone and was non-ambulatory when provoked.  Reflex responses 
were recorded at five-minute intervals until anaesthetic recovery.  The induction time was recorded as 
the time taken from alfaxalone administration to when rats lost their righting reflex.   
 
Rats were placed into dorsal recumbency to establish the loss of righting reflex and maintained in this 
position until they could voluntarily right themselves.  The time in dorsal recumbency was recorded 
as the immobilisation time.  The cutaneous, pedal and tail pinch reflexes were monitored throughout 
the procedure as a gauge of anaesthetic depth.  Rats-tooth forceps were used to deliver the noxious 
stimulus by pinching the ventral abdominal skin for the cutaneous skin pinch response, hind paw 
webbing for the pedal reflex, and the tail tip for the tail pinch reflex.  Any avoidance response, such as 
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tail flicking and limb withdrawal, was recorded as a positive response to noxious stimuli.  Surgical 
anaesthesia time was recorded from immobilised rats that showed negative responses to all noxious 
stimuli.   
 
A pulse oximeter was applied to the front paw of the rat to obtain oxygen saturation data.  Pulse 
oximetry readings were recorded every five minutes during the immobilisation period.  An infrared 
thermometer was used to non-invasively monitor cutaneous body temperature from the ventral 
abdominal skin.  Twitching score was recorded and quantified according to the twitch score (Table 
3.1).  Other anaesthetic parameters measured included respiratory rate, respiratory effort, response to 
auditory stimulus and mucous membrane colour.   
 
Control data for 20 mg.kg
-1
 IP (n =4,) were sourced from the preliminary study to reduce animal 
numbers (Appendix 2.2).  This decision was made for animal welfare grounds as well as to ensure 
anaesthetised rats stayed within a tight age and weight range.  A drug wash out period of seven days 
was given between anaesthetics to avoid the possibility of drug accumulation in subsequent 
anaesthetics.   
 
All experiments were performed by one operator in an effort to maintain consistency with response 
recordings. GraphPad Prism generated statistics for each premedication anaesthetic protocol.  All 
statistical analyses were compared to control rats from the preliminary study.  Rats that failed to 
achieve anaesthesia were recorded in data tables and not included in the statistical analysis. Twitching 
score was presented as median and inter-quartile range and statistical significance was achieved using 
Kruskal-Wallis nonparametric ANOVA.  All other data are presented as mean  SD.  A one-way 
ANOVA was performed on data, followed by Dunnett’s Multiple Comparison where a P-value of 
<0.05 was considered significant.   
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Table 3.1.  Alfaxalone anaesthesia cross-over design 
The cross-over design for anaesthesia shows the time line for which rats received one of four 
premedication agents in combination with alfaxalone anaesthesia.  A one week wash-out period was 
used between anaesthetics.  
 Medetomidine 
Medetomidine-
Butorphanol ACP-Methadone ACP-Xylazine 
Week 1 
Rat 1 Rat 5 Rat 9 Rat 13 
Rat 2 Rat 6 Rat 10 Rat 14 
Rat 3 Rat 7 Rat 11 Rat 15 
Rat 4 Rat 8 Rat 12 Rat 16 
Week 2 
Rat 13 Rat 1 Rat 5 Rat 9 
Rat 14 Rat 2 Rat 6 Rat 10 
Rat 15 Rat 3 Rat 7 Rat 11 
Rat 16 Rat 4 Rat 8 Rat 12 
Week 3 
Rat 9 Rat 13 Rat 1 Rat 5 
Rat 10 Rat 14 Rat 2 Rat 6 
Rat 11 Rat 17 Rat 3 Rat 7 
Rat 12 Rat 18 Rat 4 Rat 8 
Week 4 
Rat 5 Rat 9 Rat 13 Rat 1 
Rat 6 Rat 10 Rat 14 Rat 2 
Rat 7 Rat 11 Rat 17 Rat 3 
Rat 8 Rat 12 Rat 18 Rat 4 
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 Results 
 
Level of sedation following premedication 
Premedication agents were allowed 10 minutes to act and levels of sedation were recorded prior to 
alfaxalone administration.  ACP-methadone premedication produced the lightest overall level of 
sedation with 75% of rats lightly sedated and 25% moderately sedated (Appendix 3.1).   
ACP-xylazine produced varying sedation levels, and of the sixteen rats administered this 
premedication combination, three rats were lightly sedated, eight showed moderate sedation and five 
were heavily sedated (Appendix 3.2).  The majority of rats were moderately sedated with 
medetomidine: 62.5% of rats were moderately sedated, 12.5% lightly sedated and 25% were heavily 
sedated (Appendix 3.3).  Sedation with medetomidine-butorphanol was varied but the majority of rats 
achieved light to moderate sedation prior to alfaxalone administration.  Of the sixteen rats given 
medetomidine-butorphanol, six were lightly sedated, seven showed moderate sedation and three rats 
were deeply sedated.  Overall, ACP-methadone showed the lightest average sedation levels followed 
by medetomidine-butorphanol, ACP-xylazine and with medetomidine the heaviest average sedation 
levels. 
    
Induction time following alfaxalone administration 
Induction times were recorded from the time rats were administered alfaxalone, to the time they lost 
their righting reflex.  From the levels of sedations we achieved, we expected faster inductions with 
more heavily sedated rats.  This did not appear to be the case.  There were no significant differences 
between induction times compared to control rats (Table 3.2).  75% of rats within the control group 
achieved anaesthetic induction.  The mean induction time was 3.9 ± 1.3 minutes. 
ACP-methadone induced anaesthesia in 15 of 16 rats.  The mean induction time was 4.5 ± 3.6 minutes 
however most rats were induced within five minutes, with only one rat taking 17 minutes before 
losing their righting reflex (Appendix 3.1).  If this rat was omitted from the data, the mean induction 
time would be decreased by almost a minute.  ACP-xylazine produced anaesthetic induction in 14 of 
16 rats.  The mean induction time was 2.4 ± 1.3 minutes and similarly to ACP-methadone, one of 
these 14 rats took much longer to lose their righting reflex than the others (Appendix 3.2).  But of the 
remainder, nine of them were induced within two minutes of alfaxalone administration.  
Medetomidine produced a 100% anaesthetic induction rate. One rat was already heavily sedated and 
allowed placement into dorsal recumbency prior to alfaxalone administration.  Induction times ranged 
between 0 to 6 minutes (Appendix 3.3) and the mean induction time was 2.0 ± 1.5 minutes (Table 
3.2).  As with medetomidine premedication, medetomidine-butorphanol also achieved anaesthetic 
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induction in all sixteen rats (Appendix 3.4). One rat took 10 minutes to lose its righting reflex with the 
remaining 15 rats taking only three minutes or less.  The mean induction time was 2.9 ± 2.0 min. 
 
Immobilisation time following alfaxalone administration 
The immobilisation time was recorded from the time the rat lost their righting reflex to the time they 
regained sternal recumbency.  We predicted that a longer immobilisation would follow a deeper 
sedation level.  This was apparent as there was no significant difference in immobilisation times of 
ACP-methadone or ACP-xylazine, but a marked prolongation of immobilisation time with the 
addition of medetomidine and medetomidine-butorphanol.  The mean immobilisation time achieved 
for control rats was 39.8 ± 7.4 minutes and ranged between 31 to 58 minutes.   
ACP-methadone produced a mean immobilisation time of 54.6 ± 15.0 minutes.  This was not 
significantly longer than that achieved by control rats. The addition of ACP-xylazine also did not 
show a significant increase in immobilisation time.  The mean anaesthetic immobilisation time for 
ACP-xylazine was observed at 66.5 ± 24.2 minutes.  Both medetomidine and medetomidine-
butorphanol both significantly extended immobilisation time.  An immobilisation time of 133 ± 34.1 
minutes was achieved by medetomidine with the minimum immobilisation time of 65 minutes 
(Appendix 3.3).  An immobilisation period of 120.2 ± 29.6 was observed for medetomidine-
butorphanol anaesthetic.  Interestingly, we predicted that the sedation levels achieved would have an 
impact increasing anaesthetic immobilisation times.  This was true to some extent however; ACP-
xylazine produced on average a deeper sedation than medetomidine-butorphanol but was much less 
effective at extending immobilisation time. 
 
Surgical anaesthesia time following alfaxalone administration 
Surgical anaesthesia was recorded within the immobilisation period when they were non-responsive 
to noxious stimuli.  Control rats did not develop surgical anaesthesia at any time during alfaxalone 
anaesthesia.  We postulated that premedication agents would improve alfaxalone anaesthesia.  For an 
anaesthetic to be effective, it needs to allow for surgical intervention.  We expect the addition of 
premedication agents to improve the period of surgical anaesthesia.  
Only one of 16 rats developed surgical anaesthesia for 20 minutes following ACP-methadone.   
ACP-xylazine was more effective with 7 of 16 rats reaching a surgical plane of anaesthesia.  
Medetomidine and medetomidine-butorphanol were the most effective agents with 14 of 16 rats and 
13 of 16 rats reaching a surgical plane of anaesthesia respectively.  The mean surgical anaesthetic 
time achieved was 43  29 minutes for medetomidine and 53  37 minutes for medetomidine-
butorphanol.  Results showed that ACP-methadone and ACP-xylazine were least effective at 
producing a surgical anaesthetic plane.  However it was observed that there were still two rats in each 
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of the medetomidine and medetomidine-butorphanol groups that did not reach this anaesthetic depth.  
This suggests inadequate anaesthesia following an initial dose, a common complicating factor with 
many injectable anaesthetic agents as shown in the rodent anaesthetic survey.  
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Anaesthetic parameters 
Control    
mean SD n    
Induction Time (min) 4.1 1.2 9    
Immobilisation Time (min) 39.8 7.4 9    
Surgical Anaesthetic Time (min) 0 0 12    
Oxygen Saturation (%) 92.6 0.8 11    
Respiratory Rate (bpm) 82 4.1 11    
Cutaneous Temperature (
o
C) 32.9 0.7 12    
 Median IQR n    
Twitch Score 2.0 2.5 12    
Anaesthetic parameters 
ACP-Methadone ACP-Xylazine 
mean SD n mean SD n 
Induction Time (min) 4.5 3.6 15 2.4 1.3 14 
Immobilisation Time (min) 54.6 15.0 16 66.5 24.2 16 
Surgical Anaesthetic Time (min) 1.3 5 16 8.8 16 16 
Oxygen Saturation (%) 94.1 0.8 15 93.3 2.1 16 
Respiratory Rate (bpm) 79 6.5 16 72 8.0 16 
Cutaneous Temperature (
o
C) 32.5 0.7 16 31.9 0.3 16 
 Median IQR n Median IQR n 
Twitch Score 1.0 1.7 16 0 1.0 16 
Anaesthetic parameters 
Medetomidine Medetomidine-Butorphanol 
mean SD n mean SD n 
Induction Time (min) 2.0 1.5 16 2.9 2 16 
Immobilisation Time (min) 133.0 34.1 14 120.2 29.6 16 
Surgical Anaesthetic Time (min) 43 29 14 53 37 16 
Oxygen Saturation (%) 89.5 3.1 16 87.0 3.6 16 
Respiratory Rate (bpm) 63 11.0 16 57 8.4 16 
Cutaneous Temperature (
o
C) 32.7 0.8 16 32.4 0.4 16 
 Median IQR n Median IQR n 
Twitch Score 0 1.0 16 0 1.0 16 
 
Table 3.2. Summary of alfaxalone anaesthetic outcomes 
The table shows the anaesthetic parameters for the premedication agents used in conjunction with 
alfaxalone.  Twitch score is presented as Median and Interquartile Range (IQR) and other data is 
presented as mean ± SD  
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Figure 3.1 Alfaxalone anaesthesia in rats in combination with premedication agents 
a)  No significant alterations in induction time were observed between premedication agent 
combinations b) Rats premedicated with medetomidine and medetomidine-butorphanol were 
immobilised for a significantly longer time period compared to control c) Medetomidine and 
medetomidine-butorphanol premedication provided longer surgical anaesthetic times but this time 
was unpredictable.  All data is presented as mean  SD.  *** indicates a P value ≤ 0.001 
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Incidence of twitching following alfaxalone anaesthetic regimen 
Control rats showed a 75% incidence of twitching, with most of the twitching considered moderate to 
severe in nature (Figure 3.2).  ACP-methadone was ineffective at decreasing the incidence of 
twitching and in contrast, actually increased the incidence of twitching to 87.5% and did not appear to 
decrease the severity of twitching (Appendix 3.1).  The other three pre-anaesthetic agents were 
however much more effective at reducing twitching than ACP-methadone.  ACP-xylazine showed a 
37.5% incidence of twitching, with more than half of these rats only showing mild twitching 
(Appendix 3.2).  Seven of 16 rats twitched with medetomidine premedication, but all of these rats 
only showed mild signs of twitching (Appendix 3.3).  Six of 16 rats showed mild twitching after 
medetomidine-butorphanol premedication.  It was interesting to note that two rats twitched during all 
four anaesthetic protocols and one rat did not twitch during any anaesthetic protocol in this cross over 
study.   
 
Oxygen saturation during alfaxalone anaesthetic protocols 
It is not often that oxygen saturation is measured during rodent anaesthesia. However, in the setting of 
laboratory rodent anaesthesia and surgery, it is uncommon for rats or mice to receive supplementary 
oxygen during an injectable anaesthetic protocol.  It is for this reason we need to determine whether 
alfaxalone maintains normal blood oxygen saturation while a rat is spontaneously breathing room air.  
 
The mean peripheral arterial oxygen saturation level (SpO2) for rats premedicated with ACP-
methadone and ACP-xylazine were not significantly different from that of control rats (Table 3.2). 
The SpO2 for these rats remained above 90% of control levels throughout the procedure (Figure 3.3).   
SpO2 for medetomidine and medetomidine-butorphanol, however, were significantly lower than that 
seen in control.  Following administration of alfaxalone, an observed decrease in SpO2 was apparent 
at T= 2 minutes and for medetomidine and medetomidine-butorphanol anaesthetic protocols, this 
decrease in SpO2 was pronounced by T=3 minutes.  During this time the SpO2 was seen to drop below 
80% at T=15 minutes with medetomidine-butorphanol. 
 
Respiration rate during alfaxalone anaesthetic protocols  
The mean respiratory rate for control rats during immobilisation was 82  4.1 breaths per minutes.  
ACP-methadone did not significantly reduce respiration compared with control rats (Figure 3.4).  
ACP-xylazine, and, even more so, medetomidine and medetomidine-butorphanol significantly 
depressed respiration rate in rats.  The respiration rate decrease observed for medetomidine and 
medetomidine-butorphanol was most apparent between T= 15-20 minutes, where it then appeared to 
slowly recover over the anaesthetic period (Figure 3.6).  Marked anaesthetic cardiorespiratory 
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depression was observed with the medetomidine-containing premedication agents, that were not 
observed with ACP-containing premedications. 
 
Skin temperature drops during alfaxalone anaesthesia 
ACP-methadone and ACP-xylazine did not alter mean skin temperature compared with control rats.  
Medetomidine and medetomidine-butorphanol protocols showed significantly lower skin 
temperatures than that observed for control rats (Figure 3.5).  Medetomidine and medetomidine-
butorphanol developed a mean decrease of 0.5
 o
C and 0.9 
o
C from control rats at 32.9  0.7 oC.  
 
Mortality with medetomidine protocol 
Rat 2.7.14 and Rat 2.7.16 died under the medetomidine protocol despite continuous anaesthetic 
monitoring.  Both rats developed an irregular respiratory rhythm towards the end of anaesthesia, not 
seen in the other fourteen rats undergoing the same anaesthetic protocol.  Unusual signs were 
observed that were not present during other rat anaesthetics.  At T= 70, Rat 2.7.14 developed dull 
pink mucous membrane colour, hyperaemic ears and cold extremities were apparent and serial 
cutaneous skin temperature recordings were normal.  Rat 2.7.16 was observed to have red urine at T= 
24 and a dull cyanotic tail at T= 45.  Rat 2.7.14 was lightly sedated and rat 2.7.16 was deeply sedated 
prior to alfaxalone administration.  Rats were breathing room air throughout the procedure and 
supplementary oxygen was not available.  On post mortem examination, no gross pathological 
findings were evident in either rat.  For the remainder of the rats, anaesthetic recovery was uneventful.    
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Figure 3.2. Twitching score for rats receiving alfaxalone anaesthesia following various 
premedication agents 
The severity of twitching was reduced in the presence of ACP-xylazine, medetomidine and 
medetomidine-butorphanol. Data is presented as median with inter-quartile range.  *** indicates a P 
value ≤ 0.001 
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Figure 3.3.  Mean oxygen saturation for alfaxalone in the presence of premedication agents 
The mean percentage of peripheral blood oxygen saturation (SpO2) was measured at five-minute 
intervals during the immobilisation period for each premedication-alfaxalone anaesthetic protocol. A 
marked reduction in oxygen saturation was observed when medetomidine and medetomidine-
butorphanol was administered.  Data are presented as a mean. ** indicates a P value ≤ 0.01, *** 
indicates a P value ≤ 0.001 
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Figure 3.4. Respiratory rate in rats during alfaxalone anaesthesia with premedication agents  
This figure depicts the mean respiratory rate of rats from individual premedication groups recorded at 
five-minute intervals.  Medetomidine and medetomidine-butorphanol caused prolonged respiratory 
depression up to 100 minutes.  Note Control, ACP-methadone and ACP-xylazine rat data was 
recorded until 55 minutes.  Recordings were discontinued on anaesthetic recovery a) data is presented 
as a mean b) data is presented as mean ± SD.  ** indicates a P value ≤ 0.01, *** indicates a P value ≤ 
0.001  
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Figure 3.5. Mean skin temperature in rats following alfaxalone anaesthesia with premedication 
agents 
Infrared skin temperature readings were recorded every five minutes during the alfaxalone anaesthetic 
protocol.  Rats premedicated with medetomidine and medetomidine-butorphanol showed significantly 
lower body temperatures than ACP-methadone and ACP-xylazine premedication agents. Data is 
presented as mean ± SD. * indicates a P value ≤ 0.05, *** indicates a P value ≤ 0.001 
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 Discussion 
 
Our rat pharmacokinetic study demonstrated that 20 mg.kg
-1
 IP alfaxalone produced sustained plasma 
levels of alfaxalone for up to 60 minutes (Lau et al., 2013).  Due to these sustained alfaxalone levels 
at 20 mg.kg
-1
, we postulated that an increase in plasma alfaxalone concentration would increase 
immobilisation duration due to these sustained levels.  This proved not to be the case for SC and IP 
alfaxalone doses; in addition, twitching occurred in 75% of rats receiving IP alfaxalone.  An even 
higher concentration of 30 mg.kg
-1
 alfaxalone was trialled, in which results were essentially similar to 
those for 20 mg.kg
-1
 alfaxalone.  These pilot studies suggested that alfaxalone was not a suitable 
candidate for sole anaesthetic use.  Similar findings were reported in cats showing that singly 
administered alfaxalone, either IM or SC, was inappropriate for anaesthetic induction and 
maintenance of anaesthesia (Grubb et al., 2013).  Even though the anaesthetic effects of alfaxalone 
was unpredictable, we could see that alfaxalone had a wide margin of safety, as shown by the three 
fold increase in dose in these preliminary trials, and we were therefore keen to pursue an effective 
alfaxalone anaesthetic protocol by combination with other commonly used anaesthetic 
premedications.   
 
Neuroleptanalgesia 
Neuroleptanalgesia is commonly performed in human clinical anaesthesia and we believed that the 
addition of a sedative analgesic would help us markedly improve alfaxalone anaesthesia.  Our 
premedication choices were based on commonly available veterinary premedications.  The doses of 
these premedication combinations were optimised so that rats were sedated but still able to ambulate 
when stimulated.  ACP-methadone, ACP-xylazine, medetomidine and medetomidine-butorphanol 
combinations were investigated in conjunction with 20 mg.kg
-1
 IP alfaxalone.  Results showed that 
ACP-methadone did not significantly improve alfaxalone anaesthesia.  ACP-xylazine reduced the 
severity of twitching; however there was no major improvement in immobilisation and surgical 
anaesthetic times.  Medetomidine and medetomidine-butorphanol combinations markedly improved 
immobilisation times and produced a period of surgical anaesthesia.  Additionally there was a 
reduction in the incidence and severity of twitching.  Regardless of these improvements, we did 
observe two mortalities during the medetomidine protocol that was not expected.   
 
 
 
 
 
 89 
 
 
Alfaxalone anaesthetic variability 
Pharmacodynamic data from Chapter  2 showed that anaesthetic induction occurred consistently 
within 60 seconds of IV injection and at 5 mg.kg
-1
 IV alfaxalone, the sleep times achieved were 
within 9-12 minutes (Lau et al., 2013).  Alfaxalone could be due to many different factors associated 
with the route of administration.  The IP route of administration is slow to absorb into the circulation 
when compared to the IV route and large quantities of drug are required to produce the same effect 
(Flecknell, 1993b).  Compounds administered IP are primarily absorbed by the portal circulation, with 
a small amount being absorbed through the lymphatic system draining into the systemic circulation 
(Lukas et al., 1971).  The result of this is a high degree of first pass metabolism (Lukas et al., 1971), 
which in turn decreases the amount of drug available in the systemic circulation and could be a 
contributor in anaesthetic depth variation in this study.  Some drugs are taken up into adipose tissues 
of the abdominal cavity, and drugs administered IP can diffuse from the abdominal cavity directly 
into the abdominal tissues (Betschart et al., 1988).  This sequestration of drug could lead to variability 
in the amount of alfaxalone that is absorbed into the systemic circulation.   
 
We cannot discount intraperitoneal injection error as a possible cause of anaesthetic variability.  A 
study using iodinated oily media showed radiographically that errors occurred in 19.6% of 127 
Sprague Dawley rats that were administered intraperitoneal injections (Lewis et al., 1966).  This error 
involves a volume of injection partially injected into the gastrointestinal tract, subcutaneously, retro-
peritoneally or into the urinary bladder rather than into the peritoneal cavity (Lewis et al., 1966).  This 
Variation in injection technique is inevitable between different people, so all injections were 
performed by one operator, myself.  All IP injections were administered into the right lower ventral 
abdominal quadrant while rats were tilted forwards to avoid organs such as the caecum.  Even with 
these extra precautionary measures, there is still the possibility that some injections could have been 
given extra-peritoneally.   
 
Alfaxalone showed a high margin of safety 
We postulated that increasing doses of alfaxalone would improve alfaxalone anaesthesia, but one 
factor that was evident was the fact that a three fold increase in alfaxalone dose from 10 mg.kg
-1
 to 30 
mg.kg
-1
 did not increase adverse anaesthetic effects on rats.  This shows alfaxalone to have a wide 
margin of safety in rats, similar to findings reported in other species (Ferre et al., 2006, Muir et al., 
2008, Whittem et al., 2008).  We know that delivery of a single predetermined dose of an anaesthetic 
agent can give an individual dose response ranging from inadequate anaesthesia to death (Smith, 
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1993).  So the fact that we see a three fold increase in drug dose without any adverse responses 
showed alfaxalone to have a high margin of safety. 
 
Surgical anaesthesia with alfaxalone anaesthetic protocols 
Surgical anaesthesia was only produced consistently in rats administered medetomidine or 
medetomidine-butorphanol premedication agents.  Surgical anaesthesia was subjectively examined in 
this study, where a negative response to noxious stimuli was recorded as consistent with surgical 
anaesthesia.  Other investigators used measures for surgical anaesthesia such as the complete loss of 
the pedal withdrawal reflex (Alves et al.).  Others observed that rats could continue to respond to a toe 
pinch after they stopped responding to the abdominal and tail pinch (Field et al., 1993).  The type of 
surgical stimulus applied would dictate which anaesthetic regimen can provide adequate 
immobilisation and analgesia.  Ultimately, once the responses to nociceptive reflexes are lost, 
performing surgery is the best gauge of surgical anaesthesia.  However, individual rats underwent 
multiple anaesthetics, so multiple surgical incisions would be necessary to include this in our tests, 
and so this was not done.   
 
Respiratory parameters with alfaxalone anaesthetic protocols 
The pulse oximeter gives a non-invasive estimate of arterial oxygen saturation which correlates well 
with arterial oxygen saturation measured in arterial blood samples (Hackett, 2002).   Therefore pulse 
oximetry readings gave us a good indicator of general oxygenation in the rats.   In our investigation, 
rats under alfaxalone anaesthesia with premedication maintained voluntary respiration of room air, 
mucous membrane colours remained visibly pink.  Acceptable SpO2 levels were maintained in ACP-
methadone, ACP-xylazine and control rats at above 90%.  Medetomidine and medetomidine-
butorphanol premedication however dropped SpO2 levels below 90%.  A recent study showed that 
cats given IM alfaxalone anaesthesia maintained SpO2 levels above 85% the majority of time whilst 
breathing room air (Grubb et al., 2013). The addition of the α2- adrenergic agonists, xylazine or 
medetomidine appeared to be associated with respiratory depression, consistent with the reduction in 
SpO2 levels with these premedications.  The addition of capnographic readings would have given 
further information on blood carbon dioxide saturation; however the reliability of these measurements 
would be problematic without intubation, which is difficult in rats.   
 
Neuro-excitation (twitching) is a prominent side effect of alfaxalone  
The preliminary studies showed that neuro-excitation (twitching) during anaesthesia was consistently 
produced by IM, SC and IP alfaxalone administration.  Additionally, the incidence and severity of this 
twitching was not greatly reduced with increasing doses of alfaxalone.  The addition of premedication 
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agents was trialled, to attempt to reduce the incidence and severity of twitching.  We found that ACP-
xylazine, medetomidine and medetomidine-butorphanol, but not ACP-methadone, reduced the 
incidence and severity of twitching.  ACP-methadone was the only premedication agent that did not 
contain an α2- adrenergic agonist drug.  Therefore the inclusion of an α2- adrenergic receptor agonist 
could be one factor contributing to the reduction in the incidence and severity of the alfaxalone-
induced twitching.  Individual rat variability in evincing this side effect could also potentially play a 
role in twitching.  There was a trend for rats that twitched during one anaesthetic regimen, to twitch 
during a subsequent anaesthetic regimen. Rat 2.7.2 and Rat 2.7.4 showed signs of twitching following 
every anaesthetic protocol, while Rat 2.7.10 did not show signs of twitching on any occasion.  These 
observations were consistent with pilot study results where twitching was seen on multiple occasions 
following alfaxalone anaesthesia on an individual rat (Figure 3.2).   
 
 
Mortalities following medetomidine-alfaxalone anaesthesia 
Published data showed mortality rates with both ketamine-diazepam at 60 mg.kg
-1
-7.5 mg.kg
-1
 and 80 
mg.kg
-1
-10 mg.kg
-1
 of 9% and of 6% for fentanyl-droperidol (Wixson et al., 1987a).  Wixson et al 
(1987) evaluated the use of ketamine-xylazine, ketamine-diazepam, fentanyl-droperidol and 
pentobarbital combinations given IP in rats at several dose rates.  At high doses of all drugs examined 
by Wixson et al, profound and protracted respiratory and cardiovascular depression was noted.  This 
was discussed as likely inhibiting the return of homeostatic control mechanisms and therefore causing 
increased mortality (Wixson et al., 1987b).  Two mortalities were seen in our current study.  The two 
rats that died were given medetomidine premedication.  Medetomidine is a selective α2- adrenergic 
agonist drug that markedly potentiates the effects of other anaesthetic agents (Virtanen, 1989, 
Gopalan et al., 2005, Sladky et al., 2000).  α2- adrenergic receptor agonist activity in the brainstem 
plays a role in decreasing blood pressure (MacMillan et al., 1996).  Similar to the findings by Wixson 
et al (1987), these contributing factors in our study could have inhibited the return of homeostatic 
control, leading to irreversible morbidity and ultimately mortality.  A reversal agent such as 
atipamezole was not used for medetomidine in this study however; the addition of such an agent at 
first signs of hyperaemia or respiratory irregularity may have prevented morbidity and, ultimately, 
mortality of Rat 2.7.14 and Rat 2.7.16.  This is of course in making the assumption that medetomidine 
is the causative agent.  The lack of rodent specific monitoring equipment was not available for this 
study and this scenario would likely be similar for many researchers.    
 
Medetomidine provided a smooth induction, longer anaesthetic time and very consistently provided 
surgical anaesthesia, but cannot be recommended at the current sedation dose due to anaesthetic-
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related mortalities.  Medetomidine-butorphanol premedication showed very similar anaesthetic 
qualities to medetomidine without mortality.  This premedication provided surgical anaesthesia 
without prolonged recovery.  The medetomidine-butorphanol protocol was sufficient to provide an 
adequate plane of anaesthesia for short painful surgical procedures.  The ease of administration as 
well as the minimal equipment required is a huge advantage when choosing an anaesthetic regimen, 
however finding the correct anaesthetic combination has proven difficult.  In rodents, adjustment is 
not available with injectable agents via SC, IM and IP routes, where a calculated dose is given in a 
single injection (Roughan et al., 1999).  Therefore a safe and predictable anaesthetic agent is 
preferred.   
 
Alfaxalone could potentially be used as part of an anaesthetic protocol, if premedication agents could 
be optimised, and if neuro-excitation could be reduced.  Veterinarians have anecdotally used 
premedication agents in an effort to reduce or abolish this neuro-excitation in cats and dogs.  In rats, 
this study showed that the severity of twitching could be significantly reduced with the addition of 
premedication agents.  The use of combination anaesthesia also proved to produce more consistent 
anaesthetic outcomes between rats.  Alfaxalone was safe in rats up to the maximum tested dose of 30 
mg.kg
-1
 IP.  However, when an anaesthetic is said to be “safe”, this provides a false sense of security 
as there is always a possibility for complications.  Pilot studies indicated that alfaxalone could easily 
be given at three times the starting dose without morbidity or mortality, however mortality occurred 
with the addition of medetomidine premedication.  It must be noted however, that caution should be 
taken when using medetomidine, at 0.5 mg.kg
-1
 in conjunction with 20 mg.kg
-1 
alfaxalone, and it may 
be necessary to incorporate a reversal agent into the anaesthetic regimen for α2 adrenergic agonists to 
reduce cardiorespiratory depression and recovery time.   
 
The initial hypothesis that premedication agents could potentially improve alfaxalone anaesthetic 
consistency and possibly abolish twitching was consistent with the findings from this study.  
However, as twitching was a major undesirable complication of alfaxalone anaesthesia, further 
investigations to determine the mechanism of twitching are necessary.  There are indications that 
alfaxalone has strychnine-sensitive glycinergic receptor effects (Weir et al., 2004) that could be a 
contributor to the neuroexcitation.  Further examination into the effects of alfaxalone on glycinergic 
synaptic transmission to motor neurones will give insight into what mechanisms might underlie the 
neuro-excitation seen with alfaxalone anaesthesia. 
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CHAPTER FOUR 
Alfaxalone Causes Reduction of Glycinergic Inhibitory Inputs and Activates a Depolarising 
current in Rat Hypoglossal Motor Neurons 
 
Abstract 
We investigated the effects of alfaxalone on inhibitory synaptic transmission to hypoglossal 
motorneurons (HMNs).  Whole cell recordings were performed on HMNs in transverse brainstem 
slices (300µM thickness) prepared from 10-14 day old Wistar rats anaesthetised with sodium 
pentobarbitone (100 mg.kg
-1
 IP).  Spontaneous and evoked inhibitory post-synaptic currents (IPSCs) 
were recorded at a holding potential of –60mV, using a CsCl-based internal solution, in the presence 
of the non-NMDA and NMDA glutamate receptor blockers NBQX (10µM) and APV (50µM). 
Spontaneous data was recorded for a pilot study using bath application of 25µM alfaxalone (n=6 
HMNs).  The addition of the GABAAR antagonist bicuculline (5µM) was bath-applied in control 
solutions for all subsequent studies of the effect of alfaxalone.  An alfaxalone dose response study was 
performed with bath application of alfaxalone at increasing concentrations of 10nM, 30nM, 100nM, 
300nM, 1µM, 3µM and 10µM (n=7 HMNs).  Both spontaneous and evoked IPSCs were recorded. An 
inter-stimulus interval of 150ms was set for the evoked IPSC paired pulse recordings to measure 
paired pulse ratio (PPR).  25µM alfaxalone significantly reduced spontaneous IPSC peak amplitude, 
half-width and frequency.  Alfaxalone did not alter spontaneous IPSC peak amplitude, rise time or 
half width up to 10µM, but a significant reduction in frequency was noticeable from 3µM and the 
degree of this reduction increased in a dose-dependent manner.  A concentration-dependent reduction 
in evoked IPSC amplitude was apparent from 30nM, producing a maximal mean difference of –
138.1pA, equivalent to 35.8 ±15.4% of control at 10µM.  Prolongation of evoked IPSC rise time was 
significantly noticeable from 1µM and increased evoked IPSC decay time was significant at 10µM 
alfaxalone.  Alfaxalone did not alter evoked IPSC half-width, paired pulse ratio or HMN input 
resistance.  Baseline holding current at -60 mV moved consistently in an inward direction with 
significant inward changes at 10µM alfaxalone.  These results are consistent with alfaxalone-induced 
glycine receptor (GlyR) modulation, causing a delay in channel opening, and prolongation of channel 
opening.  A decrease in spontaneous IPSC frequency is suggestive of presynaptic depression by 
alfaxalone, while the decrease in spontaneous and evoked IPSC amplitude may be either pre- or 
postsynaptically mediated.  These results show that alfaxalone reduces glycinergic inhibitory 
transmission to rat HMNs via a combination of pre- and postsynaptic mechanisms, and activates an 
inward current, which remains to be identified.  These responses to alfaxalone are likely to make 
HMNs more excitable, and may therefore underlie neuro-excitation during alfaxalone anaesthesia. 
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Introduction 
 
During alfaxalone anaesthetic, exaggerated neuro-excitatory motor responses, commonly referred to 
as twitching, have been reported in cats, dogs, horses and pigs during recovery (Keates, 2003, Ferre et 
al., 2006, Goodwin et al., 2011, Mathis et al.).  This neuro-excitation was also consistently observed 
during our clinical studies in rats (Chapter 3), when alfaxalone was administered IV, IM and SC.  
Neuro-excitation is an unwelcome side effect of alfaxalone anaesthesia and limits its use as a viable 
alternative to other injectable rodent anaesthetic agents.  The use of various premedication agents 
reduced the incidence and severity of twitching, however none of the trialled agents were able to 
abolish the neuro-excitation and/or had significant adverse effects on the quality of anaesthesia.   
 
Alfaxalone is a positive allosteric modulator of the γ-aminobutyric acid type A receptor (GABAAR) 
and it is through this action that it is thought to exert its anaesthetic effects (Lambert et al., 1996).  As 
GABAAR activation is the major contributor to alfaxalone’s anaesthetic effects, we looked at effects 
of alfaxalone on other receptors or ion channels that could potentially cause neuro-excitation.  
Alfaxalone, and other neurosteroids, also modulate voltage-activated calcium (Ca
2+
) channels and 
glycine-activated chloride channels (Prince and Simmonds, 1992, Lambert et al., 1996, ffrench-
Mullen et al., 1994).  The glycine receptor (GlyR) is of particular interest, as glycinergic 
neurotransmission is a major regulator of muscle tone (Biro and Maksay, 2004, Maksay et al., 2002, 
Wu et al., 1997).  GlyR activity mediates inhibitory synaptic transmission between interneurons and 
motor neurons (MN) and suppression of the GlyR will produce undesirable consequences (Lynch, 
2009).  An abnormal reduction in the conductance of glycine-gated chloride channels cause startle 
disease, hyperkeplexia, that manifests as temporary muscle rigidity to unexpected stimuli (Lynch, 
2004).  Abnormal GlyR suppression also occurs with tetanus toxicity and strychnine poisoning.  
Tetanus neurotoxin inhibits presynaptic exocytosis of glycine, causing muscle rigidity and 
paroxysmal muscle contractions (Shin et al., 2012, Williamson et al., 1992, Bergey et al., 1987).  
Strychnine is a heterocyclic alkaloid that potently and specifically blocks GlyRs, thus inhibiting 
postsynaptic glycinergic activity, and producing a characteristic hyper-reflexia, progressing to intense 
muscle spasms and convulsions (Gundlach, 1990, Parker et al., 2011).   These presynaptic and 
postsynaptic inhibitory effects on the GlyR lead us to believe that the neuro-excitation caused by 
alfaxalone could also be of due to suppression of GlyR activation on motor neurons. 
 
Different steroid compounds have vastly different effects on the GlyR, where neurosteroids have been 
shown to cause subunit composition dependent bi-directional modulation of GlyRs (Laube et al., 
2002).  The synthetic steroid RU5135 possesses convulsant properties and has been identified as a 
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strychnine sensitive GlyR antagonist (Paul and Purdy, 1992).  In contrast, alfaxalone was reported to 
have no effect on GlyRs in cultured neurons (Hill-Venning et al., 1996, Simmonds, 1983). Other 
studies have shown that alfaxalone weakly potentiated strychnine-sensitive GlyR activity elicited by 
glycine application, but was unable to elicit a current response in the absence of glycine (Weir et al., 
2004, Mascia et al., 1996).  This weak potentiation of GlyR responses to glycine occurred at a mean 
EC50 of 27.8µM alfaxalone (Weir et al., 2004).  Similarly, homomeric α1 GlyR expressed in Xenopus 
laevis oocytes were weakly potentiated by 6µM alfaxalone on addition of glycine (Mascia et al., 
1996).   The neurosteroid pregnenolone 3β-sulphate directly modulated GlyRs in the chick embryonic 
spinal cord (Wu et al., 1997) and bi-directional allosteric modulation of the GlyR has been observed 
with minaxolone (Biro and Maksay, 2004).   
 
Previous electrophysiological studies of the effects of neurosteroids were performed on GlyRs in 
cultured neurons, Xenopus laevis oocytes and chick embryos, but not in the mammalian neuromotor 
system. Different neurosteroids also have been shown to produce markedly different modulatory 
effects on the GlyR (Laube et al., 2002).  It is therefore important to directly determine the effect of 
alfaxalone on mammalian motor neurons and identify whether alfaxalone produces GlyR inhibition or 
potentiation at clinical dose ranges.  Here we investigated the effects of alfaxalone on hypoglossal 
motor neurons (HMNs) of Wistar rats, using whole cell patch clamp recording techniques under 
voltage clamp conditions in in vitro brainstem slices. We hypothesise that alfaxalone causes inhibition 
of the GlyR and of inhibitory neurotransmission at clinically relevant doses and could likely cause 
alfaxalone induced neuroexcitation. 
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Materials and Methods 
 
Slice Preparation 
Whole cell recordings were performed using in vitro brain stem slices from juvenile Wistar rats of 
either sex (10-14 days old).  Rats were anaesthetised using sodium pentobarbitone (100 mg.kg
-1
 IP). 
When deep anaesthesia was established, the rat was swiftly decapitated. The skull, cerebrum, 
cerebellum and the neck muscles were removed to expose the brainstem.  The brainstem was then 
placed into an icy-cold bath of artificial cerebrospinal fluid (aCSF) for cutting (see solutions), which 
was bubbled with carbogen (95%O2, 5%CO2).  Transverse slices at a thickness of 300μM were cut 
with a DSK Microslicer DTK-1000 (TED Pella Inc) and incubated for 35-50 min in the same cutting 
aCSF at 35
o
C.  The slices were then maintained at room temperature (19-21
o
C) in a maintenance 
aCSF (see solutions), bubbled with carbogen. 
 
Solutions 
The aCSF solution used for cutting and initial incubation of slices contained (in mM) 130 NaCl, 26 
NaHCO3, 3 KCl, 5 MgCl2, 1 CaCl2, 1.25 NaPO4,10 Glucose.  The maintenance aCSF solution, was a 
similar solution with the exception of 2 CaCl2 and 1 MgCl2.   
The patch pipette internal solution contained (in mM) 120CsCl, 4 NaCl, 4 MgCl2, 0.001 CaCl2, 10 Cs 
N-2-hydroxyethyl-piperazine-N’-2ethanesulfonic acid (HEPES), 10 Cesium ethylene glycol-bis(-
aminoethyl ether)-N,N,N,N-tetra-acetic acid (EGTA), pH adjusted to 7.2 with CsOH and osmolarity 
was adjusted to 290-300mOsM with sucrose. Osmolarity was measured with a vapour osmometer.  3 
adenosine 5’-triphosphate (ATP-Mg) and 0.3 guanosine 5-triphosphate-tris (hydroxymethyl) 
aminomethane (GTP-Tris) was added to the internal solution before use.  
DL-2-amino-5-phosphonopentanoic acid (APV, Sigma, 50μM) and NBQX disodium salt hydrate 
(Sigma, 10μM) were added into the external bath solutions to block N-methyl-D-aspartate (NMDA) 
and non-NMDA glutamate receptor activity (both DL-α-amino-3-hydroxy-5-methyl-4-isoxazole 
proprionic acid (AMPA) and kainate receptors.1(S),9(R)-(-)-Bicuculline methchloride (Sigma, 5μM) 
and Strychnine (Sigma, 500nM) solutions were added to the external bath solution to block GABAA 
receptor and Glycine receptor activity respectively. 
 
Drugs 
3-α-hydroxy-5-α-pregna-11, 20-dione (Alfaxalone, a generous gift of Jurox Pty Ltd) was dissolved in 
hydroxypropyl substituted β-cyclodextrin (HPCD, a gift of Jurox Pty Ltd) to a ratio of 1:8 to make a 
stock concentration of 10mM alfaxalone, then diluted to the required bath concentration of 10nM, 
30nM, 100nM, 300nM, 1μM, 3μM, 10μM and 25μM.  50μM APV and 10μM NBQX were added into 
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all control baths to block NMDA and non-NMDA glutamate receptors, isolating IPSC activity.  
1(S),9(R)-(-)-Bicuculline methchloride (Sigma, 5μM) and strychnine hydrochloride (Sigma, 500nM) 
solutions were added to the external bath solution to block GABAAR and GlyR activity respectively.  
The stock solution solvent (DMSO, ethanol or HPCD) was always diluted by a factor of 1000 or > in 
the external bathing solution, and had no effect when applied alone at these concentrations.  
Application of drugs via the bathing fluid was always for >2min; the time taken to completely 
exchange the recording chamber solution was typically <40s.  The alfaxalone dose response study was 
only applied to one HMN per slice. 
 
Electrophysiological recordings 
Brainstem slices were submerged in a mounted microscope chamber with a volume of ~ 0.5 mL and 
were continuously superfused with maintenance aCSF at a rate of 1.5-2mL/min.  Patch electrodes 
were pulled from thin-walled borosilicate glass capillary tubes without a filament (Vitrex Medical) on 
a two-stage electrode puller (PP-83, Narishige); patch electrodes had a final DC resistance of 2-3MΩ 
when filled with the internal solution and a tip diameter of 1-2 μm.  Recordings were performed at 
room temperature (19-21
o
C) with the patch electrode connected to the headstage of an Axopatch 1D 
patch-clamp amplifier (Axon instruments).   HMNs were visually identified by their size, shape, 
location in the hypoglossal motor nucleus (nXII), and whole cell capacitance (>20pF).  Whole cell 
recordings were obtained by the “blow and seal” method (Stuart et al., 1993), where positive pressure 
(10-15kPa) was maintained in the pipette to allow surrounding neuropil to be cleaned away as the 
pipette tip is guided onto the surface of the target HMN (Bellingham and Berger, 1996).   
The program pCLAMP 8 (Axon Instruments) was used to apply voltage commands and record whole 
cell currents and measure responses.  Spontaneous and evoked inhibitory postsynaptic current (IPSC) 
activity was recorded with the HMN voltage clamped at a membrane potential of –60mV.  For evoked 
IPSC recordings, a bipolar concentric stimulation electrode (Frederick Haer Company) was placed in 
the reticular formation ventrolateral to the border of the hypoglossal motor nucleus, and a stimulus 
current of 0.5-1.1mA and 0.1 ms duration was applied to reliably evoked an IPSC with consistent first 
pulse IPSC amplitudes.  The recorded signal was amplified (2-20x) and low pass filtered with a cut-
off frequency of 2kHz by the Axopatch 1D amplifier before digitization with a 16-bit digitizer 
(Digidata 1320A, Axon Instruments) and recording on a PC hard disk (Dell Optiplex, running 
Windows XP Professional).  Data was acquired as episodic sweeps of 1.04sec duration for evoked 
IPSCs, or as continuous blocks of data of 2 min duration for spontaneous IPSCs.  For evoked IPSCs, 
the first stimulus pulse was preceded by a short (20 ms) voltage step of -10 mV, to monitor input 
resistance (Rn) and series resistance. 
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Alfaxalone Pilot Study 
Alfaxalone was bath applied at 25μM (n=6) to rat HMNs in the presence of excitatory glutamate 
receptor antagonists APV and NBQX.  Only spontaneous IPSC waveform parameters were recorded.   
 
Inhibitory Neurotransmission Pilot Study 
Control IPSCs recordings were performed in the presence of APV and NBQX to determine the 
proportions of GABAAR and GlyR contributing to IPSCs recorded from rat HMNs.  After control 
recordings, 5μM bicuculline was then bath applied to selectively block GABAAR, and both 
spontaneous and evoked IPSC activity was recorded.  This was followed by the addition of 500nM 
strychnine to selectively block GlyRs and both spontaneous and evoked IPSCs were recorded.  Under 
the latter conditions, no spontaneous or evoked synaptic activity was present. 
 
Alfaxalone Dose Response Study 
Control recordings were performed in the presence of APV, NBQX and bicuculline to isolate 
glycinergic IPSCs.  A dose response study was performed with alfaxalone bath-applied at 10nM, 
30nM, 100nM, 300nM, 1μM, 3μM and 10μM (n=7) to rat hypoglossal motor neurones.  Both 
spontaneous and evoked IPSCs were recorded.   
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Data analysis 
Data measurements were made with Clampfit 10 (Axon Instruments).  Waveform parameters 
(amplitude, 10-90% rise time, half-width, decay time constant) and baseline holding current (Ihold) 
were measured, as well as the interval time between IPSCs for spontaneous recordings and input 
resistance (Rn) for evoked recordings.  The IPSC paired pulse ratio was calculated as the mean peak 
amplitude of the averaged second evoked IPSC divided by the mean peak amplitude of the averaged 
first evoked IPSC.  The decay phase of individual evoked IPSCs were fitted with a mono-exponential 
function (ʄ (t) = Ae-t/τ + C) where A = amplitude, t = time, τ= decay time constant.  This data was 
imported into Excel 2007 (Microsoft) and further analysed with custom written Visual Basic for 
Applications routines as described in Bellingham & Berger (1996).  Drug induced changes were 
determined by finding the maximal change of 10 to 12 consecutive responses as compared with the 
same number of responses for a control average immediately before drug application (Bellingham and 
Berger, 1996).  Statistical significance was shown in graphs by using asterisks.  * depicts a P value 
≤0.05, ** depicts a P value ≤ 0.01, and *** depicts a P value ≤ 0.001.  Data are shown as Mean  SD 
and statistical significance was determined by a one-way ANOVA or paired two-tailed T-test 
followed by dunnett’s multiple comparison post test and accepted at P <0.05 using Graphpad Prism 5 
software. 
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Results 
Alfaxalone pilot study 
First we determined whether alfaxalone at a high clinical dose could modulate spontaneous inhibitory 
transmission in HMNs.  An initial dose of 25µM alfaxalone was applied to HMNs in the presence of 
APV (50μM) and NBQX (10μM).   
 
Alfaxalone caused spontaneous IPSC size, shape and frequency augmentation 
Alfaxalone significantly decreased spontaneous IPSC peak amplitude and half-width, but not rise 
time.  IPSC peak amplitude decreased to 71 ± 15.8% of control and IPSC half-width was reduced 
from 4.6  2.6 to 2.7  2.0 ms on bath application of alfaxalone (Figure 4.1).  Bath application of 
alfaxalone markedly increased IPSC interval time by 346 ± 111% of control.  The cause of 
spontaneous IPSC amplitude depression could be presynaptic or postsynaptic in origin.  Increased 
IPSC interval suggests direct presynaptic depression of inhibitory synaptic release by alfaxalone.  The 
reduction in spontaneous IPSC halfwidth, however is consistent with postsynaptic GABAAR or GlyR 
channel modulation.  
 
Alfaxalone produced an inward current shift 
The baseline holding current was significantly shifted by three fold (2.99  0.76 increase) in an 
inward direction (Table 4.1).  The production of an inward holding current suggests activation of 
postsynaptic ion channels by alfaxalone. 
 
Inhibitory Neurotransmission Pilot Study 
These pilot results showed 25µM alfaxalone caused suppression of inhibitory neurotransmission to rat 
HMNs.  To determine whether these suppressive effects were acting on glycinergic or GABAAR 
mediated synaptic responses, an additional pilot study was performed to determine the contribution of 
these two receptors to spontaneous and evoked IPSCs in rat HMNs.  The GABAAR blocker 
bicuculline, followed by the GlyR blocker strychnine, were bath applied to identify the proportion of 
inhibitory activity attributable to the GABAAR and GlyR.   
 
Bicuculline did not significantly alter IPSC size, shape or frequency 
Bath application of the GABA blocker bicuculline (5µM) did not significantly alter spontaneous or 
evoked IPSC peak amplitude, rise time or half width (Table 4.2).  This shows that there is minimal 
GABAergic influence in rat HMNs in our recording conditions.   
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Strychnine abolished spontaneous and evoked IPSC activity 
As the addition of bicuculline did not significantly alter IPSC activity, we expected inhibitory 
synaptic transmission to be glycinergic in nature.  The addition of the GlyR blocker strychnine 
(500nM) completely blocked evoked IPSC pulses and almost all spontaneous IPSCs (Figure 4.2).  
This cessation of IPSC activity confirmed that the majority of the inhibitory transmission in rat HMNs 
were attributable to strychnine-sensitive GlyRs.  For all future experiments, bicuculline was applied to 
definitively exclude any contribution of GABAARs to inhibitory synaptic transmission.  
  
 102 
 
 
c
o
n
tr
o
l
2
5 
M
 A
lf
a
x
a
lo
n
e
-8 0
-6 0
-4 0
-2 0
0
A
m
p
li
tu
d
e
 (
p
A
)

 S
D *
c
o
n
tr
o
l
2
5 
M
 A
lf
a
x
a
lo
n
e
0
1
2
3
4
In
te
r
v
a
l 
T
im
e
 (
s
e
c
)

 S
D
* *
c
o
n
tr
o
l
2
5 
M
 A
lf
a
x
a
lo
n
e
0
2
4
6
8
H
a
lf
 w
id
th
 (
m
s
)

 S
D *
c
o
n
tr
o
l
2
5 
M
 A
lf
a
x
a
lo
n
e
0 .0
0 .5
1 .0
1 .5
2 .0
2 .5
R
is
e
 T
im
e
 (
m
s
)

 S
D
a )
c )
b )
d )
e )
B
a
s
e
li
n
e
 h
o
ld
in
g
 c
u
r
r
e
n
t 
(p
A
)

 S
D
c
o
n
tr
o
l
2
5 
M
 A
lf
a
x
a
lo
n
e
-2 0 0 0
-1 5 0 0
-1 0 0 0
-5 0 0
0
**
 
Figure 4.1. Effects of 25µM Alfaxalone on the spontaneous IPSC amplitude  
Spontaneous IPSC activity from HMNs (n=6) of 9-11 day Wistar rats. 50µM APV and 10µM NBQX 
were added to block NMDA and non-NMDA glutamate receptors.  a) alfaxalone caused significant 
IPSC amplitude reduction, b) and decreased IPSC frequency.  c) A reduction in IPSC half width was 
noted, however d) alfaxalone did not alter IPSC rise time, e) A significant inward shift in baseline 
holding current was observed.  All data is presented as mean  SD. Significance was determined from 
normalised control data. * indicates a P value ≤ 0.05, ** indicates a P value ≤ 0.01 
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Parameters Control 25μM Alfaxalone Statistical 
Spontaneous mean SD n mean SD n Significance 
Amplitude (pA) -39.2 17.2 6 -26.9 11.0 6 * 
Rise Time (ms) 1.5 0.5 6 1.4 0.9 6 ns 
Half Width (ms) 4.5 2.7 6 2.7 2.0 6 * 
Interval Time (ms) 0.7 0.4 6 2.4 1.1 6 ** 
Baseline Current (pA) -323.6 403.5 6 -850.8 1029.0 6 ** 
 
Table 4.1. Effects of 25 µM alfaxalone on spontaneous IPSC activity 
Whole cell patch clamping was performed to record spontaneous IPSC activity from HMNs of 9-11 
day Wistar rats. 50µM APV and 10µM NBQX were added to block NMDA and non-NMDA 
glutamate receptors. 25µM alfaxalone significantly altered spontaneous IPSC amplitude, half width 
and frequency but not rise time.  An inward shift in current was also detected.  All data is presented as 
mean  SD. * indicates a P value ≤ 0.05, ** indicates a P value ≤ 0.01  
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a) Control
b) Bicuculline
c) Strychnine
20pA
1 sec
 
Figure 4.2. Representative traces showing the effects of bicuculline and strychnine on 
spontaneous IPSC activity 
Spontaneous IPSC activity was recorded in a hypoglossal motor neurone of a 10-day-old Wistar rat.   
a) Spontaneous IPSC activity in the presence of 50μM APV and 10μM NBQX.   
b) There were no significant changes in spontaneous IPSC waveform parameters or frequency in the 
presence of 5μM bicuculline.  c) 500nM Strychnine caused complete cessation of spontaneous IPSC 
activity in two of four cells, increasing the interval time to a maximum of two IPSC events within a 
two-minute period. 
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Parameters Control 5µM Bicuculline 500nM Strychnine 
Spontaneous mean SD n mean SD n mean SD n 
Amplitude (pA) -46.1 6.44 4 -40.9 13.6 4 No IPSCs detected 4* 
Rise Time (ms) 1.3 0.6 4 1.5 0.8 4 No IPSCs detected 4* 
Half Width (ms) 5.6 3.35 4 4.9 4.6 4 No IPSCs detected 4* 
Interval time (ms) 2.2 0.95 4 3.7 2.3 4 No IPSCs detected 4* 
Evoked mean SD n mean SD n mean SD n 
Amplitude (pA) -103.9 37.97 4 -70.5 63.9 4 no response 4* 
Rise Time (ms) 3.4 1.794 4 3.7 1.4 4 no response 4* 
Half Width (ms) 8.9 3.8 4 7.5 1.5 4 no response 4* 
Baseline Current (pA) -265.4 106.8 4 -191.8 125.7 4 no response 4* 
Paired Pulse Ratio 1.7 0.33 4 1.5 0.2 4 no response 4* 
 
 
Table 4.2. Effects of bicuculline and strychnine on spontaneous and evoked IPSC activity 
No significant changes in spontaneous or evoked IPSC waveform changes were noted with the 
addition of 5µM bicuculline.  However, a marked reduction in IPSC activity was observed on addition 
of strychnine. 
* Strychnine caused complete cessation of evoked and spontaneous IPSC activity in 2 cells. 
Only one IPSC appeared in one cell and two IPSCs in another cell within a 2-minute file recording 
period.  This is in comparison to 61 to 83 observed events for 2 minute files recorded from HMNs in 
the presence of bicuculline. 
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Alfaxalone dose response study 
Pilot recordings showed that a high concentration of alfaxalone induced suppression of GlyR-
mediated inhibitory synaptic activity.  Following on from this finding, a dose response study of the 
effects of alfaxalone on glycinergic synaptic transmission was carried out to determine at what dose 
the suppressive effects of alfaxalone began at, and whether these changes occurred at clinically 
relevant doses.  Our rat pharmacokinetic studies revealed the MEC of alfaxalone in a rat as 1.45 ± 
0.79 and 2.06 ± 0.38mg/L for 2 mg.kg
-1
 and 5 mg.kg
-1
 dose ranges respectively.  With a molar mass 
of alfaxalone at 332.5g/mol, the MEC equivalent in molar concentrations is 4.36 and 6.02µM 
respectively.  We expected suppression of glycinergic neurotransmission to occur at or below these 
concentrations, as most neuro-excitation was observed during anaesthetic recovery when alfaxalone 
concentrations should be declining. 
 
Alfaxalone did not significantly alter spontaneous IPSC size  
Alfaxalone did not significantly alter spontaneous IPSC size and shape at concentrations up to 10µM.  
However, the spontaneous IPSC peak amplitude size ranged markedly, from –8.1pA to –653.5pA.  A 
paradoxical increase in spontaneous IPSC amplitude was also observed at alfaxalone concentrations 
of 1µM and 3µM, increasing by an observed 107  42% and 105  56% from control respectively.  
This increase was consistent, as it was noticed in 5 of the 7 cell recordings (Table 4.3).   
 
Alfaxalone caused a dose-dependent decrease in IPSC frequency 
A dose dependent increase in spontaneous IPSC interval was apparent from 3µM alfaxalone and IPSC 
interval increased to 3.44  5.63-fold longer than control IPSC interval at 10µM alfaxalone (Figure 
4.3.3).  This reduction in frequency indicates a decrease in presynaptic excitability may reduce 
glycinergic transmission. 
 
Alfaxalone did not change spontaneous IPSC shape 
Spontaneous IPSC rise time was not significantly changed by alfaxalone concentrations up to 10µM.   
A maximal reduction was observed at 1µM with IPSC rise time at 61.4 ± 22.78% of control (Figure 
4.3.3).  Spontaneous IPSC half width was unaltered at all concentrations up to 10µM alfaxalone. 
 
Alfaxalone caused a dose dependent reduction in evoked IPSC amplitude 
Reduction in the evoked IPSC peak amplitude was apparent from 30nM alfaxalone; evoked EPSC 
amplitude decreased in a dose-dependent manner, to a maximal mean difference of –138.1pA from 
control at 10µM alfaxalone (Figure 4.3.3).  Similar to spontaneous IPSC peak amplitude findings, 
evoked IPSC size also varied markedly and ranged from –8.1pA to –658.1pA.  This reduction in 
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evoked IPSC size suggests that alfaxalone causes a direct decrease in postsynaptic sensitivity of GlyR 
to glycine.   
 
Alfaxalone cause dose dependent alterations in evoked IPSC shape  
Alfaxalone increased the evoked IPSC rise time in a dose dependent manner.  Significantly longer rise 
times were observed from 1µM alfaxalone, with a maximal increase of 2.3 ± 0.64 fold longer at 10µM 
(Figure 4.3.3).  Overall, evoked IPSC half width was not significantly altered by alfaxalone 
concentrations up to 10µM; however half width increased in a dose dependent manner at low 
alfaxalone concentrations, with a maximal increase of 127.4 ± 15.6% of control at 300nM.  Evoked 
IPSC half width then decreased, to a minimum of 77.5 ± 44.28% of control at 10µM (Figure 4.3.3).  
Alfaxalone produced a dose dependent increase in evoked IPSC decay time, with a significant 2.7 ± 
1.1 fold increase from control occurring at 10µM (Figure 4.3.4).  These results show modulation of 
postsynaptic GlyR channel activity, starting from low micromolar concentrations of alfaxalone. 
 
Alfaxalone did not affect paired pulse ratio (PPR) 
PPR was unaltered at up to 10µM alfaxalone; paired pulse facilitation (PPF) was consistent 
throughout the alfaxalone dose range (Figure 4.3.3).  This shows that alfaxalone does not significantly 
alter Ca
2+
 dependent neurotransmitter release of glycine, and suggests that the decrease in 
spontaneous IPSC frequency was due to a decrease in presynaptic excitability rather than modulation 
of presynaptic terminal Ca
2+
 influx. 
 
Alfaxalone produced an inward current without altering input resistance 
A dose dependent inward shift in baseline holding current was observed up to 10µM alfaxalone.  A 
significant inward shift of 173.3 ± 50.2% of control was apparent at 10µM alfaxalone (Figure 4.3.6).  
Rn however was not affected by alfaxalone (Figure 4.3.6).  One would expect an increase in Rn 
concurrent with the activation of an inward current, however no significant Rn changes were observed. 
 
Alfaxalone caused an increase in baseline current noise at high concentrations 
An increase in baseline noise was observed in some recordings, this increase in noise was more 
pronounced at high micromolar concentrations of applied alfaxalone.  This increased current noise 
may suggest a tonic effect of alfaxalone but these effects were not investigated further.  
 
Alfaxalone caused glycinergic IPSC inhibition at clinically relevant doses 
These results confirmed that alfaxalone caused suppression of glycinergic synaptic transmission in a 
dose dependent manner.  A decrease in evoked IPSC amplitude was observed from 30nM, increased 
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evoked IPSC rise time from 1µM, and decreased IPSC frequency from 3µM.  These changes fall 
below the plasma concentrations of 4.36 to 6.02µM required for anaesthesia with alfaxalone.  In 
addition, alfaxalone elicited an inward current shift and increased evoked IPSC decay time constant at 
10µM.  Therefore these data shows that the concentrations at which glycinergic transmission is 
suppressed in rat HMNs are below those necessary to produce anaesthetic immobilisation, consistent 
with neuro-excitation occurring during recovery from anaesthesia with alfaxalone.  
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Figure 4.3.1. Representative spontaneous IPSC activity in rat hypoglossal motor neurones at 
increasing concentrations of Alfaxalone 
Spontaneous IPSC recordings were performed under voltage clamp conditions at a membrane 
potential of –60mV.  Note the reduction in spontaneous IPSC frequency and amplitude at increasing 
concentrations of alfaxalone. 
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Figure 4.3.2. Spontaneous IPSC parameters with increasing concentrations of alfaxalone 
a) Spontaneous IPSC peak amplitude was unaltered by alfaxalone.  However b) spontaneous IPSC 
frequency was significantly reduced at micromolar concentrations of alfaxalone. c) Alfaxalone did not 
change spontaneous IPSC half width d) or rise time.  All data is represented as mean  SD. 
* indicates a P value ≤ 0.05, *** indicates a P value ≤ 0.001 
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Figure 4.3.3. Evoked IPSC parameters with increasing concentrations of alfaxalone  
a) A dose-dependent reduction in evoked IPSC amplitude was apparent from 10nM and was 
significant for all concentrations from 300 nM upwards. b) PPR was unchanged by alfaxalone.  c) 
There was no change in evoked IPSC half width, although half width appeared to increase at low 
conentrations and then decrease at higher concentrations of alfaxalone.  d) evoked IPSC rise time was 
significantly prolonged from 1µM alfaxalone.  All data is represented as mean  SD. 
* indicates a P value ≤ 0.05, ** indicates a P value ≤ 0.01, *** indicates a P value ≤ 0.001  
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Figure 4.3.4. Evoked IPSC decay time increased with increasing concentrations of alfaxalone 
a) Significant prolongation of IPSC decay time was observed at 10µM alfaxalone, and was apparent at 
lower concentrations b) Superimposed traces show the extended decay time of evoked IPSCs, after 
scaling to peak amplitude.  The concentration of bath-applied alfaxalone is indicated in the colour 
legend to the right of the trace.  *** indicates a P value ≤ 0.001  
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Figure 4.3.5. Representative paired pulse evoked IPSCs show equivalent decreases in IPSC 
amplitude at micromolar concentrations of alfaxalone, without change in PPR 
Superimposed traces showing glycinergic IPSCs evoked by paired pulse stimulation with an 
interstimulus interval of 150ms.  The concentration of bath-applied alfaxalone is indicated in the 
colour legend to the right of the trace.  Increasing concentrations of alfaxalone up to10µM did not 
significantly alter the paired pulse ratio.  Note the proportional decrease in both first and second pulse 
evoked IPSC peak amplitude at micromolar concentrations of alfaxalone.   
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Figure 4.3.6. Effects of increasing concentrations of alfaxalone on baseline holding current and 
input resistance 
a)  Baseline holding current was unaffected by increasing doses of alfaxalone up to 10μM where a 
significant inward shift in holding current was produced.  The baseline current in alfaxalone has been 
normalized to the baseline current in control recording conditions.  b) Alfaxalone did not change 
HMN input resistance at any concentration of alfaxalone.  All data is presented as mean  SD.   
* indicates a P value ≤ 0.05 
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Spontaneous Parameters                 
    Control 10nM 30nM 100nM 300nM 1μM 3μM 10μM 
  Mean -56.26 -49.74 -45.5 -47.33 -45.94 -54.36 -52.34 -40.61 
Amplitude SD 21.75 20.83 16.59 24.76 13.48 20.13 26.74 17.22 
(pA) n 7 7 7 7 7 7 7 7 
  Significance 
(<0.05) 
ns ns ns ns ns ns ns 
  Mean 8.386 7.986 5.271 5.071 5.157 4.571 6.357 7.129 
Rise Time SD 3.877 2.774 2.193 2.227 1.655 1.208 2.418 1.743 
(ms) n 7 7 7 7 7 7 7 7 
  Significance 
(<0.05) 
ns ns ns ns ns ns ns 
  Mean 6.129 5.786 5.914 6.3 6.329 6.114 5.843 5.029 
Half Width SD 1.688 1.797 1.832 2.007 1.884 2.048 2.521 1.678 
(ms) n 7 7 7 7 7 7 7 7 
  Significance 
(<0.05) 
ns ns ns ns ns ns ns 
  Mean 0.97 0.99 1.16 1.3 1.3 1.75 2.33 3.67 
Interval Time SD 0.52 0.56 0.62 0.72 0.72 1.48 1.24 2.3 
(s) n 7 7 7 7 7 7 7 7 
  Significance 
(<0.05) 
ns ns ns ns ns * *** 
Evoked Parameters                 
    Control 10nM 30nM 100nM 300nM 1μM 3μM 10μM 
  Mean -217.1 -183.5 -164.8 -155.2 -156.4 -135.6 -118.1 -79.02 
Amplitude SD 132.9 96.44 99.18 102.8 108 110.3 105.6 66.89 
(pA) n 7 7 7 7 7 7 7 7 
  Significance 
(<0.05) 
ns * ** ** *** *** *** 
  Mean 2.484 2.68 3.107 3.413 3.712 4.44 4.855 5.802 
Rise Time SD 1.153 1.059 1.47 1.966 2.444 2.73 2.709 2.983 
(ms) n 7 7 7 7 7 7 7 7 
  Significance 
(<0.05) 
ns ns ns ns *** *** *** 
  Mean 13.48 14.55 16.13 16.39 16.92 16.29 14.28 9.767 
Half Width SD 4.16 3.691 4.771 4.454 4.767 3.462 4.498 4.722 
(ms) n 7 7 7 7 7 7 7 7 
  Significance 
(<0.05) 
ns ns ns ns ns ns ns 
  Mean 18.23 21.07 22.58 24.05 24.51 23.05 28.06 45.42 
Decay Time SD 6.631 5.844 7.171 7.193 8.501 4.983 10.39 13.26 
(ms) n 7 7 7 7 7 7 7 7 
  Significance 
(<0.05) 
ns ns ns ns ns ns *** 
  Mean 1.62 2.11 1.79 1.69 1.55 1.98 1.5 1.81 
Paired Pulse SD 0.42 1.13 0.39 0.56 0.4 0.78 0.5 1.06 
Ratio n 7 7 7 7 7 7 7 7 
  Significance 
(<0.05) 
ns ns ns ns ns ns ns 
  Mean -148.5 -157.5 -155.6 -157.5 -159.8 -167.9 -196 -237.7 
Baseline Current SD 60.65 52.87 53.39 53.76 53.1 51.79 62.48 58.97 
(pA) n 7 7 7 7 7 7 7 7 
  Significance 
(<0.05) 
ns ns ns ns ns ns * 
  Mean 159.4 150.5 143.8 146.2 145.5 145.6 163.1 144.7 
Input Resistance SD 68.79 61.23 64.64 55.08 52.21 51.66 59.86 61.28 
(mΩ) n 7 7 7 7 7 7 7 7 
  Significance 
(<0.05) 
ns ns ns ns ns ns ns 
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Table 4.3. Alfaxalone Spontaneous and Evoked IPSC Data Parameters  
See previous page 
A significant increase in IPSC frequency was apparent from 3µM.  Evoked IPSC peak amplitude was 
depressed from 30nM. Evoked IPSC rise time and decay time were prolonged. 
* indicates a P value ≤ 0.05, ** indicates a P value ≤ 0.01, *** indicates a P value ≤ 0.001 
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Discussion 
Alfaxalone induced neuro-excitation regularly during anaesthetic recovery in rats; neuro-excitation 
was characterised by spontaneous muscle contractions and muscle rigidity.  These signs are similar to 
those that manifest from diseases such as hyperekplexia or tetanus or strychnine poisoning, all of 
which occur due to abnormal suppression of synaptic inhibition of motor neurons by GlyRs.  Here we 
hypothesised that alfaxalone produces suppression of glycinergic inhibition of rat HMNs at clinically 
relevant doses.  Different neurosteroids have been reported to produce vastly different effects on 
GlyRs, including positive or negative GlyR modulation, so it was firstly important to determine 
whether alfaxalone produced any suppressive effects on GlyR-mediated synaptic transmission.  A 
pilot study was performed at a supra-clinical dose of 25µM alfaxalone, and results showed that 
alfaxalone did indeed suppress glycinergic activity.  Secondly, we aimed to determine whether 
alfaxalone produced suppression of GlyR inhibition at clinically relevant doses.  Our previous 
pharmacokinetic study in rats determined the minimum plasma level to produce anaesthetic 
immobilisation in rats was 4.36µM for 2mg.kg
-1
 IV and 6.02µM at 5mg.kg
-1
 IV.  Results presented in 
this chapter showed that alfaxalone suppressed GlyR inhibition in a dose dependent manner.  Reduced 
amplitude of evoked glycinergic IPSCs was apparent from 30nM, with the majority of postsynaptic 
changes in glycinergic IPSCs being observed within low micromolar alfaxalone concentrations.  
These data are in agreement with our initial hypothesis that alfaxalone produces suppression of GlyR 
inhibition at clinically relevant doses, and that this suppression could likely be the cause of neuro-
excitation during alfaxalone anaesthesia. 
 
Juvenile rats possess adult inhibitory glycinergic function 
Juvenile rats with an age range of 10 to 14 days old were used for the electrophysiological 
experiments.   The brainstems in younger rats are less myelinated and therefore provide fewer 
complications to securing a motor neuron seal.  Neonatal rats possess a different proportion of GlyR 
subunits than adult animals.  In situ hybridisation studies  in rats showed a dramatic increase in 
expression of adult α1 GlyR subunit mRNA within the first two weeks of life (Singer et al., 1998).  
Moreover, they also noted that the level of neonatal α2 GlyR subunit mRNA decreased to background 
levels by day 18.  Motor neurones change markedly in the first two weeks and have acquired adult-
like electrophysiological and morphological properties by approximately 16 days of age (Berger et al., 
1996, Singer and Berger, 2000).  There is the potential that α2 GlyR subunits could contribute to some 
of the glyicinergic activity, however we would expect the majority of glycinergic activity to be 
mediated by the adult α1 GlyR. 
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Have Alfaxalone suppresses glycinergic synaptic transmission to rat HMNs by both presynaptic and 
postsynaptic effects. 
The addition of 25µM alfaxalone caused a marked reduction in both spontaneous IPSC amplitude and 
frequency, which is suggestive of presynaptic suppression of inhibitory neurotransmission.  However, 
spontaneous IPSC half width changes at 25µM alfaxalone indicated postsynaptic modulation of 
GlyRs by alfaxalone.  Therefore the pilot study of the effects of alfaxalone showed both presynaptic 
and postsynaptic effects on glycinergic IPSCs by alfaxalone.  Due to the absence of GABAAR 
blockers, it was unclear what proportion of IPSC suppression could be attributed to effects on 
GABAergic or glycinergic components of the IPSC. 
 
The predominant component of the IPSC in juvenile rat HMNs is due to glycinergic inhibitory 
transmission 
The hypoglossal motor nucleus contains the highest GlyR density of any area within the CNS (Singer 
and Berger, 2000, Singer and Berger, 1999).  This suggests that the great majority of IPSC activity of 
HMNs would be attributable to glycinergic synaptic transmission, and it was for this reason our 
experiments were performed in HMNs.  However, previous studies have shown that glycinergic 
synaptic transmission to HMNs undergoes changes during postnatal development (Singer et al 1999). 
In addition, others have shown that co-transmission of GABA and glycine from the same presynaptic 
vesicle was possible in brainstem and spinal cord MNs, where dual component miniature IPSCs with 
GABAergic and glycinergic components were observed (O'Brien and Berger, 1999, Mitchell et al., 
2007, Jonas et al., 1998).   It has also been shown that 5µM bicuculline blocked 96.7 ± 1.1% of 
GABAAR responses and only 5.7 ± 7.5% of GlyR responses, while 500nM strychnine blocked 97.2 ± 
2.4% of GlyR responses and only 11.3 ±10.5% of GABAAR mediated responses in one to five day old 
Sprague Dawley rat HMNs (O'Brien and Berger, 1999). To confirm that GlyRs were the major 
inhibitory influence in the juvenile rat HMN, a pilot study with the selective antagonists bicuculline 
and strychnine was performed. The addition of 5µM bicuculline to control external solutions did not 
significantly change spontaneous or evoked IPSC waveform parameters, suggesting minimal 
GABAergic influence in juvenile rat HMNs.  The addition of 500 nM strychnine in the presence of 
bicuculline abolished evoked IPSCs, and abolished or markedly reduced spontaneous IPSC activity, 
confirming that the great majority of inhibitory synaptic activity in juvenile rat HMNs was glycinergic 
in nature. In order to rule out effects of alfaxalone on GABAAR as a confounding factor in our 
alfaxalone dose response study, 5µM bicuculline was applied to the bath solutions for the main study 
to block GABAARs. 
 
Alfaxalone causes a decrease in spontaneous IPSC amplitude and frequency at higher concentration 
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In our pilot study, alfaxalone at 25µM decreased spontaneous IPSC amplitude, increased spontaneous 
IPSC half width and increased the interval between spontaneous IPSCs.  These effects are consistent 
with a presynaptic reduction in glycinergic transmission and postsynaptic modulation of GlyR 
activity.  However, in the main dose response study, alfaxalone at up to 10µM did not have significant 
effects on spontaneous IPSC amplitude or half width, but significantly increased IPSC interval at 3 
and 10µM.   As we observed depression of evoked IPSC amplitude at much lower concentrations 
(from 30 nM upwards), one reason for an absence of depression of spontaneous IPSC amplitude at 
low alfaxalone concentration may be the large variability in spontaneous IPSC amplitude, which 
masked small changes in average amplitude.  Other investigators have noted that spontaneous and 
miniature glycinergic IPSC amplitude size are highly variable (Mitchell et al., 2007, Singer and 
Berger, 1999, Lim et al., 2003, Lim et al., 1999).  However, spontaneous IPSC amplitude depression 
may also occur through presynaptic mechanisms which depress presynaptic excitability; one test for 
future studies of the effect of alfaxalone would be to see if miniature IPSC amplitude and frequency 
are decreased in the presence of presynaptic activity blockers such as tetrodotoxin.  While the 
decrease in spontaneous IPSC frequency at alfaxalone concentration ≥ 3µM is consistent with a 
decrease in presynaptic glycine release, the absence of a change in PPR of evoked IPSCs suggests that 
the presynaptic actions of alfaxalone are less prominent than postsynaptic modulation of GlyRs.  Our 
data does not give insight into how alfaxalone might cause a reduction in presynaptic excitability, and 
whether alfaxalone directly decreases Ca
2+
 transients within the presynaptic terminal or indirectly 
regulates presynaptic excitability by other pathways is yet to be determined. 
 
 
Alfaxalone causes dose dependent reduction in evoked IPSC amplitude and shape. 
In the dose response study of evoked IPSCs, alfaxalone concentration started at 10nM and increased 
incrementally logwise to 10µM. A reduction in evoked IPSC peak amplitude was first observed at 
30nM alfaxalone concentrations, and this reduction progressively increased in size to a maximal 
reduction to 36% of control amplitude at 10µM alfaxalone.  This reduction in evoked IPSC size could 
be due to either a presynaptic depression of glycine release, or postsynaptic down regulation of GlyR 
activity.   
 
However, other changes in the evoked IPSC are consistent with the latter interpretation rather than the 
former.  Evoked IPSC rise time was increased from 1µM alfaxalone and evoked IPSC decay time at 
10µM alfaxalone concentrations.  Glycinergic IPSC decay phases are reportedly limited by GlyR 
channel opening and closure rather than glycine transmitter rebinding or GlyR desensitisation (Singer 
and Berger, 1999, Singer et al., 1998, Legendre, 1998).  The rise time of glycine-evoked currents 
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resulting from recombinant mammalian α1 and α1β GlyR channel openings or native GlyRs in 
Zebrafish brain neurons is glycine concentration-dependent, in that rise time decreased with 
increasing glycine concentrations (Mohammadi et al., 2003, Legendre, 1998).  A presynaptic 
reduction in glycine release therefore might result in delayed GlyR channel opening and therefore an 
increase in IPSC rise time, consistent with a shift to a “reluctant” gating state which has been reported 
to contribute to the kinetics miniature IPSCs mediated by GlyRs in Zebrafish brain neurons 
(Legendre, 1998).  However, the amplitude of miniature IPSCs is independent of their rise time, 
consistent with a saturating concentration of glycine at postsynaptic GlyRs (Legendre, 1998).    
Increases in evoked IPSC rise time and decay time prolongation are also consistent with postsynaptic 
modulation of the GlyRs, suggesting that alfaxalone increases the latency to opening of GlyRs by 
synaptically released glycine, and either delays GlyR closure or increases the probability of channel 
opening. 
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Alfaxalone did not alter PPR. 
Alfaxalone did not alter PPR of evoked IPSCs, which showed stable PPF up to 10µM alfaxalone 
concentration (Figure 4.3.3).  The addition of increasing concentrations of alfaxalone led to a dose-
dependent decrease in both first and second IPSC peak amplitude but did not alter the PPR.  PPF is 
indicative of a low overall probability of glycine release from the presynaptic membrane. As there 
was no change significant change in PPR throughout the alfaxalone dose response, this is a significant 
piece of evidence that alfaxalone does not directly influence the Ca
2+
 dependent release of glycine 
from pre-synaptic terminals.   
 
Taken together, changes in the evoked EPSC amplitude and time course, and a lack of change in PPR 
are strongly suggestive of postsynaptic GlyR modulation by alfaxalone, leading to amplitude 
reduction and prolongation of IPSC rise time and decay time.  Our results at this stage are compatible 
with a direct modulation of GlyRs by alfaxalone, but we cannot be rule out the possibility that 
application of alfaxalone causes an indirect modulation of GlyR by activating other receptors, ion 
channels or signalling pathways. 
 
 
Alfaxalone suppresses glycinergic transmission at clinically relevant doses. 
The minimum plasma concentration to maintain sleep in rats was calculated at between 4.36 to 
6.02µM alfaxalone. These results are consistent with previous studies where the concentration of 
alfaxalone associated with surgical anaesthesia in humans is within the low micromolar 
concentrations (Harrison and Simmonds, 1984).  Neuro-excitation was observed most frequently 
during anaesthetic recovery in rats.  This observation suggests that neuroexcitation would typically 
occur at or below concentrations of alfaxalone needed to maintain sleep.  Our data demonstrate that 
alfaxalone caused suppression of glycinergic inhibition from nanomolar concentrations; however 
most of the inhibitory effects of alfaxalone on glycinergic IPSCs were seen at low micromolar 
concentrations. Evoked IPSC peak amplitude was significantly depressed at 30nM alfaxalone, IPSC 
rise time was prolonged from 1µM alfaxalone and spontaneous IPSC frequency reduction was 
apparent from 3µM.   Our results are compatible with a postsynaptic modulation of GlyR channel 
activity starting at low alfaxalone concentrations, with a decrease in presynaptic release of glycine at 
higher concentrations. 
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High alfaxalone concentrations potentially activates multiple channels 
Higher doses of alfaxalone caused a noticeable increase in baseline noise in some cells.  This effect 
was usually observed at concentrations above 1µM alfaxalone.  This increase in baseline noise was 
also reported in an alfaxalone dose range study where doses of above 100μM were applied to 
transfected HEK 293 cell lines (Foadi et al., 2012).   Increased membrane noise was detected when 
alfaxalone (1-100µM) was applied to bovine chromaffin cells under voltage clamp conditions at 
negative potentials (Cottrell et al., 1987).  These results are consistent with our present alfaxalone 
findings in HMNs and could potentially be due to activation of other channels by alfaxalone.   
 
Alfaxalone produced an inward current without altering input resistance 
Alfaxalone elicited an inward current in rat HMNs at 10µM, but the cause of this inward shift is still 
not clear, as it was not accompanied by a significant change in input resistance.  The application of 
alfaxalone (1-100µM) to bovine chromaffin cells was reported to cause simultaneous activation of 
GABAA channels and inhibition of nicotinic acetylcholine channels, in whole cell patch clamp 
recording with a CsCl pipette solution that produced a net inward current through chloride-permeable 
channels (Cottrell et al., 1987).  Although we used roughly equivalent recording conditions in these 
experiments, it is unlikely that an inward current was generated by activation of GABAA channels, 
due to the presence of bicuculline in our external recording solutions. 
 
Alternate explanations for the inward current include activation of the hyperpolarisation-activated 
cation (IH) current or modulation of the transient receptor potential (TRP) channels.  The IH current is 
an anomalous rectifying cationic current that produces an increased inward membrane conductance 
during hyperpolarisation from resting membrane potential, and, importantly, has been reported in 
juvenile rat HMNs (Bayliss et al., 1994).  The IH current has been shown to play an important role in 
setting the resting membrane potential of HMNs as deletion of the HCN1 gene, which encodes for IH, 
resulted in significant hyperpolarisation of resting membrane potential (Chen et al., 2009, Chen et al., 
2005, Bellingham, 2013).  IH automatically inactivates at depolarised membrane potentials.  A 
positive shift in the voltage dependent IH will lead to a more positive membrane potential, provided 
there is no change in leak K
+
 conductance  (Ireland et al., 2012, Wenker et al., 2012).   The inward 
current caused by high alfaxalone concentrations could thus be due to a positive shift in the voltage 
activation of the IH current; this mechanism would also be compatible with a lack of change in Rn, as 
the slowly activating IH current is not directly assessed by the brief membrane pulses which were 
used to measure Rn.   
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However, the lack of change in Rn may simply be due to the inability of a somatic recording pipette to 
measure changes in Rn originating from remote dendritic membrane.  Evidence for this is seen in the 
largely dendritic excitatory synaptic inputs from the respiratory pattern generator, which produce a 
large change in conductance that is not associated with a change in input resistance.  Other possible 
sources of an inward current elicited by neurosteroids include activation of TRP channels, a large 
family of non-selective cation permeable channels that are found in most mammalian cell types and 
are known to have a role in modulation of intracellular Ca
2+
 (Clapham et al., 2001, Desai and 
Clapham, 2005, Pedersen et al., 2005, Moran et al., 2004).  TRP channels are often functionally 
associated with G protein-coupled receptors such as cannabinoid receptors (Moran et al., 2004).  
Further investigation is necessary to help identify whether activation of TRP channels might be a 
source of this alfaxalone induced inward current, and this is part of the investigations carried out in 
the final chapter of this thesis. 
 
The overall results presented in this chapter suggest that alfaxalone produces a reduction in GlyR 
inhibition by both presynaptic and postsynaptic mechanisms.   Alfaxalone leads to a decrease in 
glycine release from the presynaptic terminal and causes postsynaptic GlyR channel modulation, 
which together reduce the strength of glycinergic inhibition received by rat HMNs.  Alfaxalone also 
induced an inward current without significant change in input resistance.  These effects of alfaxalone 
occurred at or below clinically relevant anaesthetic doses.  It is still unclear however as to how 
alfaxalone mediates these changes; however, we hypothesise that there are possibly multiple 
mechanisms involved.  We are aware of the important role that cannabinoid receptors (CBR) can 
directly modulate both glycine release and GlyR function (Mukhtarov et al., 2005, Lozovaya et al., 
2005).  CBR are G protein-coupled receptors and a functional association has been identified between 
these receptors and TRP channels (Moran et al., 2004).  We therefore propose that alfaxalone induces 
endocannabinoid synthesis by increased intracellular Ca
2+
 from TRP channel activation, resulting in 
endocannabinoid release which modulates glycine release in the presynaptic terminal and/or 
postsynaptic GlyR activity by activation of CBRs.   
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CHAPTER FIVE  
The role of cannabinoid receptors in the electrophysiological effects of alfaxalone on the rat 
hypoglossal motor neurons 
 
Abstract 
 
Alfaxalone was shown to cause inhibition of glycinergic transmission to rat HMNs.  This reduction in 
inhibitory activity has also been postulated as the cause of neuro-excitation during alfaxalone 
anaesthesia. It is hypothesised that the reduction in glycinergic synaptic transmission caused by 
alfaxalone is induced partly by activation of TRP channels and the endocannabinoid synthesis 
pathway.  Here we investigated the effects of alfaxalone on HMNs in the presence of the cannabinoid 
1 receptor (CB1R) agonist WIN55,212-2, the CB1R inverse agonist AM251 and the CB1R antagonist 
NESS0327, using whole cell patch clamp techniques under voltage clamp conditions.  Whole cell 
recordings were performed on HMNs in transverse brainstem slices (300μM thickness) prepared from 
10-14 day old Wistar rats anaesthetised with sodium pentobarbitone (100 mg.kg
-1
 IP).  Spontaneous 
and evoked inhibitory post-synaptic currents (IPSC) were recorded at a holding potential of –60mV, 
using a CsCl-based internal solution, in the presence of the non-NMDA and NMDA glutamate 
receptor blockers NBQX (10µM), APV (50µM) and the GABAAR antagonist bicuculline (5µM) was 
bath-applied in control solutions for all studies.  A WIN55,212-2 dose response study was performed 
with bath application of 10nM, 30nM, 100nM, 300nM, 1μM and 3μM WIN55,212-2.  Subsequent 
studies involved pre-application of WIN55,212-2 (300nM), AM251 (1µM), NESS0327 (100pM) or 2-
APB (100µM) to a control bath, followed by application of 1μM, 3μM and 10μM of alfaxalone.  
WIN55,212-2 significantly decreased evoked IPSC amplitude to 50.85 ± 17.20% of control at 10nM 
showing a dose dependent decrease to 41.41 ± 18.85% of control at 3µM concentration.  Non-linear 
fitting of a dose response curve yielded an EC50 value of 18 nM.  Significant spontaneous IPSC 
amplitude depression was apparent from 3µM alfaxalone and reduced IPSC frequency was apparent 
from 10µM alfaxalone in the presence of WIN55,212-2.   AM251 (1µM) and NESS0327 (100pM) 
blocked evoked IPSC amplitude reductions and evoked IPSC event prolongation.  No significant 
changes in spontaneous IPSC peak amplitude, frequency, half width and decay time or baseline 
holding current were apparent on co-application of 2-APB and alfaxalone.  Results of this study 
support our hypothesis that alfaxalone causes a reduction in glycinergic transmission via the 
endocannabinoid signalling pathway and produces an inward current through activation of TRP 
channels.  The resultant increase in neuronal excitation would clinically manifest as neuro-excitation 
and could underlie the mechanism to which causes the alfaxalone twitch.  A combination anaesthetic 
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comprising of alfaxalone with a CB1R antagonist, could potentially stop the alfaxalone twitch and 
markedly improve alfaxalone anaesthesia for laboratory rodents but also other veterinary species.   
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Introduction 
 
Most neurosteroids are active at a wide range of receptors (Webb and Lynch, 2007), making it 
difficult to determine a priori what receptor mechanism mediates suppression of glycinergic inputs by 
alfaxalone.  Glycinergic inputs to HMNs can be modulated presynaptically by a wide variety of G-
protein coupled receptors (metabotropic Glutamate Rs, aminergic Rs, muscarinic Rs, purinergic Rs, 
peptidergic Rs, GABABR and cannabinoid Rs) and by steroidal compounds (Rekling et al., 2000, 
Pagnotta et al., 2005).  Postsynaptic modulation of glycinergic Rs by cannabinoid Rs has also been 
reported (Mukhtarov et al., 2005, Lozovaya et al., 2011).  Cannabinoid receptors (CBR) are of 
particular interest, as they are known to reside on the presynaptic GlyR terminal and are involved in 
modulation of glycine release (Lozovaya et al., 2005, Lozovaya et al., 2011). 
The Cannabis sativa plant has been long known for its mood-altering effects and has long been used 
as a recreational drug (Hejazi et al., 2006, Ledent et al., 1999).  Cannabinoids modulates many areas 
of the brain and spinal cord to produce modulatory effects on a multitude of actions through the CB1R 
including learning and memory, movement, food intake and antinociception (Hejazi et al., 2006, 
Pertwee, 1999). 
 
The synthesis of endocannabinoids anandamide and 2-arachidonoyl glycerol (2-AG) is triggered by 
an increase in cytoplasmic Ca
2+
 (Wilson and Nicoll, 2001, Bardell and Barker, 2010, Kreitzer and 
Regehr, 2002) and depolarisation-dependent release from neurons (Pertwee, 1999, Mukhtarov et al., 
2005).  The resultant endogenously synthesised cannabinoids then function as neuromodulators or 
neurotransmitters (Pertwee, 1999, Alger, 2002, Lozovaya et al., 2011, Wilson and Nicoll, 2001).  
These lipophilic molecules can mediate effects that are not associated with CBRs and can modulate 
voltage-gated Ca
2+
, Na
+
 and various K
+ 
channels (Oz, 2006, Hejazi et al., 2006, Oliver et al., 2004, 
Kreitzer and Regehr, 2002).  However, the endocannabinoid activation of the CB1R is of particular 
interest, as CB1R activation has been shown to reduce glycinergic inputs to HMNs, and could thus be 
the cause of alfaxalone induced inhibition of presynaptic glycinergic transmission.    
 
CBRs are G protein-coupled receptors with two known receptor types with CB1R predominantly 
found in the CNS and CB2R mainly in peripheral tissues (Pertwee, 1997, Pertwee, 2005).  Therefore it 
is thought that the majority of cannabinoid effects within the brain is mediated by CB1Rs of neurons 
(Navarrete and Araque).  Retrograde cannabinoid signalling involves the activation of CB1R and 
consequently decreases glycine release by modulating intracellular Ca
2+
 transients (Mukhtarov et al., 
2005, Navarrete and Araque). In HMNs, glycinergic synaptic currents are partially modulated 
presynaptically by retrograde cannabinoid signalling (Mukhtarov et al., 2005) and also by directly 
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modulating the postsynaptic GlyR (Lozovaya et al., 2011, Webb and Lynch, 2007).  We hypothesise 
that alfaxalone has direct effects on the production of endocannabinoids thereby reducing glycinergic 
transmission via CB1Rs.   
 
Since their discoveries, there have been numerous developments of CB1R and CB2R selective drugs 
(Pertwee, 2005).  CB1R agonists produce therapeutically beneficial properties such as analgesic, 
anticonvulsant, and antiemetic effects (Ledent et al., 1999).  Specifically, the synthetic cannabinoid, 
WIN55,212-2 reversed hyperalgesia and allodynia in a rat model of neuropathic pain (Bridges et al., 
2001).  The CB1R antagonist AM251 has inverse agonist activity and possesses significant 
antinociceptive properties at low doses (McMahon and Koek, 2007, Chambers et al., 2006) (Naderi et 
al.), potentially making it a useful adjunct for anaesthesia.  However, the CB1R inverse agonist 
SR141716 possesses significant psychiatric side effects including anxiety, depression and suicidality 
due to its constitutive CB1R activity (Meye et al., 2012).  The potent CB1R competitive antagonist 
NESS0327 has no antinociceptive activity and lacks the negative constitutive effects of CB1R inverse 
agonists (Ruiu et al., 2003, Meye et al., 2012).  For this study, we examined both CB1R inverse 
agonist AM251 and CB1R competitive antagonist NESS0327 for their differential effects at the CB1R.   
 
Transient receptor potential (TRP) channels are a family of ligand-gated cation channels, where many 
of these channels are permeable to Ca
2+
 (Pedersen et al., 2005).  These non-selective cation channels 
are involved in a diverse range of regulatory mechanisms including thermoregulation, olfaction, 
osmoregulation, pressure and acid sensation, stretch-evoked responses and many more (Clapham, 
2007, Desai and Clapham, 2005, Clapham et al., 2001, Di Marzo and De Petrocellis, 2010, 
Venkatachalam and Montell, 2007).  Few TRP channel endogenous ligands have been identified but 
the result of TRP channel activation is cell depolarisation and Ca
2+
 influx (Wu et al., 2010, Bardell 
and Barker, 2010).   Many TRP channels are potentiated by intracellular phospholipase C activation 
and also by activation of G protein-coupled receptors and tyrosine kinase receptors (Wu et al., 2010, 
Clapham et al., 2001).  Additionally, elevations in intracellular Ca
2+
 modulates almost all TRP 
channels (Wu et al., 2010, Bardell and Barker, 2010).  Evidence of direct activation of a TRP channel 
(TRPM3) by an endogenous neurosteroid pregnenalone sulphate was shown in pancreatic β cells 
(Wagner et al., 2008, Nilius and Voets, 2008).  This highlights the possibility of direct activation of 
TRP channels within the brain by other neurosteroids such as alfaxalone.  Furthermore, activation of 
TRP channels may be associated with heightening the startle response by elevating sensations related 
to pain and thermoregulatory responses (Clapham et al., 2001).  2-APB is a non-specific blocker of 
most TRP channel activity, with the exception of TRPV2, which is activated by 2-APB . We 
hypothesise that alfaxalone induces an inward current by activating TRP channels.  We also propose 
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that the depolarisation and Ca
2+
 influx due to TRP channel activation is likely the mechanism that 
triggers endocannabinoid synthesis and retrograde cannabinoid signalling.     
 
Here we investigated the effects of alfaxalone on HMNs in the presence of CB1R agonist WIN55,212-
2, CB1R inverse agonist AM251 and CB1R antagonist NESS0327, using whole cell patch clamp 
techniques under voltage clamp conditions.  We expect the application of CB1R agonist WIN55,212-2 
to mimick the inhibition of glycinergic neurotransmission in a manner similar to that of alfaxalone, 
and to occlude alfaxalone effects.  We also expect CB1R antagonists AM251 and NESS0327 to 
suppress alfaxalone-induced inhibition of glycinergic transmission.  Finally, we expect that the 
addition of a TRP channel blocker, 2-APB, will block the inward current produced by alfaxalone and 
thereby reduce alfaxalone induced inhibition of glycinergic transmission. 
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Materials and Methods 
 
Slice Preparation 
Slice preparation was performed as per Chapter 4 Materials and Methods. 
 
Solutions 
Solutions were prepared as per Chapter 4 Materials and Methods.  Variations to this involved the 
addition of (S),9(R)-(-)-Bicuculline methchloride (Sigma, 5μM) to the external control bath solution 
to block GABA receptor activity. 
  
Drugs 
3-α-hydroxy-5-α-pregna-11, 20-dione (Alfaxalone, a gift of Jurox Pty Ltd) was dissolved in 
hydroxypropyl substituted β-cyclodextrin (HPCD, a gift of Jurox Pty Ltd) to a ratio of 1:8 to make a 
stock concentration of 10mM, then diluted to the required bath concentration of 10nM, 30nM, 
100nM, 300nM, 1μM, 3μM and 10μM.   
 [R]-[+]-[2,3-Dihydro-5-methyl-3-[4-morpholinylmethly]pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-
naphthalenylmethanone mesylate (WIN 55, 212-2) was dissolved in DMSO at concentration of 
100mM to produce a stock concentration of  10mM/L, then diluted to the required bath concentration 
of 10nM, 30nM, 100nM, 300nM, 1μM and 3μM.  N-[piperidin-1-yl]-5-[4-iodophenyl]-1-[2,4-
dichlorophenyl]-4-methyl-1 H-pyrazole-3-carboxamide (AM251) was dissolved in DMSO at 
concentration of 10mg/mL to produce a stock concentration of  10mM/L, then diluted to the required 
bath concentration of 1μM.  N-piperidinyl-[8-chloro-1-(2,4-dichlorophenyl)-1,4,5,6-
tetrahydrobenzo[6,7] cyclohepta[1,2-c]pyrazole-3-carboxamide] (NESS0327) was dissolved in 
DMSO at concentration of 0.25mg/mL while bubbled in carbogen for 10 minutes.  A final stock 
concentration of 100μM/L was diluted to the required bath concentration of 100pM. 2-
aminoethoxydiphenyl borate (2-APB) was dissolved in 95% ethanol to make a stock solution of 
100mM/L and diluted to the required bath concentration of 100μM. 
The stock solution solvent (DMSO, ethanol or HPCD) was always diluted by a factor of 1000 or >, 
and had no effect when applied at these concentrations.  Application of drug via the bathing fluid was 
always for >2min; the time taken to completely exchange the recording chamber solution was 
typically <40s.  The alfaxalone dose response study was only applied to one HMN per slice. 
 
Electrophysiological recordings 
Brain slice preparation and recordings were performed as per Chapter 4 Materials and Methods.   
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Data analysis 
Data measurements were analysed as per Chapter 4 Materials and Methods.  Data are shown as Mean 
 SD and statistical significance was determined by a one-way ANOVA or paired two-tailed T-test 
followed by dunnett’s multiple comparison post test and accepted at P<0.05 using Graphpad Prism 5 
software. 
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Results 
We hypothesise that alfaxalone causes inhibition of glycinergic transmission by activation of CB1R.  
Therefore, we first needed to determine whether direct activation of CB1Rs caused modulatory effects 
on glycinergic transmission similar to those of alfaxalone in rat HMNs.  We predict that the 
application of a potent CB1R agonist WIN55,212-2 will mimic the effects of alfaxalone.  Control data 
for spontaneous and evoked recordings were obtained in the presence of APV (50μM), NBQX 
(10μM) and bicuculline methchloride (5μM) to exclude excitatory and GABAergic synaptic input, 
and therefore isolate glycinergic synaptic activity.   
 
 
WIN55,212-2 dose response study  
Spontaneous IPSC recordings were only recorded in two cells and therefore statistical analysis was 
not possible. We could however see a trend towards a dose dependent decrease in IPSC size and 
frequency (Table 5.1).  IPSC amplitude decreased from -96.9 ± 4.4pA at control to 32.9 ± 13.3pA at 
3µM WIN55,212-2.  IPSC interval time was lengthened from 0.3 ± 0.1 sec at control to 4.4 ± 2.3 sec 
at 3µM (Table 5.1). 
 
 
WIN55,212-2 reduces evoked IPSC size but did not alter evoked IPSC shape 
WIN55,212-2 at 10 nM significantly reduced evoked IPSC amplitude to 50.85 ± 17.20% of control 
(Figure 5.1.1).  This decrease in evoked IPSC amplitude was slightly larger at higher concentrations 
of  WIN55,212-2, reaching 41.41 ± 18.85% of control at 3µM concentration.  Non-linear fitting of a 
dose response curve yielded an EC50 value of 18 nM.  We also observe within the WIN55,212-2 dose 
response study, we see maximal amplitude reduction.  The decrease in IPSC amplitude however was 
not accompanied by a significant change in IPSC shape parameters, as rise time, half width and decay 
time were not changed at any concentration of WIN55,212-2.  The reduction of evoked IPSC 
amplitude could be caused by either a decrease in presynaptic glycine release or postsynaptic 
inhibition of the GlyR. 
 
 
WIN55,212-2 had no effect on PPR 
PPR was not altered by increasing concentrations of WIN55,212-2 up to 3µM. This effect shows that 
WIN55,212-2 does not significantly change Ca
2+
 dependent glycine release from the presynaptic 
terminal. 
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WIN55,212-2 did not alter baseline holding current or input resistance 
WIN55,212-2 did not change baseline current at concentrations up to 3μM.  In contrast, there was a 
possible trend towards the development of an outward current at 3µM WIN55,212-2, although this 
trend did not reach significance.  HMN Rn also remained steady throughout the WIN55,212-2 dose 
response study.  This lack of change in baseline holding current and Rn implies that the development 
of an inward current is unlikely due to CB1R activation. 
 
 
Both WIN55,212-2 and alfaxalone caused GlyR inhibition 
Although no statistical analysis was performed during spontaneous recordings, the reduction in 
spontaneous IPSC amplitude and frequency are consistent with presynaptic depression of glycine 
release, similarly to the results from the alfaxalone dose response study of spontaneous IPSCs. A 
reduction in evoked IPSC amplitude was observed in both WIN55,212-2 and alfaxalone dose 
response studies.  Neither WIN55,212-2 nor alfaxalone affected PPR or Rn.  Alfaxalone did however 
cause evoked IPSC rise time prolongation and development of an inward current that was not 
apparent with application of WIN55,212-2.   
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Figure 5.1.1.  Evoked IPSC amplitude is reduced by increasing concentrations of WIN55,212-2 
a) WIN55,212-2 significantly decreased IPSC amplitude starting at the lowest bath applied 
concentration of 10nM, and continuing up to 3µM.  No other alterations in evoked IPSC waveform 
parameters were observed with bath application of WIN55,212-2 to HMNs.  Significance was 
calculated relative to normalised control data (1 way ANOVA and Dunnett’s multiple comparison) 
and all data is presented as mean ± SD. *** indicates a P value ≤ 0.001 
b) Representative traces of evoked IPSCs highlights the marked decrease in IPSC amplitude in the 
presence of different concentrations of WIN55,212-2, without change in IPSC shape or PPR. 
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Spontaneous Parameters               
    Control WIN55,212-2 
      10nM  30nM 100nM 300nM 1μM 3μM 
  Mean -96.9 -78.2 -63.5 -35.5 -31.4 -32.9   
Amplitude  SD 4.4 16.3 11.4 21.3 16.3 13.3   
(pA) n 2 2 2 2 2 2   
  Mean 6.7 6.4 2.3 3.2 4.1 4.5   
Rise Time  SD 5.4 4.9 1.4 0.4 0.7 2.3   
(ms) n 2 2 2 2 2 2   
  Mean 6.4 6.1 6.5 6.5 7.6 7.8   
Half Width  SD 3.8 3.3 3.3 3.5 2.3 4.3   
(ms) n 2 2 2 2 2 2   
  Mean 0.31 0.4 0.6 0.9 3.6 4.4   
Interval Time  SD 0.1 0.2 0.2 0.4 2.6 2.3   
(s) n 2 2 2 2 2 2   
Evoked Parameters               
    Control WIN55,212-2 
      10nM  30nM 100nM 300nM 1μM 3μM 
  Mean -111.7 -49.5 -40.5 -38.4 -36.2 -37.9 -37.6 
Amplitude  SD 67.4 21.1 24.5 17.2 21.6 15.9 22.4 
(pA) n 7 7 7 6 6 6 5 
  Significance (<0.05) *** *** *** *** *** *** 
  Mean 2.4 3.0 3.5 3.0 3.5 3.2 3.0 
Rise Time  SD 0.7 0.6 1.2 0.7 1.6 1.7 0.9 
(ms) n 7 7 6 6 6 6 5 
  Significance (<0.05) ns ns ns ns ns ns 
  Mean 8.3 8.5 8.5 8.7 8.9 9.4 7.9 
Half Width SD 2.3 1.7 4.1 3.5 4.1 5.1 4.0 
(ms) n 7 7 7 6 6 6 5 
  Significance (<0.05) ns ns Ns ns ns ns 
  Mean 8.1 6.7 6.7 6.0 9.9 6.6 12.6 
Decay Time SD 3.1 2.7 3.3 4.2 7.1 3.1 6.7 
 (ms) n 7 7 7 6 6 6 5 
  Significance (<0.05) ns ns ns ns ns ns 
  Mean 1.9 2.0 1.8 2.2 1.6 1.8 1.8 
Paired Pulse SD 0.7 0.7 0.8 0.5 0.5 0.8 0.7 
Ratio n 7 7 7 6 6 6 5 
  Significance (<0.05) ns ns ns ns ns ns 
  Mean -158.8 -191.3 -200.8 -181.2 -166.8 -180.1 -117.4 
Baseline Current  SD 112.8 133.5 126.2 132.8 125.7 134.4 55.4 
(pA) n 7 7 7 6 6 6 5 
  Significance (<0.05) ns ns ns ns ns ns 
  Mean 196.1 188.6 181.8 194.2 192 196.8 207.7 
Input Resistance SD 124.9 134.4 135.3 149.2 152.1 151.1 132.4 
(mO) n 7 7 7 6 6 6 5 
  Significance (<0.05) ns ns ns ns ns ns 
 Table 5.1. Spontaneous and evoked IPSC data for WIN 55,212-2 dose response study 
Spontaneous IPSC recordings were performed on two cells and therefore significant statistical 
analysis was not performed.  Evoked IPSC amplitude reduction was observed from 10nM. 
*** indicates a P value ≤ 0.001  
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The effects of alfaxalone in the presence of CB1R agonist WIN55,212-2 
 
We postulated that alfaxalone caused inhibition of glycinergic transmission by activation of CB1R 
receptors.   We therefore expected the WIN55,212-2 dose response study to mimick the effects of 
alfaxalone on GlyR synaptic activity.  Results showed that there were similarities between the two 
dose response studies; however, to substantiate this effect, we would need to next see the effects of 
alfaxalone in the presence of WIN55,212-2.  As WIN55,212-2 is a highly potent CB1R ligand, we 
would predict that it will partially occlude effects of alfaxalone at low concentration by competition 
for the CB1R binding site.  Significant suppression of GlyR activity was apparent from 10nM 
WIN55,212-2, and a half maximal effective concentration (EC50) for evoked IPSC amplitude 
reduction was calculated to be 18nM WIN55,121-2.  To ensure a full CB1R agonist effect, the 
WIN55,212-2 concentration in this study was chosen to be 300nM. Alfaxalone was applied at 
micromolar concentrations as most of the effects of alfaxalone were apparent at these concentrations.  
Control recordings were performed in the presence of presence of APV (50μM), NBQX (10μM), 
bicuculline methchloride (5μM) and WIN55,212-2 (300nM). 
 
Alfaxalone reduced spontaneous IPSC size without altering IPSC shape or frequency 
Alfaxalone significantly reduced spontaneous IPSC peak amplitude from 3µM where a reduction of 
65.5 ± 12.7% from control was observed.  This decrease in IPSC amplitude was not accompanied by 
spontaneous IPSC rise time or half width changes (Figure 5.2.1).  IPSC frequency decreased in a dose 
dependent manner, but this effect was not significantly apparent until 10µM alfaxalone.  IPSC interval 
time was increased from 1.0 ± 0.5 sec to 9.8 ± 4.0 sec at 10µM alfaxalone.   
 
Alfaxalone reduced evoked IPSC size  
A significant decrease in evoked IPSC peak amplitude was apparent at 3μM alfaxalone and a further 
decrease to 58.7 ± 23.8% of control was seen at 10µM alfaxalone (Figure 5.2.2).   
 
Alfaxalone prolonged evoked IPSC decay time 
Evoked IPSC decay time prolongation was observed at 10µM alfaxalone, increasing to 176.9 ± 79.9% 
of control.  Evoked IPSC rise time and half width also appeared to increase in a dose dependent 
manner, but these changes were not statistically significant.     
 
Alfaxalone did not alter PPR 
The addition of alfaxalone in the presence of WIN55,212-2 did not affect PPR (Table 5.2) 
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Alfaxalone produced an inward current without altering input resistance 
An inward current was observed on application of 10μM alfaxalone where a 2.5 ± 1.1 fold increase in 
inward holding current was observed compared to control. Rn was unchanged by alfaxalone in the 
presence of WIN55,212-2. 
 
WIN55,212-2 delayed the suppressive effects of alfaxalone on glycinergic IPSCs 
We expected the pre-application of the CB1R with WIN55,212-2  would reduce the inhibitory effects 
of alfaxalone by competitive binding with CB1Rs causing reduction in glycinergic transmission and 
therefore reduce the effectiveness of alfaxalone to indirectly activate CB1Rs.  
There were several comparable differences between the alfaxalone dose response study and the effects 
of alfaxalone with WIN55,212-2  pre-application.  Alfaxalone alone did not alter spontaneous IPSC 
amplitude, but in the presence of WIN55,212-2, a noticeable amplitude reduction was apparent from 
3µM alfaxalone.  IPSC frequency was decreased by alfaxalone in both studies but a less pronounced 
reduction was noticed with pre-application of WIN55,212-2. 
Evoked IPSC amplitude reduction was noticeable from 30nM for alfaxalone applied alone; however a 
decrease in evoked IPSC amplitude was only observed at 3 and 10µM alfaxalone in the presence of 
WIN55,212-2.  Pre-application of WIN55,212-2 blocked the evoked IPSC rise time prolongation 
caused by alfaxalone.  IPSC decay times were prolonged from 10µM alfaxalone with or without the 
pre-application of WIN55,212.  In addition, the development of an inward current was still observed 
at 10µM alfaxalone when WIN55,212-2 was present.  Overall, this comparison shows that pre-
application of the CB1R agonist WIN55,212-2 reduced the effects of alfaxalone on  glycinergic 
transmission, but had no influence on the development of a depolarising current.  This indicates that 
both WIN55,212-2 and alfaxalone are likely to activate CB1Rs which depress glycinergic 
transmission to HMNs.  
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Figure 5.2.1.  Spontaneous IPSC parameters for increasing concentrations of alfaxalone in the 
presence of 300nM WIN55,212-2 
a)  Pre-application of WIN55,212-2 caused significant spontaneous IPSC amplitude depression at 
3µM and 10µM alfaxalone.  b) A increase in IPSC interval was apparent at 3µM and was significant 
at 10µM alfaxalone c) there were no significant changes in IPSC rise time d) or IPSC halfwidth on 
coapplication of WIN55,212-2 and alfaxalone.  Significance was calculated from normalised data and 
all data is presented as mean ± SD.  * indicates a P value ≤ 0.05, ** indicates a P value ≤ 0.01 
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Figure 5.2.2.  Evoked IPSC parameters for increasing concentrations of alfaxalone in the 
presence of 300nM WIN55,212-2 
a)  In the presence of WIN55,212-2, alfaxalone caused IPSC amplitude depression at 3 and 10 µM.  b) 
PPR was not affected by alfaxalone c) nor was rise time, d) or halfwidth e) but decay time was 
prolonged from 10µM alfaxalone with pre-application of  WIN55,212-2f) A significant inward shift 
in baseline holding current was observed at 10µM alfaxalone in the presence of WIN55,212-2,.  
Significance was calculated from normalised data and all data is presented as mean ± SD.   
* indicates a P value ≤ 0.05, ** indicates a P value ≤ 0.01 
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Figure 5.2.3.  Representative trace of evoked IPSC recordings of increasing alfaxalone 
concentrations in the presence of 300nM WIN55,212-2 
Pre-administration of WIN55,212-2 to alfaxalone caused a dose dependent decrease in evoked IPSC 
amplitude of both first and second pulses. IPSC rise time was unaltered, while decay time was slightly 
prolonged following application of 10µM alfaxalone with WIN55,212-2.  The PPR was unaltered in 
the presence of either WIN55,212-2 alone or with micromolar concentrations of alfaxalone.     
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Spontaneous Parameters     
  WIN55,212-2 Alfaxalone 
  300nM 1μM 3μM 10μM 
 Mean -45.0 -36.5 -29.3 -27.5 
Amplitude SD 8.1 7.2 6.8 9.3 
(pA) n 5 5 5 3 
  P <0.05 ns ** ** 
 Mean 6.3 3.8 4.3 4.2 
Rise Time SD 2.2 1.4 1.2 1.5 
(ms) n 5 5 5 3 
  P <0.05 ns ns ns 
 Mean 4.6 5.4 4.9 4.2 
Half Width SD 1.2 1.6 1.7 0.9 
(ms) n 5 5 5 3 
  P <0.05 ns ns ns 
 Mean 1.9 4.3 6.2 9.8 
Interval Time SD 0.5 6.4 5.3 4.0 
 n 5 5 5 3 
  P <0.05 ns ns * 
Evoked Parameters     
  WIN55,212-2 Alfaxalone 
  300nM 1μM 3μM 10μM 
 Mean -295.2 -248.7 -158.9 -140.6 
Amplitude SD 61.84 48.05 42.72 112.5 
(pA) n 5 5 3 3 
  P <0.05 ns * ** 
 Mean 2.0 2.3 3.1 4.0 
Rise Time SD 0.5 0.5 0.9 2.3 
(ms) n 5 5 3 3 
  P <0.05 ns ns ns 
 Mean 7.8 9.2 10.7 10.9 
Half Width SD 0.9 1.7 0.9 2.2 
(ms) n 5 5 3 3 
  P <0.05 ns ns ns 
 Mean 6.0 6.5 9.5 11.4 
Decay Time SD 1.3 1.8 1.1 3.2 
(ms) n 5 5 3 3 
  P <0.05 ns ns * 
 Mean 1.4 1.3 1.2 1.2 
Paired Pulse SD 0.4 0.2 0.1 0.2 
Ratio n 5 5 3 3 
  P <0.05 ns ns ns 
Baseline Mean -118.5 -127.2 -106.7 -215.0 
Current SD 39.0 29.9 35.0 4.0 
(pA) n 5 5 3 3 
  P <0.05 ns ns ** 
Input Mean 156.1 153.7 157.2 134.4 
Resistance SD 77.4 63.9 65.9 35.7 
(mΩ) n 5 5 3 3 
  P <0.05 ns ns ns 
Table 5.2. Spontaneous and evoked IPSC parameters for increasing concentrations of 
alfaxalone in the presence of 300nM WIN 55,212-2 
* indicates a P value ≤ 0.05, ** indicates a P value ≤ 0.01, *** indicates a P value ≤ 0.001 
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The effects of alfaxalone in the presence of CB1R inverse agonist AM251  
These data showed that WIN55,212-2 blocked many of the inhibitory effects of alfaxalone on 
glycinergic transmission without altering the inward current elicited by alfaxalone.  These results 
strongly suggest that alfaxalone may act through CBR activation to suppress glycinergic transmission.  
To provide further evidence to support this hypothesis, we would expect the pre-application of a 
CB1R inverse agonist AM251 to block the inhibitory effects of alfaxalone on glycinergic 
transmission.  As an inverse agonist, we would also expect to see antagonism of any constitutive 
CB1R activity in the absence of an agonist, and therefore we may potentially see an increase in 
glycinergic transmission with application of AM251 alone.   
 
AM251 alone did not alter spontaneous or evoked glycinergic transmission  
1µM AM251 was bath-applied in a control aCSF containing APV (50μM), NBQX (10μM) and 
bicuculline methchloride (5μM).  No significant changes in spontaneous or evoked IPSC parameters 
were observed (Table 5.3).  A slight increase in IPSC frequency was observed between AM251 and 
control conditions, but this increase was not significant. This slight increase in IPSC frequency could 
be due to a reduction in constitutive CB1R activity produced by this inverse agonist.  However, the 
lack of any significant effects o application of AM251 alone suggests that constitutive CB1R activity 
does not modulate glycinergic transmission to HMNs. 
 
Alfaxalone did not alter spontaneous IPSC size or frequency in the presence of AM251 
Alfaxalone did not alter spontaneous IPSC peak amplitude at concentrations up to 10µM following 
pre-application of AM251 (Figure 5.3.2).  Spontaneous IPSC frequency also remained constant at all 
concentrations of alfaxalone and did not significantly differ from that seen in AM251 alone.   
 
Alfaxalone caused reduction in spontaneous IPSC rise time but did not change half width in the 
presence of AM251 
 A significant reduction in spontaneous IPSC rise time was observed at all micromolar concentrations 
of alfaxalone (Figure 5.3.2) in the presence of AM251. A maximal reduction to 51.5 ± 13.4% was 
seen at 3µM alfaxalone compare to rise time in AM251 alone.  In contrast, alfaxalone did not alter 
spontaneous IPSC half width at any concentration in the presence of AM251. 
 
Alfaxalone did not alter evoked IPSC amplitude or shape in the presence of AM251 
Evoked IPSC amplitude and shape were not significantly altered by alfaxalone following pre-
application of AM251.  Mean evoked IPSC peak amplitude showed increased variability at high 
concentrations of alfaxalone; amplitudes ranging from -38.7 to -136.0pA at 10µM alfaxalone (Figure 
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5.3.3).  Evoked IPSC rise time showed similar variability at 10µM alfaxalone.  Evoked IPSC half 
width and decay time were unaltered through the dose range. 
 
PPR was unaffected by either AM251 or alfaxalone in the presence of AM251 
The addition of AM251 alone did not significantly change evoked IPSC PPR, and nor did co-
application of AM251 and alfaxalone.  
 
Baseline holding current and input resistance was unaltered by alfaxalone 
Baseline holding current was not significantly altered by the addition of AM251 alone, or by 
alfaxalone in the presence of AM251. However, there were large variations in holding current 
following addition of 10µM alfaxalone in the presence of AM251, with a mean change ± SD of -85.6 
± 99.1 (Figure 5.3.4).  An observed decrease in Rn at 10µM alfaxalone was seen, although this 
decrease was not significant.  This decrease in Rn could be a result of activation of more channels and 
could account for increased baseline noise observed in some of the recordings at 10µM alfaxalone 
(Figure 5.3.1) 
 
AM251 blocked the effects of alfaxalone on glycinergic IPSCs and on holding current 
The effects of alfaxalone on glycinergic transmission were significantly reduced in the presence of the 
CB1R inverse agonist AM251.  A reduction in spontaneous IPSC frequency was not seen following 
alfaxalone application with AM251 present, while alfaxalone applied alone produced a marked 
reduction in IPSC frequency from 3µM.  Evoked IPSC amplitude was not altered by alfaxalone with 
pre-application of AM251.  This too was in contrast to the alfaxalone dose response study, in the 
absence of AM251, where we saw marked evoked IPSC amplitude reduction from 30nM alfaxalone 
concentration.  Alfaxalone reduced spontaneous IPSC rise time with AM251 present, an effect which 
was not seen with alfaxalone applied alone.  The pre-application of AM251 blocked changes in the 
evoked IPSC rise and decay time caused by alfaxalone applied alone.  Interestingly, a depolarising 
current was not elicited by alfaxalone in the presence of AM251.  Overall, the results show that CB1R 
antagonism blocked presynaptic and postsynaptic effects of alfaxalone on glycinergic transmission, 
but also blocked the development of an inward current at 10µM alfaxalone.  
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C o n tro l
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Figure 5.3.1. Representative traces of spontaneous IPSC activity with micromolar alfaxalone 
concentrations in the presence of AM251 
AM251 alone did not alter control spontaneous IPSC activity.  No significant alterations in IPSC size 
or frequency were observed on addition of increasing concentrations of alfaxalone with AM251 
present. Note increased baseline noise was apparent in the recording on addition of 10µM alfaxalone.  
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 Figure 5.3.2. Spontaneous IPSC amplitude for increasing concentrations of alfaxalone in the 
presence of 1μM AM251 
a)  Spontaneous IPSC amplitude was unaltered by micromolar concentrations of alfaxalone, following 
the addition of 1µM AM251.  b) AM251 also blocked the reduction in spontaneous IPSC frequency 
caused by alfaxalone applied alone.  c) A significant decrease in spontaneous IPSC rise time was 
observed with application of micromolar concentrations of alfaxalone, following the pre-application 
of 1µM AM251; this effect was not present with alfaxalone applied without AM251.  Significance 
was calculated from normalised data and all data is presented as mean ± SD.  ** indicates a P value ≤ 
0.01, *** indicates a P value ≤ 0.001 
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Figure 5.3.3. Evoked IPSC parameters for increasing micromolar concentrations of alfaxalone 
with pre-application of 1μM AM251 
a)  The pre-application of 1µM AM251 blocked the evoked IPSC amplitude reduction caused by 
micromolar concentrations of alfaxalone. b) PPR was unaltered by alfaxalone in the presence of 
AM251.  c)  The marked reduction in evoked IPSC rise time reduction seen from 1µM alfaxalone was 
abolished by prior application of 1 µM AM251.  (d) Evoked IPSC half-width and e) IPSC decay time 
were not altered by micromolar alfaxalone after the addition of AM251 Significance was calculated 
from normalised data and all data is presented as mean ± SD.  
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Figure 5.3.4. HMN holding current at -60 mV and Rn following micromolar concentrations of 
alfaxalone co-applied with 1μM AM251 
a) Baseline holding current was altered by alfaxalone following pre-application of AM251 b) There 
was no significant change in Rn with micromolar alfaxalone in the presence of AM251; however there 
was a trend towards Rn reduction with 10µM alfaxalone  
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Spontaneous Parameters           
    Control AM251 Alfaxalone 
      1μM 1μM  3μM 10μM 
  Mean -53.3 -49.5 -53.2 -62.5 -55.4 
Amplitude  SD 23.2 16.1 22.9 25.6 25.7 
(pA) n 8 8 8 6 6 
    ns P <0.05 ns ns ns 
  Mean 4.9 4.6 2.7 2.7 3.8 
Rise Time  SD 2.7 2.3 1.0 1.0 1.5 
(ms) n 8 8 8 6 6 
    ns P <0.05 ** *** ** 
  Mean 4.9 5.1 5.0 5.2 5.3 
Half Width  SD 1.7 2. 1.8 2.0 1.8 
(ms) n 8 8 8 6 6 
    ns P <0.05 ns ns ns 
  Mean 1.4 1.1 1.2 0.7 0.8 
Interval Time  SD 1.5 1.2 1.3 0.2 0.2 
  n 8 8 8 6 6 
    ns P <0.05 ns ns ns 
Evoked Parameters           
    Control AM251 Alfaxalone 
      1μM 1μM  3μM 10μM 
  Mean -97.9 -103.8 -93.9 -53.9 -72.7 
Amplitude  SD 19.9 48.2 61.2 14.6 54.9 
(pA) n 6 6 6 3 3 
    ns P <0.05 ns ns ns 
  Mean 3.1 3.1 3.3 4.8 6.2 
Rise Time  SD 1.6 1.4 1.1 1.6 3.5 
(ms) n 6 6 6 3 3 
    ns P <0.05 ns ns ns 
  Mean 11.6 9.9 11.1 12.5 13.9 
Half Width SD 8.8 4.6 4.6 3.4 8.9 
(ms) n 6 6 6 3 3 
    ns P <0.05 ns ns ns 
  Mean 10.9 9.9 14.6 12.7 13.3 
Decay Time SD 9.0 5.1 9.0 5.1 11.9 
 (ms) n 6 6 6 3 3 
    ns P <0.05 ns ns ns 
Paired Mean 1.6 1.7 1.9 1.7 1.5 
Pulse SD 0.4 0.5 0.8 0.2 0.1 
Ratio n 6 6 6 3 3 
    ns P <0.05 ns ns ns 
Baseline Mean -117.2 -118.6 -186.0 -61.2 -85.6 
Current SD 38.3 96.3 242.1 57.6 99.1 
(pA) n 6 6 6 3 3 
    ns P <0.05 ns ns ns 
Input Mean 183.5 202.9 205.1 332.6 254.6 
Resistance SD 92.0 103.3 103.2 103.8 39.7 
(mO) n 5 5 5 2 2 
    ns P <0.05 ns ns ns 
Table 5.3. Spontaneous and evoked IPSC parameters for micromolar concentrations of 
alfaxalone in the presence of 1μM AM251 
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 The effects of alfaxalone in the presence of CB1R antagonist NESS0327 on glycinergic 
transmission  
These data show that the presence of AM251 blocked effects of alfaxalone on glycinergic 
transmission and holding current. These effects strongly suggest that the reduction of glycinergic 
transmission by alfaxalone, are mediated by activation of CB1Rs.   However, it is possible that the 
inverse agonist action of AM251 may partially counteract effects of alfaxalone, complicating the 
interpretation of the effects of AM251.  In this study, we used NESS0327, a potent competitive CB1R 
without inverse agonist activity, to determine where its pre-application produced similar outcomes to 
that of AM251 on the actions of alfaxalone.  The control aCSF contained APV (50μM), NBQX 
(10μM) and bicuculline methchloride (5μM). NESS0327 (100pM) was applied to determine the 
effects of NESS0327 alone, prior to addition of alfaxalone at micromolar concentrations. 
 
NESS0327 alone did not affect spontaneous or evoked glycinergic transmission 
Application of NESS0327 alone did not significantly alter spontaneous or evoked IPSC amplitude and 
shape.  Mean spontaneous IPSC frequency was unaltered; however the interval between spontaneous 
IPSCs was more variable in the presence of NESS0327 (Table 5.4).  The PPR of evoked IPSCs 
remained unchanged, and no effects on baseline holding current or input resistance were seen.   
 
Alfaxalone did not alter spontaneous IPSC amplitude or frequency with NESS0327 
In the presence of NESS0327, spontaneous IPSC amplitude was not significantly altered by 
alfaxalone up to 10µM.  There was no significant change in spontaneous IPSC frequency following 
alfaxalone in the presence of NESS0327; however the interval range varied widely at all doses of 
alfaxalone. Spontaneous IPSC interval time ranged from 0.21 - 1.04 sec with NESS0327 alone, and 
consistently varying from 0.22 – 4.50 sec at 10µM alfaxalone in the presence of NESS0327 (Table 
5.4).    
 
Alfaxalone caused decreased spontaneous IPSC rise time in the presence of NESS0327 
Spontaneous IPSC half-width remained altered with increasing doses of alfaxalone following 
application of NESS0327.  However, a significant reduction in spontaneous IPSC rise time was 
observed (Figure 5.4.4); a marked reduction in rise time was noticed at 1µM alfaxalone with a 
decrease to 52.8 ± 14.5% of control rise time and this effect was apparent up to 10µM alfaxalone 
(Figure 5.4.1). 
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Evoked IPSC amplitude and shape were not altered by alfaxalone in the presence of NESS0327 
Evoked IPSC amplitude was not altered by alfaxalone in the presence of NESS0327.  An observed 
increase in IPSC amplitude variability was observed, with IPSC amplitudes ranging from -50.1 ± 
375.5pA for NESS0327 alone, to -30.0 ± 334.3pA at 10µM alfaxalone after NESS0327.  Similarly, no 
change in evoked IPSC shape was seen with alfaxalone in the presence of NESS0327.  Evoked IPSC 
rise time, half width and decay time remained relatively constant with the addition of increasing 
micromolar concentrations of alfaxalone (Figure 5.4.2). 
 
Alfaxalone did not affect PPR in the presence of NESS0327 
No alterations in PPR were observed with micromolar alfaxalone in the presence of NESS0327 
(Figure 5.4.2).  This is consistent with neither NESS0327 nor alfaxalone altering the Ca
2+
 dependent 
presynaptic release of glycine. 
 
Baseline holding current and input resistance was unchanged by alfaxalone  
Baseline holding current was not significantly altered by alfaxalone up to 10µM in the presence of 
NESS0327 (Figure 5.4.3).  Rn also remained unchanged up to 10µM alfaxalone (Figure 5.3.1) 
 
NESS0327 mimicked the effects of AM251 in blocking the effects of alfaxalone 
We predicted a similar blockade of the inhibitory effects of alfaxalone following NESS0327 
application, as previously seen following AM251 application.  These results indeed showed a close 
similarity in the actions of AM251 and NESS0327.  Spontaneous IPSC frequency reduction caused by 
alfaxalone was blocked by both AM251 and NESS0327.  Dose dependent evoked IPSC amplitude 
reductions caused by alfaxalone were blocked by both AM251 and NESS0327.  Alfaxalone alone 
caused marked prolongation in both IPSC rise and decay times, an effect which the prior application 
of either NESS0327 or AM251 was able to block.  In addition to this, pre-application of AM251 or 
NESS0327 revealed a reduction in spontaneous IPSC rise time with the application of alfaxalone.  
The presence of NESS0327 blocked the inward current observed with 10µM alfaxalone, as did 
AM251.  Overall, the results show that CB1R antagonism with NESS0327 blocked presynaptic and 
postsynaptic effects of alfaxalone in a manner identical to that of AM251. These results undoubtedly 
provide strong evidence for CB1R activation by alfaxalone in causing suppression of glycinergic 
transmission. 
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Figure 5.4.1.  Spontaneous IPSC parameters for increasing concentrations of alfaxalone in the 
presence of 100pM NESS0327 
a)  Spontaneous IPSC amplitude were unaltered by alfaxalone following the addition of 100pM 
NESS0327.  b) NESS0327 also blocked the reduction in spontaneous IPSC frequency caused by 
alfaxalone.  c) A significant decrease in spontaneous IPSC rise time was observed with the addition 
alfaxalone in the presence of  100pM NESS0327, which was not presence with alfaxalone applied by 
itself d) Spontaneous IPSC half width was not altered by alfaxalone with NESS0327 present.  All data 
is presented as mean ± SD.  ** indicates a P value ≤ 0.01, *** indicates a P value ≤ 0.001 
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Figure 5.4.2.   Evoked IPSC parameters were not altered by increasing concentrations of 
alfaxalone in the presence of 100pM NESS0327 
a)  The addition of 100pM NESS0327 blocked reduction in evoked IPSC amplitude caused by 
alfaxalone alone b) PPR was unaltered.  c)  The marked reduction in evoked IPSC rise time with 
micromolar alfaxalone was abolished by prior application of 100pM NESS0327.  (d) Evoked IPSC 
half-width was unchanged by alfaxalone when NESS0327 was present.  e) Evoked IPSC decay time 
prolongation caused by alfaxalone at 10µM was abolished by prior application of 100pM NESS0327.  
All data is presented as mean ± SD. 
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Figure 5.4.3. Baseline holding current and input resistance data for alfaxalone in the presence of 
NESS0327 
a) Baseline holding current changes caused by alfaxalone alone was not apparent in the presence of 
NESS0327. b) Input resistance remained unaltered by micromolar alfaxalone in the presence of 
NESS0327. All data is presented as mean ± SD.  
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Figure 5.4.4. Representative traces of evoked IPSCs exposed to increasing alfaxalone 
concentrations in the presence of 100pM NESS0327   
a)  There were no significant alterations in evoked IPSCs parameters following alfaxalone application 
in the presence of NESS0327.  Pre-application of 100pM NESS0327 blocked evoked IPSC amplitude 
reductions caused by alfaxalone.  Evoked IPSC decay time prolongation, apparent with 10µM 
alfaxalone applied alone, were abolished by the pre-addition of NESS0327.  b)  Evoked IPSC rise 
time changes caused by alfaxalone were also removed with the pre-addition of NESS0327. 
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Spontaneous 
Parameters 
    
      
    Control NESS0327 Alfaxalone 
      100pM 1μM  3μM 10μM 
  Mean -51.97 -50.64 -49.66 -47.43 -47.27 
Amplitude  SD 16.88 14.26 15.8 11.38 14.87 
(pA) n 9 9 9 9 9 
    ns P <0.05 ns ns ns 
  Mean 4.544 4.433 2.211 2.567 3.022 
Rise Time  SD 1.363 1.45 0.454 0.691 1.041 
(ms) n 9 9 9 9 9 
    ns P <0.05 *** *** ** 
  Mean 4.578 4.333 4.367 4.556 4.833 
Half Width  SD 1.818 1.396 1.623 1.519 1.525 
(ms) n 9 9 9 9 9 
    ns P <0.05 ns ns ns 
  Mean 0.4167 0.8503 0.8619 0.898 1.078 
Interval Time  SD 0.1696 1.22 1.167 1.07 1.321 
  n 9 9 9 9 9 
    ns P <0.05 ns ns ns 
Evoked Parameters           
    Control NESS0327 Alfaxalone 
      100pM 1μM  3μM 10μM 
  Mean -245.8 -232.4 -246.4 -228.3 -204.8 
Amplitude  SD 95.44 131.8 117.3 140.2 122.1 
(pA) n 5 5 5 3 3 
    ns P <0.05 ns ns ns 
  Mean 3.285 3.07 3.45 3.05 3.38 
Rise Time  SD 1.322 1.19 1.30 1.04 1.37 
(ms) n 5 5 5 3 3 
    ns P <0.05 ns ns ns 
  Mean 8.057 7.41 8.18 9.67 8.96 
Half Width SD 1.577 1.15 1.00 2.52 1.06 
(ms) n 5 5 5 3 3 
    ns P <0.05 ns ns ns 
  Mean 6.947 5.88 6.41 6.59 6.70 
Decay Time SD 1.954 1.10 1.00 0.47 0.13 
 (ms) n 5 5 5 3 3 
    ns P <0.05 ns ns ns 
  Mean 1.488 1.525 1.292 1.153 1.239 
Paired Pulse SD 0.1471 0.3098 0.1575 0.1633 0.08061 
Ratio n 5 5 5 3 3 
    ns P <0.05 ns ns ns 
Baseline Mean -107.6 -159.4 -156.2 -141.8 -177.7 
Current SD 27.08 43.13 67.81 66.07 101 
(pA) n 5 5 5 3 3 
    ns P <0.05 ns ns ns 
Input Mean 119.4 112.1 112 121.6 107.6 
Resistance SD 39.67 28.66 25.04 32.27 21.97 
(mΩ) n 5 5 5 4 3 
    ns P <0.05 ns ns ns 
Table 5.4. Spontaneous and evoked IPSC parameters for micromolar concentrations of 
alfaxalone in the presence of 100pM NESS0327 
** indicates a P value ≤ 0.01, *** indicates a P value ≤ 0.001 
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 Effects of alfaxalone on glycinergic transmission in the presence of a non-specific TRP Channel 
antagonist, 2-APB 
We hypothesised that the inward current elicited by alfaxalone was due to TRP channel activation.  
We also hypothesised that the activation of TRP channels and the subsequent Ca
2+
 influx is the trigger 
for endocannabinoid synthesis and retrograde cannabinoid signalling.    We therefore expect pre-
application of the non-specific TRP channel blocker 2-APB to eliminate the inward current shift 
caused by alfaxalone alone.  In addition, we expect a decrease in CB1R activity due to blockade of 
endocannabinoid synthesis following 2-APB.  Spontaneous IPSC and holding current recordings were 
performed with a control bath containing APV (50μM), NBQX (10μM) and bicuculline methchloride 
(5μM) and compared to recordings on addition of 2-APB (100pM). 
 
2-APB did not affect spontaneous glycinergic transmission 
The addition of 2-APB did not significantly affect spontaneous IPSC amplitude, shape or frequency.  
Holding current and input resistance was also unchanged by 2-APB application.  This suggests that 
endogenous TRP channel activity is minimal in the control recording conditions (Table 5.5).   
 
 Alfaxalone did not affect spontaneous IPSC amplitude or frequency in the presence of 2-APB 
Neither spontaneous IPSC amplitude nor frequency were significantly altered by alfaxalone in the 
presence of 2-APB.  There was however a trend towards an increase in IPSC frequency up to 10µM 
alfaxalone (Table 5.5). 
 
Alfaxalone caused spontaneous IPSC shape augmentations 
1µM and 3µM but not 10µM alfaxalone caused a marked reduction in spontaneous IPSC rise time 
with 2-APB present (Table 5.5).  Spontaneous IPSC half width or decay time however were 
unaffected by alfaxalone in the presence of 2-APB.   
  
Alfaxalone did not alter baseline holding current in the presence of 2-APB 
The baseline holding current was not significantly altered at up to 10µM alfaxalone with 2-APB 
present (Table 5.5).  A large variation in baseline holding current was seen between cells, which 
ranged from -174.2pA to -814.1pA  with 2-APB application alone and -144.5pA to -831.0pA with 
3µM alfaxalone applied after 2-APB.  At 10µM alfaxalone, a range from -180.4pA to -306.8pA was 
noted however these data represents n=2. 
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2-ABP blocked the effects of alfaxalone on glycinergic inhibition 
Although only spontaneous IPSC activity was recorded, it was clear that the TRP channel blocker 2-
APB blocked presynaptic and postsynaptic effects of alfaxalone on glycinergic transmission and 
holding current.  2-APB prevented the spontaneous IPSC frequency reduction caused by alfaxalone 
along, as well as abolishing spontaneous IPSC amplitude by alfaxalone.  Interestingly, 2-APB also 
revealed a reduction in spontaneous IPSC rise time following alfaxalone application, a similar effect 
to that seen with pre-application of AM251 and NESS0327.  Alfaxalone did not cause an inward 
change in baseline holding current in the presence of 2-APB; in contrast, a trend towards an outward 
current shift at 10µM alfaxalone was observed.  Here we showed that a non-specific TRP channel 
blocker produced effects very similar to those seen after CB1R blockade.  These data suggests a 
signalling inter-relationship between TRP channels and CB1R activity.  These results are supportive 
of our hypothesis that alfaxalone modulates TRP channels to elicit an inward current that can then 
modulate the cannabinoid signalling pathway. 
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Figure 5.5.1.  Representative spontaneous IPSC traces in the presence of 2-APB and in 
combination micromolar concentrations of alfaxalone 
Ten-second traces of spontaneous IPSC recordings in rat hypoglossal motor neurons showed no 
significant changes in spontaneous IPSC peak amplitude, frequency, half width and decay time or 
baseline holding current with application of 2-APB alone, and prior to micromolar concentrations of 
alfaxalone. Note the variations in spontaneous IPSC peak amplitudes evident with all traces. 
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Figure 5.5.2. Representative average spontaneous IPSC trace during co-application of 2-APB 
and alfaxalone 
Representative spontaneous IPSC traces depict a reduction in spontaneous IPSC rise time regardless 
of peak amplitude variations with administration of alfaxalone in the presence of 2-APB.   
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Spontaneous Parameters           
    Control 2-APB  Alfaxalone 
      100pM 1μM  3μM 10μM 
  Mean -251.8 -276.7 -257.5 -273.5 -262.7 
Amplitude  SD 217.2 238.7 215.9 240.4 302.1 
(pA) n 4 4 4 4 2 
    ns P <0.05 ns ns ns 
  Mean 5.8 5.4 3.1 3.1 4.1 
Rise Time  SD 1.8 1.2 0.6 0.6 1.0 
(ms) n 4 4 4 4 2 
    ns P <0.05 *** ** ns 
  Mean 5.4 5.3 5.6 5.8 6.6 
Half Width  SD 1.5 0.5 0.8 1.2 0.8 
(ms) n 4 4 4 4 2 
    ns P <0.05 ns ns ns 
 
Mean 13.6 13.5 13.8 14.0 13.8 
Decay Time SD 1.3 1.9 0.9 1.8 1.5 
(ms) n 4 4 4 4 2 
  
ns P <0.05 ns ns ns 
  Mean 1.6 2.4 3.2 2.5 0.4 
Interval Time  SD 0.9 3.3 5.5 4.2 0.2 
(sec) n 4 4 4 4 2 
    Ns P <0.05 ns ns ns 
Holding Mean -444.0 -478.6 -408.1 -396.4 -245.6 
Current SD 325.8 334.1 296 303.2 86.55 
(pA) n 4 4 4 4 2 
    ns P <0.05 ns ns ns 
 
Table 5.5. Spontaneous IPSC kinetics for micromolar concentrations of alfaxalone in the 
presence of 2-APB 
** indicates a P value ≤ 0.01, *** indicates a P value ≤ 0.001 
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Discussion 
W have here investigated the hypothesis that alfaxalone modulates glycinergic transmission to rat 
HMNs by activating the cannabinoid receptor signalling pathway.  We tested the effects of alfaxalone 
on glycinergic transmission in rat HMNs in the presence of a potent CB1R agonist WIN55,212-2, a 
CB1R inverse agonist AM251, a potent CB1R antagonist NESS0327 and a non-specific TRP channel 
antagonist 2-APB.  First, we saw that the inhibitory effects of the CB1R agonist WIN55,212-2 on 
glycinergic transmission were similar to those caused by alfaxalone, which was suggestive of CB1R 
activation by alfaxalone; WIN55,212-2 also partly occluded the effects of alfaxalone.  We then saw 
that antagonism of the CB1R by either AM251 or NESS0327 blocked the inhibitory effects of 
alfaxalone on glycinergic transmission.  These results showed that alfaxalone indeed causes activation 
of the CB1R, thereby reducing glycinergic transmission.  However, we also saw that CB1R 
antagonism blocked some of the postsynaptic effects of alfaxalone, including evoked IPSC amplitude 
reduction without changes in PPR and changes in IPSC shape parameters.  Additionally, we showed 
that both CB1R blockers abolished the inward shift in holding current elicited by alfaxalone.  Finally, 
the addition of 2-APB blocked not only the inward shift in holding current elicited by alfaxalone, but 
also blocked the reduction in spontaneous IPSC amplitude and frequency caused by and decreased 
spontaneous IPSC rise time.  As 2-APB has no direct effects on CB1Rs, we interpret this data as 
showing that alfaxalone directly modulates TRP channels to produce an inward current which triggers 
the endocannabinoid signalling pathway to ultimately activate CB1Rs which reduce glycinergic 
transmission to HMNs.  Our results are consistently supportive of this hypothesis. 
 
WIN55,212-2, a CB1R agonist, potently suppressed glycinergic transmission to HMNs 
Previous studies have shown that endocannabinoids generated within HMNs by strong depolarization 
can reduce glycinergic transmission to HMNs by activating presynaptic CB1Rs (Mukhtarov et al., 
2005).   Key evidence for this mechanism included a change in PPR and blockade of reduction of 
glycinergic IPSCs by application of WIN55,212-2.  We therefore expected to see a depression of 
glycinergic transmission with the application of the CB1R agonist WIN55,212-2.  The results from the 
WIN55,212-2 dose response study were consistent with this expected presynaptic depression in some 
aspects but not in others. The decrease in spontaneous IPSC amplitude and frequency seen on addition 
of WIN55,212-2 are consistent with a decrease in glycine release from the presynaptic terminal, but 
could also be due to a reduction in the spontaneous activity of presynaptic neurons..  However, the 
PPR of evoked IPSCs was not altered by WIN55,212-2, which suggests that the CB1Rs activated by 
WIN55,212-2 are not presynaptic.  In contrast to alfaxalone alone, the application of WIN55,212-2 
did not produce postsynaptic effects on glycinergic IPSCs caused by alfaxalone, as WIN55,212-2 did 
not cause increases in either IPSC rise time and decay time prolongation. This suggests that these 
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effects of alfaxalone may not be mediated by CB1Rs.  Finally, the marked suppression of both 
spontaneous and evoked IPSC amplitude was evident at low nanomolar concentrations of 
WIN55,212-2, with a calculated EC50 of 18 nM.  This value is similar to that for binding to CB1Rs, 
suggesting that off target effects on other receptors or channels do not produce the effects of 
WIN55,212-2 (Pertwee et al., 2010). 
 
WIN55,212-2 markedly reduced effects of alfaxalone on glycinergic transmission to HMNs 
As WIN55,212-2 by itself induced a reduction in IPSC amplitude and frequency similar to that of 
alfaxalone alone, suggesting that both drugs act through a common mechanism to cause inhibition of 
glycinergic transmission.  A test of this hypothesis is to show that WIN55,212-2 occludes the effects 
of alfaxalone at lower doses of alfaxalone. We therefore performed an alfaxalone dose response study 
in the presence of WIN55,212-2 at 300 nM to largely saturate CB1R binding. Under these conditions, 
effects of alfaxalone on glycinergic transmission were not seen at until 3µM alfaxalone. As alfaxalone 
applied alone caused inhibition of glycinergic IPSCs at nanomolar concentrations, these results 
suggest that the pre-application of WIN55,212-2 occupied CB1R and prevented the actions of 
alfaxalone until sufficiently high concentrations of alfaxalone were achieved. 
 
Both a CB1R inverse agonist and a CB1R antagonist had little effect on glycinergic transmission to 
HMNs indicating a lack of endocannabinoid modulation. 
Application of either 1µM AM251 or 100pM NESS0327 alone caused no significant changes in 
spontaneous or evoked IPSC amplitude and shape.  These results suggest that endogenous activation 
of CB1R do not contribute significantly to modulation of glycinergic activity in the rat HMN in 
control conditions.  As an inverse agonist, we expected AM251 would increase spontaneous IPSC 
frequency and IPSC amplitude, by reducing constitutive CB1R activity.  We observed only a slight 
and insignificant increase in IPSC frequency following AM251 application compared to control.  This 
suggests that little constitutive CB1Rs activity is present under our experimental conditions.  As 
NESS0327 is a neutral competitive antagonist, we did not expect any change in IPSC activity in the 
absence of an agonist.   
 
CB1R antagonism markedly reduced the effects of alfaxalone on glycinergic transmission to HMNs 
We predicted that both AM251 and NESS0327 would block the effects of alfaxalone on glycinergic 
inhibition.  Pre-application of AM251 or NESS0327 indeed blocked the reduction in spontaneous 
IPSC frequency, and the reduction in amplitude of both spontaneous and evoked IPSC amplitude, 
therefore strongly implicating CB1R activation as a mechanism for alfaxalone induced reduction of 
glycinergic transmission.  Interestingly, when CB1Rs were blocked by these antagonists, the 
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application of alfaxalone caused reductions in IPSC rise time and decay time; this was in marked 
contrast to the effect of alfaxalone applied alone, which caused increased IPSC rise time and decay 
time.  It has been reported that an increase in postsynaptic Ca
2+
 not only can lead to endocannabinoid 
synthesis, but also direct modulation of the GlyR seen as increased IPSC amplitude and prolongation 
of decay time (Mukhtarov et al., 2005).  In addition, it was reported that the endocannabinoid 2-AG 
caused a reduction in rise time in CB1R knockout mice, suggesting that endocannabinoids also 
possessed direct GlyR modulatory effects (Lozovaya et al., 2011).  In this case, the activation of 
endocannabinoid synthesis by alfaxalone could lead to direct endocannabinoid or Ca
2+
 modulation of 
the GlyR accounting for these differential effects on IPSC shape parameters when CB1Rs are blocked.   
Further experiments with intracellular Ca
2+
 chelators or modulators of endocannabinoid synthesis are 
needed to unravel these possible mechanisms. 
  
CB1R antagonists reduced the inward current activated by alfaxalone 
Alfaxalone applied alone consistently elicited a depolarising inward current, which was largely absent 
when alfaxalone was applied in the presence of the CB1R blockers AM251 or NESS0327.  
Interestingly, an inward current shift was not seen in the WIN55,212-2 dose response study, but was 
elicited by a high concentration (10 μM)  of alfaxalone in the presence of WIN55,212-2.  These 
findings show that blockade of CB1Rs prevented an inward current caused by alfaxalone.  However, 
the CB1R agonist WIN55,212-2 alone did not elicit the inward current seen with alfaxalone.  One 
potential explanation is that postsynaptic CB1Rs are rapidly internalized following the binding of 
WIN55,212-2 (Hsieh et al., 1999), while internalization is much slower or absent with endogenous 
endocannabinoids.  This suggests that WIN55,212-2 alone does not evoke an inward current but 
CB1R antagonists can block an inward current generated by endogenous endocannabinoids acting via 
CB1Rs.  Evidence for the existence of postsynaptic CB1Rs have been reported.  CB1R radioligand 
binding shows sparse binding in the rat hypoglossal nucleus and spinal cord ventral horn, while 
immunohistochemical studies identified postsynaptic CB1Rs in the rat lamina II islet cells of the 
spinal cord (Salio et al., 2002) and in the dendrites of large ventral horn neurones of monkeys (Ong 
and Mackie, 1999).   Our results here also suggest the existence of postsynaptic CB1Rs in the rat 
brainstem, but further investigation is necessary before these claims can be substantiated. 
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2-APB, a non-specific TRP channel blocker, markedly reduced the inward current activated by 
alfaxalone 
The inward current elicited by alfaxalone may contribute to motor neuron depolarization and thus 
neuro-excitation; in addition, it may play a permissive role in generating endogenous 
endocannabinoids which typically require a depolarization-mediated rise in intracellular Ca
2+
 for their 
synthesis and release.  We hypothesised that the inward current shift caused by alfaxalone was due to 
activation of TRP channels, which are Ca
2+
 permeable cationic channels modulated by a wide variety 
of stimuli, including neurosteroids, endogenous endocannabinoids and G-protein coupled receptors.  
To test this hypothesis, we predicted that non-specific blockade of TRP channel activity would 
remove this inward current shift, hindering endocannabinoid production and therefore all the 
downstream effects of the cannabinoid signalling pathway.  2-APB is a small molecule that inhibits 
most TRP channels, although it activates TRPV channels.    The application of 100pM 2-APB alone 
did not alter spontaneous IPSC event kinetics or change holding current.  This indicated that there was 
no significant endogenous TRP channel activity present on rat HMNs in the absence of alfaxalone.   
 
Alfaxalone applied after 2-APB elicited a marked decrease in spontaneous IPSC rise time, consistent 
the effect of alfaxalone applied after CB1R antagonists.  Other effects of alfaxalone on holding 
current, spontaneous IPSC amplitude, frequency and shape parameters were blocked by prior 
application of  2-APB, consistent with the results seen with the application of alfaxalone in the 
presence of  CB1R antagonists.  As 2-APB does not block CB1Rs, this data strongly suggests that TRP 
channel activation is the upstream mechanism for endocannabinoid production and subsequent CB1R 
acttivation. 
   
Neurosteroids themselves have also been implicated in direct activation of TRP channels, in particular 
the TRPM3 channel (Majeed et al., 2010, Nilius and Voets, 2008).  The neurosteroid pregnenolone 
sulphate rapidly activated TRPM3 channels in pancreatic β cells, indicative of direct neurosteroid 
binding to TRPM3 (Nilius and Voets, 2008, Wagner et al., 2008, Majeed et al., 2010, Majeed et al., 
2012). It was also reported that stimulation of TRPC6 channels in cath.a differentiated (CAD) 
neuronal cells increased 2-AG release, which suggests that TRPC6 channels could activate 
endocannabinoid synthesis (Bardell and Barker, 2010).  From these findings, it could be postulated 
that the neurosteroid alfaxalone could also potentially directly bind to and modulate TRP channels 
thereby increasing intracellular Ca
2+
  and facilitating endocannabinoid synthesis. 
 
More recently, there have been also several reports of interactions between endocannabinoids, CB1Rs 
and TRP channels.  The co-expression of TRPV1 channels and CB1Rs has been reported in the 
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midbrain dorsal periaqueductal gray neurons (Casarotto et al., 2012).  This study described panic 
responses produced by the TRPV1 antagonists capsazepine and SB366791, which were prevented by 
AM251, suggesting that the endocannabinoid, anandamide may exert effects via actions at both CB1R 
and TRPV1 (Casarotto et al., 2012).  In addition, the cannabinoid cannabichromene (CBC), naturally 
derived from the Cannabis sativa plant, is known to inhibit endocannabinoid reuptake and to activate 
TRP ankyrin 1-type (TRPA1) channels (Romano et al., 2013). 
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Figure 5.6. Stylistic view of the proposed mechanism of alfaxalone action on HMN synaptic 
terminal. 
Alfaxalone activates TRP channels which results in an inward current created by an influx of cations, 
resulting in a increase in intracellular Ca
2+
 in the postsynaptic neuron.  This increase in intracellular 
Ca
2+
 triggers endocannabinoid synthesis.  Endocannabinoids are retrograde messengers decrease 
neurotransmitter release by binding to presynaptic G-protein-coupled cannabinoid receptors (CB1R) 
and in turn decreases IPSC amplitude and frequency.  CB1Rs located on the postsynaptic membrane 
may also interact with the GlyRs to change IPSC amplitude and shape parameters.  Modulation of the 
GlyR from the Ca
2+
 influx or via endocannabinoids causes prolongation of total IPSC event times.   
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Results of this study support our hypothesis that alfaxalone activates the endocannabinoid signalling 
pathway in HMNs and produces an inward current through modulation of TRP channels.  We also 
have raised the possibility of postsynaptic CB1R localisation, as our results provided evidence that 
alfaxalone produced both presynaptic and postsynaptic GlyR modulation as well as causing a 
depolarising current.  The resultant changes involve a reduction in glycinergic inhibitory transmission 
and increased neuronal excitation, and would clinically manifest as increased muscle tone, twitchiness 
and neuro-excitation. These effects could underlie the mechanism behind the neuro-excitation seen 
with alfaxalone anaesthesia.  We reported in this study that antagonism of the CB1R receptor or of 
TRP channels blocked alfaxalone-induced reductions in glycinergic inhibition and development of a 
depolarising current. This exciting finding shows the potential for developing a combination 
anaesthetic regimen, comprising of alfaxalone with a CB1R antagonist or TRP channel blocker, which 
could reduce or prevent the prevalence of alfaxalone neuro-excitation and markedly improve 
alfaxalone anaesthesia for laboratory rodents and other species.   
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GENERAL DISCUSSION 
 
Rodent anaesthesia is performed routinely for husbandry and research purposes and the use of rodents 
has helped pave the way for new advancements in biomedical research.  However, it appears the 
development of improved anaesthesia has been left behind.  Anaesthetics such as ketamine-xylazine 
combination, were first administered over 30 years ago and are still commonly used today (Stickrod, 
1979, Green et al., 1981, Saha et al., 2007).  One would assume that this continued use of an 
anaesthetic combination means that it provides safe and predictable anaesthesia but this is not the 
case.  This lack of improvement in the safety and efficacy of anaesthetic regimens indicates no better 
anaesthetic agents have been investigated and a review of current anaesthetic protocols is necessary 
(Green et al., 1981). 
 
Need for a new anaesthetic protocol for laboratory rodents 
 The rodent anaesthetic survey we conducted (Chapter 2) showed that only a limited number of 
anaesthetic agent combinations appear to be utilised for rodent anaesthesia, each associated with 
complications.  Unpredictable levels of anaesthesia, hypothermia, apnoea and prolonged recovery 
times were repeatedly mentioned in the survey and highlighted the need for improved anaesthetic 
agents.  The rodent anaesthetic survey identified several complications associated with ketamine-
xylazine, including persistent reflexes, prolonged recovery and high mortality rates (Smith, 1993, 
Wixson et al., 1987c, Wixson et al., 1987a, Arras et al., 2001).  The shift towards increased use of 
inhalation anaesthesia has brought with it many benefits, in that supplementary oxygen is co-
administered, but also it has brought with it a false sense of security.  Inhalation agents are delivered 
in conjunction with 100% oxygen but often rodents are not intubated and the amount of anaesthetic 
delivered is dependent on the animal spontaneously breathing (Flecknell, 1993a). Alfaxalone provides 
a high margin of safety for veterinary anaesthesia, so it was prudent to determine whether alfaxalone 
was an effective anaesthetic agent for rodent anaesthesia.    
 
Alfaxalone pharmacokinetics for rats 
An IV and IP pharmacokinetic study was performed using the commercially available HPCD 
formulation of alfaxalone, Alfaxan® in rats.  The mean elimination half-life for alfaxalone was short 
at 16.2 and 17.6 minutes for 2mg.kg
-1
 and 5mg.kg
-1
 respectively. The rat alfaxalone Clp was fast at 
54.3 ± 6.8mL.min
-1
kg
-1
, which is double the speed of clearance in the cat, at 25.1 ± 7.6mL.min
-1
kg
-1 
for the same IV dose (Whittem et al., 2008). In a clinical setting, this would mean that a constant 
infusion of alfaxalone needs to be given if IV alfaxalone anaesthesia is used in rats.  Fortunately, IP 
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pharmacokinetics showed that sustained plasma levels were maintained up to 60 minutes after dosing 
with 20mg.kg
-1
 alfaxalone, although 30% of rats did not become induced for anaesthesia.   
 
Singly applied alfaxalone does not provide optimal anaesthesia 
The IM dose most predictably produced a loss of righting reflex and anaesthetic induction.  
Unfortunately, the large injection volume necessary to produce this effect precluded the use of 
alfaxalone via this route.  SC administration was the least predictable route of administration for 
alfaxalone producing highly variable induction times at 20mg.kg
-1
.  On top of this, all anaesthetic 
routes examined produced neuromuscular twitching.  This neuro-excitatory event was pronounced 
and in itself could potentially rule out the use of alfaxalone anaesthesia in rodents. Following on from 
these findings, it was clear that alfaxalone could not be used as an anaesthetic agent alone in rats and 
the administration of alfaxalone via different routes confirmed this finding.   
 
The addition of premedication agent combinations with alfaxalone anaesthesia 
It was then hypothesised that the use of added premedication agents would increase anaesthetic 
efficacy of alfaxalone and reduce the incidence and severity of twitching.  Anaesthetic immobilisation 
times and surgical anaesthetic times were markedly increased with the use of medetomidine and 
medetomidine-butorphanol premedication agents.  Acetylpromazine-xylazine, medetomidine or 
medetomidine-butorphanol premedications reduced the incidence of twitching by at least 50% and 
when twitching occurred, a marked reduction in the severity of twitching was observed.  
Acetylpromazine-methadone premedication, on the other hand was unable to produce these effects 
and even appeared to increase the incidence of twitching.  These results showed that the presence of 
an α2-adrenergic agonist drug suppressed the neuro-excitatory effects of alfaxalone but not in all rats.  
Specifically, medetomidine is a potent presynaptic and postsynaptic α2-adrenergic agonist that 
decreases the release of noradrenaline, dopamine and serotonin in a dose dependent manner (Virtanen, 
1989).  Interestingly, it has been reported that alfaxalone can also suppress norepinephrine uptake by 
interfering with desipramine binding and norepinephrine recognition in cultured adrenal medullary 
cells (Horishita et al., 2002).  The fact that alfaxalone also interferes with noradrenaline depression is 
suggestive that a reduction in noradrenaline by medetomidine will aid in the sedative effects of 
alfaxalone but it is unlikely to eliminate neuro-excitation, as alfaxalone itself already possesses 
adrenergic activity. 
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Premedication agents reduced the incidence and severity of twitching 
The use of premedication to reduce the muscular twitching caused by alfaxalone showed promising 
results.  However, it became clear that the potential mechanisms behind the alfaxalone induced neuro-
excitation needed to be established, in order to identify possible targets for premedication.   
The anaesthetic actions of alfaxalone have been attributed to its positive allosteric modulation of the 
GABAAR (Lambert et al., 1996, Lambert et al., 1995, Harrison and Simmonds, 1984).   The GlyR 
also plays an important role in fast inhibitory neurotransmission and is important for coordination of 
reflex responses and muscle tone regulation (Mukhtarov et al., 2005, Maksay et al., 2002, Biro and 
Maksay, 2004).  The GlyR is a ligand-gated chloride channel that causes postsynaptic hyper-
polarisation which mediates synaptic inhibition in the brainstem and spinal cord (Zhou et al., 2002).  
The impairment of postsynaptic α1 GlyR activity and reduction in the efficacy and potency of glycine 
has clinically manifested as hyperekplexia (Maksay et al., 2008).  The enhancement of GlyR activity 
has the potential to suppress nociceptive signals and many studies have focussed on whether 
alfaxalone possesses this property (Ahrens et al., 2008, Betz and Laube, 2006, Laube et al., 2002).  
However, previous studies have shown that the ability of alfaxalone to potentiate GlyR activity was 
minimal and the concentration of alfaxalone necessary to potentiate α1 GlyR in HEK 293 cells was 
outside the clinically relevant dose ranges (Ahrens et al., 2008).  By contrast, the inhibition of α1 
glycinergic transmission causes exaggerated startle responses, as seen with hyperekplexia and 
strychnine poisoning (Zhou et al., 2002) and we hypothesised alfaxalone might produce similar 
suppressive effects on glycinergic transmission.   
 
Alfaxalone inhibits glycinergic transmission at clinically relevant doses 
To investigate this in the context of motor output, we chose to make electrophysiological recordings 
from HMNs, a group of brainstem motor neurons which innervate the tongue muscles.  HMN are 
easily identified by their location and size, and the HMN pool contains the highest GlyR density of 
any area within the CNS (Singer and Berger, 2000, Singer and Berger, 1999).  We therefore focused 
on this area for electrophysiological recordings.  We investigated the possible inhibitory activity of 
alfaxalone on IPSCs mediated by GlyRs, by performing an alfaxalone dose response study.  
Alfaxalone caused a dose dependent decrease in IPSC size and caused IPSC rise time and decay time 
prolongation at 10µM.  IPSC peak amplitude changes were noticeable from 30nM alfaxalone and a 
reduction in IPSC frequency at 3µM alfaxalone.  These findings were suggestive of both presynaptic 
and postsynaptic modulation of GlyR activity by alfaxalone.  Rat plasma alfaxalone levels calculated 
from the IV pharmacokinetic study showed the minimum effective plasma concentration of alfaxalone 
necessary to maintain sleep was between 4.36 and 6.02µM.  As most of the twitching was 
experienced during the anaesthetic recovery period, we would expect the suppression of GlyR activity 
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to occur around these low micromolar concentrations.  These data confirms that alfaxalone could 
indeed cause GlyR inhibition at clinically relevant doses in rats.   
 
The alfaxalone dose response study found alfaxalone reduced GlyR inhibition through both 
presynaptic and postsynaptic mechanisms, and also produced a depolarising current without 
significantly altering the input resistance of HMNs.  It is unclear, however, how alfaxalone mediates 
these changes, and there is the potential for a multitude of mechanisms being involved in producing 
these inhibitory effects on GlyR neurotransmission.  Intracellular Ca
2+
 plays an important role in 
glycinergic synaptic transmission and Ca
2+
 modulation in the presynaptic nerve terminals releasing 
glycine has been linked to presynaptic CB1R activity (Mukhtarov et al., 2005).  Presynaptic CB1Rs 
are said to reduce Ca
2+
 transients and thereby reduce glycine vesicular release.  We therefore proposed 
that alfaxalone activated CB1R through endocannabinoid synthesis within HMNs, which then led to 
CB1R activation.  Due to the inward current changes caused by alfaxalone, we also proposed that 
alfaxalone activated TRP channel receptors that, when activated, produce a depolarising current and 
increases in intracellular Ca
2+
. This increase in intracellular Ca
2+
 in turn triggers the production of 
endocannabinoids and activates the cannabinoid signalling pathway. 
 
WIN55,212-2 shifted alfaxalone induced glycinergic inhibition to higher concentrations of alfaxalone 
The first experiments to help us determine whether these hypothesises are true involved the 
application of WIN55,212-2 , a potent CB1R agonist.  If alfaxalone causes inhibition of glycinergic 
transmission through activation of the CB1R, then we would expect the addition of WIN55,212-2 to 
mimick the effects of alfaxalone. WIN55,212-2 indeed produced inhibition of glycinergic 
transmission similar to that caused by alfaxalone, which was supportive of our claims of CB1R 
activation by alfaxalone.  Following on from this, an alfaxalone dose response study was performed in 
the presence of WIN55,212-2.  Pre-saturation of the CB1R with 300nM of WIN55,212-2 should cause 
activation of CB1R, and therefore we expected to see a reduction in the inhibitory effects of alfaxalone 
on glycinergic transmission. Results of this study indeed showed a shift in the development of 
alfaxalone induced glycinergic inhibition to higher concentrations of alfaxalone. 
 
Alfaxalone causes CB1R activation  
WIN55,212-2 alone mimicked the effects of alfaxalone and caused reduction of glycinergic 
inhibition.  We therefore also expected a CB1R antagonist would block reduction of glycinergic IPSCs 
caused by alfaxalone.  Antagonism of the CB1R by either AM251 or NESS0327 blocked the 
inhibitory effects of alfaxalone on glycinergic transmission.  These results showed that alfaxalone 
indeed causes activation of the CB1R, thereby reducing glycine release from the presynaptic terminal.  
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However, we noted that neither CB1R modulation nor alfaxalone caused a change in PPR, which is 
not consistent with a presynaptic change in evoked release.  In addition, we also saw that CB1R 
antagonism blocked some of the postsynaptic effects of alfaxalone, such as evoked IPSC size 
reduction and changes in IPSC shape.   
 
Alfaxalone produces an inward current  
The alfaxalone dose response study identified a significant inward current shift at 10µM or greater.  
This depolarising current was elicited by WIN55,212-2 up to 3µM in the dose response study, but was 
seen on co-application of 10µM alfaxalone in the presence of WIN55,212-2.  We showed that both 
CB1R blockers prevented the depolarising current changes seen with alfaxalone application.  
Furthermore, the addition of 2-APB, a non-specific blocker of many TRP channels, prevented not 
only the depolarising current shift caused by alfaxalone, but also blocked the presynaptic reduction in 
spontaneous IPSC frequency and decreased spontaneous IPSC rise time.   
 
These results suggest that the inward current elicited by alfaxalone does not directly involve the 
CB1R.  Early studies reported the application of alfaxalone likely activated several other channels, 
simultaneous with GABAARs.  An inward current was observed during voltage clamp experiments 
associated with increases in membrane noise in bovine chromaffin cells (Cottrell et al., 1987).  
However, on pre-application of AM251 and NESS0327, we noticed no such depolarisation effect up 
to 10µM alfaxalone.  This suggested, while direct activation of CB1Rs did not elicit an inward current, 
that the blockade of CB1Rs removed the inward current, and CB1Rs therefore somehow involved.  
There is strong evidence that CB1Rs are functionally associated with TRP channels (Moran et al., 
2004).  We postulated that the alfaxalone-activated inward current was due to activation of 
postsynaptically located TRP channels which might be modulated by CB1Rs.  
 
Alfaxalone activates TRP channels 
TRP channels are a large family of stimulus-activated cationic ion channel proteins expressed in low 
numbers per cell, but which yield small net inward currents (Clapham et al., 2001) with a Ca
2+
 ion 
component.  For this reason, an additional study was performed to determine whether these TRP 
channels were involved in the production of the alfaxalone induced inward current.  The non-specific 
TRP channel blocker 2-APB was applied to the control bath and did not alter control IPSC 
parameters.  Spontaneous IPSC recordings showed no change in baseline holding current up to 10µM 
alfaxalone.  The blockade of TRP channels also blocked spontaneous IPSC amplitude reduction as 
well as changes in rise time and decay time of glycinergic IPSCs.   These responses to TRP channel 
blockage were consistent with the results seen with CB1R blockade by application of both AM251 or 
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NESS0327.  These results are strongly supportive of TRP channel activation by alfaxalone, which 
then leads to activation of the cannabinoid signalling pathway, activation of CB1Rs and reduction of 
glycinergic transmission through pre- and postsynaptic mechanisms. 
 
TRP channel activation 
TRP channels are a large and diverse family of ion channels, whose pharmacology is still poorly 
developed.  The determination of which specific TRP channels are likely to be involved in alfaxalone-
induced changes in HMNs is beyond the scope of this thesis, but would likely yield invaluable 
insights.  2-APB will inhibit members of the TRPC, TRPM and TRPA sub-families, but has been 
reported to selectively activate several members of the TRPV sub-family, including TRPV1-3, but not 
TRPV4-6.  We tentatively conclude that it is less likely for TRPV channels to cause the inward 
current elicited by alfaxalone. There is evidence that neurosteroids can directly activate TRP 
channels; for example, direct activation of TRPM3 by the endogenous neurosteroid pregnenalone 
sulphate has been reported in pancreatic β cells (Wagner and Hellyer, 2000, Nilius and Voets, 2008, 
Clapham, 2007).  Additionally, almost all TRP channels are permeable to Ca
2+
, causing elevation in 
intracellular Ca
2+
, which in turn modulates TRP channel activity (Bardell and Barker, 2010, Wu et al., 
2010, Pedersen et al., 2005).  Endocannabinoids also modulate many TRP channels, particularly the 
TRPV sub-family.  Activation of TRPV1 by the endocannabinoid anandamide showed the possibility 
of off target activation of TRV1 channels in the brain, and these actions could precipitate anxiogenic-
like behavioural responses produced by cannabinergic compounds (McLaughlin and Gobbi, 2012, 
Saito et al., 2010).   There is also evidence suggesting that TRPV4 channels, which are not activated 
by 2-APB, can be activated by anandamide and arachidonic acid via a complex intracellular signalling 
pathway (Watanabe et al., 2003).There are thus several possible candidates for further study in the 
future. 
 
The production of an inward current by alfaxalone in the presence of WIN55,212-2, but not 
WIN55,212-2 alone poses several questions. We could hazard a guess that WIN55,212-2 does not 
directly activate TRP channels, but the production of the endocannabinoids mediated by alfaxalone 
could account for modulation of TRP channel activity.  However, we have yet to determine whether 
blocking endocannabinoid synthesis would prevent the activation of TRP channels by alfaxalone.   
Another possible explanation is the induction of CB1R internalisation by WIN55,212-2; this would 
also require experimental verification. 
 
From our current findings, we have begun to understand the potential mechanism behind alfaxalone 
induced neuro-excitation.  There are still many questions that remain unanswered, but we believe we 
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have enough evidence to suggest that CB1R or TRP channel blockade will reduce or prevent the 
inhibitory effects of alfaxalone on glycinergic transmission, thereby reducing or removing 
neuroexcitation during alfaxalone anaesthesia.  Surprisingly, any of the four drugs investigated here 
could potentially block the effects of alfaxalone.  However, there may be legal drug restrictions 
associated with the use of WIN55,212-2, due to its similarity in effect to psychoactive components of 
Cannibis sativa.  Also, clinical side effects of CB1R activation have been reported.  CB1R agonists 
have reportedly produced anxiolytic, anxiogenic or even ineffective effects clinically, with these 
biphasic effects likely associated with ranging doses causing differential effects on different regions 
of the brain (Cagni and Barros, 2013).  Local stimulation of CB1R in the basolateral amygdala has 
induced anxiogenesis: however stimulation of the central amygdala can promote anxiolytic effects 
(McLaughlin and Gobbi, 2012). Therefore it is more difficult to justify using a CB1R agonist, if a 
CB1R antagonist or TRP channel antagonist provide the same effect without the complications 
associated with psychoactive drug molecules.  The next step therefore involves the use of AM251, 
NESS0327 and 2-APB as premedications with alfaxalone anaesthesia in a clinical setting to block 
neuro-excitation in alfaxalone anaethesia.   
 
Future directions 
The progression from in vitro to in vivo studies will ultimately be the next step.  This work could 
potentially validate the current electrophysiological work performed and provide clinical evidence of 
the potential use of either TRP channel antagonists or CB1R antagonists to ameliorate the alfaxalone 
induced hyperexcitatory side effects.  Clinical trials of the CB1R antagonists and TRP channel 
antagonists as premedication adjuncts however may in themselves cause some side effects as 
previously indicated. We must therefore look further into whether one of these drugs examined, or 
drugs with similar pharmacological activity, are more likely to give us additional benefits, eg 
antinociceptive actions of some CB1R inverse agonists.   Ultimately the drug of choice will be 
determined by their clinical efficacy.   
 
Conclusion 
Regardless of what is mediating the changes caused by alfaxalone in our in vitro neurophysiological 
tests, we need to validate whether the blockade of CB1Rs or TRP channels will clinically remove the 
detrimental side effects of alfaxalone anaesthesia.  Electrophysiological studies have identified 
potential targets for in vivo clinical testing that would hopefully reduce or remove the neuro-
excitatory side effects of alfaxalone.  
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My main aim for this thesis was to develop a safe and easy to administer anaesthetic regimen for use 
in laboratory rodents.  In doing so, I have been able to identify many pitfalls associated with currently 
available rodent anaesthetic regimens.  Alfaxalone showed a lot of promise in filling this market, as 
seen with the large margin of safety it has shown in veterinary anaesthesia.  I therefore endeavoured 
to develop alfaxalone anaesthesia for laboratory rodent anaesthesia in the hope to ultimately improve 
currently available anaesthetic regimen.  I believe that, through these investigations, we are on the 
right path to improving alfaxalone anaesthesia.  Ultimately, continually improving anaesthetic 
protocols for laboratory rodents will aid both researchers and laboratory animal technicians, but most 
importantly, it will help improve animal welfare for laboratory rodents undergoing anaesthesia.  
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APPENDIX ONE 
 
The University of Queensland  
School of Veterinary Science St Lucia 
 
RODENT ANAESTHESIA SURVEY 
 
Dear Researcher, 
 
 
The National Health and Medical Research Council (NHMRC) Guidelines for laboratory 
animal anaesthesia provide a comprehensive list of anaesthetic agent combinations.  Our 
survey aims to identify the most frequently used anaesthetic regimens for rats and mice and 
to determine whether there were specific factors that have influenced your choice.  
  
Your first hand experiences in using these anaesthetic agents will collectively provide 
invaluable information on the efficacy and ease of use of specific anaesthetics.   
This in turn will help us to improve our understanding of rodent anaesthesia and therefore 
the welfare of laboratory animals undergoing anaesthesia. 
The information provided will remain anonymous.  We greatly appreciate the time you have 
taken to complete this survey.   
 
With Kind Regards, 
 
 
 
Cora Lau BVSc (Hons) 
University of Queensland  
School of Veterinary Science 
PhD Candidate 
Mob: 0413 120 931 
Email: c.lau1@uq.edu.au 
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The University of Queensland  
School of Veterinary Science St Lucia 
 
RODENT ANAESTHESIA SURVEY 
 
What age/sex/strain/colony of rat/mouse were used?  
 
Rat : 
   ………………………………………… 
 
Mouse:  
   ………………………………………… 
 
What procedure/s was the anaesthetic required for? Please list 
 
   …………………………………………. 
 
…………………………………………. 
 
   …………………………………………. 
 
   …………………………………………. 
 
 
What length of anaesthesia was required to perform the procedure/s? 
Please list 
   …………….…………………………… 
 
   …………….…………………………… 
 
…………….…………………………… 
 
   …………….……………………………   
 
Do you use gaseous or injectable anaesthesia? Or both? 
 
   ………….………………………………. 
 
Number of animals: 
   …………………………………………… 
 
What injectable anaesthetic combinations are you commonly using? 
 
Anaesthetic agent 1 : ……………………………………. 
 
Route of administration:………………………………… 
  
 Dose:…………………………………………………….. 
 (Eg. mg/kg, g/kg or mL per animal) 
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Anaesthetic agent 2 : ……………………………………. 
 
 Route of administration:………………………………… 
 
 Dose:…………………………………………………….. 
 (Eg. mg/kg, g/kg or mL per animal) 
 
Anaesthetic agent 3 :………..………………………………….. 
 
 Route of administration:………………………………… 
  
 Dose:……………………………………………………… 
 (Eg. mg/kg, g/kg or mL per animal) 
 
Do you use an anaesthetic reversal agent with this regimen? 
 
…………………………………… 
 
Do you use an additional analgesic agent? 
 
…………………………………… 
 
 
What is the usual recovery time (eg. time taken to wake up)? 
 
…………………………………… 
 
Have you encountered any complications from this anaesthetic regimen? 
Please indicate the number of animals in the box below 
(please provide a percentage if an accurate number is not known- please indicate with % ) 
 Inadequate depth of anaesthetic from initial dose 
 Needed top up of anaesthetic during procedure 
 Stopped breathing 
 Unexpected wake up 
 Took a long time to recover from anaesthetic 
 Animal was cold (if yes, was heating provided? ……………………..) 
 Death 
 Other  ………………………………………………………………… 
 
(please comment) 
…………………………………………………………………………………………. 
 
…………………………………………………………………………………………. 
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What do you feel are the advantages and disadvantages of this anaesthetic regimen? 
…………………………………………………………………………………………. 
 
…………………………………………………………………………………………. 
 
…………………………………………………………………………………………. 
 
…………………………………………………………………………………………. 
 
In your opinion, what factors would you like improved from this anaesthetic regimen? 
Eg. Faster anaesthetic recovery 
 
…………………………………………………………………………………………. 
 
…………………………………………………………………………………………. 
 
…………………………………………………………………………………………. 
 
………………………………………………………………………………………….. 
 
Is your choice of anaesthetic related to the schedule of the drug and/or availability? 
…………………………………………………………………………………………. 
 
…………………………………………………………………………………………. 
 
…………………………………………………………………………………………. 
 
………………………………………………………………………………………….. 
 
Any comments? 
 
…………………………………………………………………………………………. 
 
…………………………………………………………………………………………. 
 
…………………………………………………………………………………………. 
 
Thank you for your participation in this survey.  If you have any questions in regards to this 
survey, please feel free to contact me by email: c.lau1@uq.edu.au or mob: 0413 120 931 
 
Cora Lau BVSc (Hons) 
University of Queensland 
School of Veterinary Science 
PhD Candidate 
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APPENDIX TWO 
 
A copy of the published article from Chapter Two is attached to the end of this document 
 
Title: Plasma pharmacokinetics of alfaxalone after a single intraperitoneal or intravenous injection of 
Alfaxan® in rats  
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 Intramuscular 
 Induction time  Immobilisation time Twitch 
 (minutes) (minutes) Score 
Rat 2.1.1 2 7 ++ 
Rat 2.1.2 2 12 ++ 
Rat 2.1.3 3 7 ++ 
Rat 2.1.4 2 13 ++ 
Rat 2.1.5 4 1 - 
    
 Subcutaneous 
 Induction time  Immobilisation time Twitch 
 (minutes) (minutes) Score 
Rat 2.1.1 4 1 - 
Rat 2.1.2 4 4 - 
Rat 2.1.3 Not Induced + 
Rat 2.1.4 Not Induced - 
Rat 2.1.5 4 1 + 
    
 Intraperitoneal 
 Induction time  Immobilisation time Twitch 
 (minutes) (minutes) Score 
Rat 2.1.1 Not Induced - 
Rat 2.1.2 Not Induced - 
Rat 2.1.3 10 2* - 
Rat 2.1.4 Not Induced - 
Rat 2.1.5 Not Induced - 
 
Appendix 2.1.  Anaesthetic parameters for adult female Wistar rats administered a single dose 
of 10mg.kg
-1
 Alfaxalone IM, SC and IP. 
*A loss of righting reflex allowed a laterally recumbent position. 
All other rats were maintained dorsal recumbency during the immobilisation period. 
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  20mg/kg Intraperitoneal Alfaxan® 
  Induction time  Immobilisation time Twitch 
  (minutes) (minutes) Score 
Rat 2.2.1 
week 1 5 35 +++ 
week 2 3 41 ++ 
week 3 6 42 +++ 
week 4 5 31 +++ 
Rat 2.2.2 
week 1 2 58 ++ 
week 2 4 41 ++ 
week 3 Not Induced - 
week 4 5 35 +++ 
Rat 2.2.3 
week 1 3 40 ++ 
week 2 Not Induced - 
week 3 
  week 4 
Rat 2.2.4 
week 1 4 35 ++ 
week 2 Not Induced - 
week 3 
  week 4 
 Range 2 to 6 31 to 58 Total twitching 
 Mean 4.11 39.78 9 of 12 
 SD 1.20 7.35 75% 
 
 
Appendix 2.2.  Anaesthetic parameters for adult female Wistar rats administered weekly 
injections of 20mg.kg
-1
 IP Alfaxalone. 
Anaesthetic injections were administered once weekly for four consecutive weeks.  Induction time, 
immobilisation time and twitching was recorded.  Results are recorded as mean ± SD and range.  
compare 
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a) 
 20 mg.kg
-1
  Subcutaneous Alfaxan® 
 Induction time  Immobilisation time Twitch 
 (minutes) (minutes) Score 
Rat 2.3.1 Not Induced - 
Rat 2.3.2 4 2 - 
Rat 2.3.3 9 30 ++ 
Rat 2.3.4 20 25 - 
Rat 2.3.5 4 6 + 
Rat 2.3.6 10 40 - 
Rat 2.3.7 21 9 +++ 
Rat 2.3.8 Not Induced - 
Range 4 to 21 2 to 40 Total twitching 
Mean 11.33 18.67 3 of 8 
SD 7.53 15.20 37.5% 
 
b) 
 30 mg.kg
-1
  Subcutaneous Alfaxan® 
 Induction time  Immobilisation time Twitch 
 (minutes) (minutes) Score 
Rat 2.3.6 3 83 +++ 
Rat 2.3.7 5 80 +++ 
Rat 2.3.8 20 39 + 
Range 3 to 20 39 to 83 100% 
 
Appendix 2.3.  Anaesthetic parameters for adult female Wistar rats administered a single dose 
of SC Alfaxalone. 
a) The increase in variability in induction and immobilisation times in comparison to the 
previous 10 mg.kg
-1
  SC Alfaxan® study was not expected.  Following on from this study, Rats 6, 7 
and 8 were given dose of Alfaxan® a week later at 30 mg.kg
-1
.   
b) The immobilisation time increased with the increase in dose from 20 mg.kg
-1
 to 30 mg.kg
-1
 SC 
however the variability in induction time and immobilisation time between animals was still 
pronounced. 
 
 
  
 194 
 
 
 30 mg.kg
-1
 Intraperitoneal Alfaxan® 
 Induction time  Immobilisation time Twitch 
 (minutes) (minutes) Score 
SD 1 2 31 + 
SD 2 3 33 - 
SD 3 2 12 - 
SD 4 3 22 - 
SD 5 3 7 - 
SD 6 3 17 - 
SD 7 3 13 + 
SD 8 3 11 - 
SD 9 4 13 - 
SD 10 Not induced + 
SD 11 Not induced - 
SD 12 2 20 + 
SD 13 Not induced - 
SD 14 2 24 +++ 
Range 2 to 4 7 to 33 Total twitching 
Mean 2.73 18.45 5 of 14 
SD 0.65 8.39 33.7% 
 
Appendix 2.4.  Anaesthetic parameters for adult male Sprague Dawley rats administered a 
single dose of 30 mg.kg
-1
 SC Alfaxalone. 
Fourteen Sprague Dawley rats were administered a single dose of anaesthetic. Induction time, 
immobilisation time and twitching was recorded as mean ± SD and range.  Three of fourteen rats were 
not induced for anaesthesia.     
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APPENDIX THREE 
 
 
 ACP-Methadone (3 mg.kg
-1
-0.7 mg.kg
-1
 IP) 
 Sedation Induction time  Immobilisation time Twitch 
 Level (minutes) (minutes) Score 
Rat 2.7.1 Light Not Induced +++ 
Rat 2.7.2 Light 2 86 + 
Rat 2.7.3 Moderate 3 64 ++ 
Rat 2.7.4 Light 5 52 + 
Rat 2.7.5 Light 3 67 +++ 
Rat 2.7.6 Light 3 57 + 
Rat 2.7.7 Light 4 49 +++ 
Rat 2.7.8 Light 5 47 ++ 
Rat 2.7.9 Light 3 51 + 
Rat 2.7.10 Light 5 49 - 
Rat 2.7.11 Light 3 60 + 
Rat 2.7.12 Moderate 17 25 - 
Rat 2.7.13 Moderate 4 55 +++ 
Rat 2.7.15 Light 3 34 + 
Rat 2.7.17 Moderate 4 75 + 
Rat 2.7.18 Light 4 48 ++ 
 Range 2 to 17 25 to 86 Total twitching 
 Mean 4.5 54.6 14 of 16 
 SD 3.6 15.0 87.50% 
 
Appendix 3.1.  Alfaxalone Anaesthesia with ACP-Methadone Premedication 
Rats were premedicated with ACP-methadone followed by 20 mg.kg
-1
 alfaxalone.  Sedation level, 
induction time, immobilisation time and twitching was recorded as mean ± SD and range.    
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 ACP-Xylazine (3 mg.kg
-1
-3 mg.kg
-1
 IP) 
 Sedation Induction time  Immobilisation time Twitch 
 Level (minutes) (minutes) Score 
Rat 2.7.1 Moderate 13 17 + 
Rat 2.7.2 Moderate 1 132 ++ 
Rat 2.7.3 Heavy 2 85 +++ 
Rat 2.7.4 Moderate 3 54 + 
Rat 2.7.5 Moderate 4 48 - 
Rat 2.7.6 Light Not Induced - 
Rat 2.7.7 Moderate 4 74 + 
Rat 2.7.8 Heavy 2 85 + 
Rat 2.7.9 Heavy 2 68 - 
Rat 2.7.10 Light 5 40 - 
Rat 2.7.11 Moderate 1 61 - 
Rat 2.7.12 Heavy 1 64 - 
Rat 2.7.13 Moderate 2 48 - 
Rat 2.7.14 Light Not Induced - 
Rat 2.7.15 Moderate 1 56 - 
Rat 2.7.16 Heavy 3 49 - 
 Range 1 to 13 17 to 132 Total twitching 
 Mean 2.4 66.5 6 of 16 
 SD 1.3 24.2 37.50% 
 
Appendix 3.2.  Alfaxalone Anaesthesia with ACP-Xylazine Premedication  
Rats were premedicated with ACP-xylazine followed by 20 mg.kg
-1
 alfaxalone.  Sedation level, 
induction time, immobilisation time and twitching was recorded as mean ± SD and range.    
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 Medetomidine (0.5 mg.kg
-1
 IP) 
 Sedation Induction time  Immobilisation time Twitch 
 Level (minutes) (minutes) Score 
Rat 2.7.1 Moderate 4 96 + 
Rat 2.7.2 Moderate 6 85 + 
Rat 2.7.3 Moderate 3 108 - 
Rat 2.7.4 Moderate 2 129 + 
Rat 2.7.5 Moderate 1 159 + 
Rat 2.7.6 Moderate 2 151 + 
Rat 2.7.7 Heavy 1 163 + 
Rat 2.7.8 Moderate 1 160 - 
Rat 2.7.9 Heavy 0 181 - 
Rat 2.7.10 Moderate 1 145 - 
Rat 2.7.11 Moderate 2 154 - 
Rat 2.7.12 Light 2 151 + 
Rat 2.7.13 Moderate 2 65 - 
Rat 2.7.14 Light 1* prolonged - 
Rat 2.7.15 Heavy 1 115 - 
Rat 2.7.16 Heavy 2* prolonged - 
 Range 0 to 6 65 to 181 Total twitching 
 Mean 2.0 133 7 of 16 
 SD 1.5 34.1 43.75% 
 
Appendix 3.3.  Alfaxalone Anaesthesia with Medetomidine Premedication 
Rats were premedicated with medetomidine followed by 20 mg.kg
-1
 alfaxalone.  Sedation level, 
induction time, immobilisation time and twitching was recorded as mean ± SD and range.   
* indicates rat 2.7.14 and 2.7.16 died during anaesthesia.  Note rat 2.7.14 was not deeply sedated 
following premedication.  
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 Medetomidine-Butorphanol (0.35 mg.kg
-1
-0.2 mg.kg
-1
 IP) 
 Sedation Induction time  Immobilisation time Twitch 
 Level (minutes) (minutes) Score 
Rat 2.7.1 Light 3 113 - 
Rat 2.7.2 Heavy 3 140 + 
Rat 2.7.3 Moderate 1 145 + 
Rat 2.7.4 Moderate 3 100 + 
Rat 2.7.5 Moderate 3 73 + 
Rat 2.7.6 Heavy 3 110 - 
Rat 2.7.7 Light 3 81 - 
Rat 2.7.8 Light 1 164 + 
Rat 2.7.9 Moderate 2 145 - 
Rat 2.7.10 Moderate 2 120 - 
Rat 2.7.11 Light 2 139 - 
Rat 2.7.12 Heavy 3 134 - 
Rat 2.7.13 Moderate 2 144 - 
Rat 2.7.15 Moderate 3 129 - 
Rat 2.7.17 Light 2 129 - 
Rat 2.7.18 Light 10 57 + 
 Range 1 to 10 57 to 164 Total twitching 
 Mean 2.9 120.2 6 of 16 
 SD 2.0 29.6 37.50% 
 
Appendix 3.4.  Alfaxalone Anaesthesia with Medetomidine-Butorphanol Premedication 
Rats were premedicated with medetomidine-butorphanol followed by 20 mg.kg
-1
 alfaxalone.  
Sedation level, induction time, immobilisation time and twitching was recorded as mean ± SD and 
range.   
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Alfaxalone (3a-hydroxy-5a-pregnane-11, 20-dione) is a neuroactive steroid
with anaesthetic properties and a wide margin of safety. The pharmacokinetic
properties of alfaxalone administered intravenously and intraperitoneally in
rats (n = 28) were investigated. Mean t1/2elim for 2 and 5 mg/kg i.v. was 16.2
and 17.6 min, respectively, but could not be estimated for IP dosing, due to sus-
tained plasma levels for up to 60 min after injection. Clp for i.v. injection was
calculated at 57.8  23.6 and 54.3  6.8 mL/min/kg, which were 24.5%
and 23% of cardiac output, respectively. The observed Cmax was 3.0 mg/L for
IP administration, and 2.2  0.9 and 5.2  1.3 mg/L for 2 and 5 mg/kg i.v.
administration, respectively. AUC0–60 was 96.2 minmg/L for IP dosing. The
relative bioavailability for IP dosing was 26% and 28% compared to i.v. dosing.
Differences in t1/2elim and Clp from previous pharmacokinetic studies in rats are
likely due to variations in alfaxalone formulation rather than sex differences.
Alfaxan given IP caused sustained levels of alfaxalone, no apnoea and longer
sleep times than i.v. dosing, although immobilization was not induced in 30%
of rats given Alfaxan IP. A pharmacodynamic study of the effects of combin-
ing IP injection of Alfaxan with other premedication agents is worthwhile, to
determine whether improved anaesthesia induction could ultimately provide
an alternative anaesthetic regimen for rats.
(Paper received 13 January 2013; accepted for publication 26 March 2013)
Mark C. Bellingham, School of Biomedical Sciences, University of Queensland,
Brisbane, Qld 4072, Australia. E-mail: mark.bellingham@uq.edu.au
INTRODUCTION
Alfaxalone (3a-hydroxy-5a-pregnane-11, 20-dione) is a neu-
roactive steroid with anaesthetic properties due to its positive
allosteric modulation of the gamma aminobutyric acid type
A (GABAA) receptor (Visser et al., 2000). Alfaxalone solubi-
lized with the excipient 2-hydroxypropyl-b-cyclodextrin
(HPCD) is available as Alfaxan (Jurox Pty Ltd, Rutherford,
NSW, Australia), which is registered for the induction and
maintenance of anaesthetic in both dogs and cats in multi-
ple countries. Studies have shown that intravenous Alfaxan
provides satisfactory induction of anaesthesia in dogs (Ferre
et al., 2006), cats (Zaki et al., 2009), horses and pigs
(Keates, 2003; Whittem et al., 2008; Goodwin et al., 2011,
2012), with a fivefold margin of safety at supraclinical doses
in dogs (Ferre et al., 2006; Muir et al., 2008) and cats
(Whittem et al., 2008). The pharmacokinetic parameters of
alfaxalone have been defined in cats (single/multiple doses),
dogs (single dose) and horses (single dose) (Ferre et al.,
2006; Whittem et al., 2008; Pasloske et al., 2009; Goodwin
et al., 2011, 2012).
Rodents are commonly anaesthetized for veterinary and bio-
medical research purposes with a single intraperitoneal (IP)
injection. While IP injection is technically simple and requires
minimal animal restraint, a single dose of anaesthetic can
lead to highly variable anaesthetic effects (Flecknell, 1993).
Therefore, it is important for an injectable agent to have a
wide margin of safety to account for variation in anaesthetic
responses between individuals. Alfaxalone has been investi-
gated in rats in varying formulations including acetonitrile
(Visser et al., 2000) and the alfaxalone/alfadolone combina-
tion for humans (Althesin, GlaxoSmithKline, UK) and
animals (Saffan, Pitman-Moore, Terre Haute, IN, USA),
equivalent to 9 mg/mL alfaxalone in the solvent Cremophor
EL (Child et al., 1972). As yet no work has been performed in
rodents with the commercially available formulation Alfa-
xan, which is devoid of alfadolone and Cremophor EL. In
this study, we investigated the single-dose pharmacokinetics of
© 2013 John Wiley & Sons Ltd 1
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alfaxalone, administered intravenously or intraperitoneally as
Alfaxan in rats.
All experiments were performed after approval by the Uni-
versity of Queensland Animal Ethics Committee (Approval
number: 301/10). Adult female Wistar rats (7–10 weeks,
244.2  39.4 g, n = 28) housed in a barrier-maintained ani-
mal facility with a 12/12 h light/dark cycle and fed standard
rat pellets and water ad libitum were used. For IP dosing, a sin-
gle injection (20 mg/kg, n = 18) of Alfaxan (Batch # 60091)
was administered intraperitoneally into the right lower quad-
rant of the ventral abdomen. Serial blood samples collected
from a cut on the tail tip were taken from 10 rats at 4, 6, 10,
15, 20, 30, 45 and 60 min postinjection; samples were not
collected from all 10 rats at all times, due to variability in time
to recovery from immobilization (Table 1) or failure to collect a
sufficient volume of blood at different time points. A single
intracardiac blood sample was collected at one of these times
postinjection in another eight rats following termination. This
sampling collectively gave sample times of 4, 6, 10, 15, 20,
30, 45 and 60 min with varying numbers of animals sampled
per time point for IP injection (see Fig. 1 for number of ani-
mals sampled per time point). For i.v. dosing, an indwelling i.v.
catheter (polyethylene tubing 50 mm length, 0.50 mm OD,
0.20 mm ID) was introduced into the femoral vein, following
anaesthesia with isoflurane gas using a Tec 3 isoflurane
vapourizer attached to a rodent circuit and size 1, 6.0 cm
anaesthetic face mask (all from Vetquip, Castle Hill, NSW, Aus-
tralia). The catheter was fixed to the skin with cyanoacrylate
adhesive. Rats recovered from isoflurane anaesthesia for 30–
60 min postimplantation prior to i.v. dosing. Alfaxan (Batch
# 60091), diluted to 1 mg/mL with sterile water for injection
(Norbrook, Tullamarine, Vic, Australia), was administered by
slow, continuous i.v. infusion over 60 sec (2 mg/kg, n = 5;
5 mg/kg, n = 5). For all animals, the time from injection to
immobilization (failure of the rat to right itself from lateral or
dorsal recumbency) and to recovery (the time at which sternal
recumbency was restored) was recorded as induction and
recovery times, respectively, and the difference between these
times was calculated as sleep time. Tail tip blood samples
(maximum volume 200 lL, maximum total volume 1.6 mL)
Table 1. Various pharmacodynamic parameters for individual adult Wistar rats administered an injection of Alfaxan (Jurox Pty Ltd) at 2 and
5 mg/kg i.v., and 20 mg/kg IP
Rat ID Induction time (sec) Sleep time (min) Apnoea (sec) Twitch on induction (y/n) Twitch on recovery (y/n)
2 mg/kg i.v.
Rat 4.3 20 22 100 n n
Rat 5.3 10 7 170 n n
Rat 6.3 60 8 0 n n
Rat 7.3 40 6 0 n y
Rat 12.3 60 9 0 n y
Mean 38 10.4 54
SD 22.8 6.6 78.0
Range 10–60 6–22 0–170 No twitching 2 of 5 twitched
5 mg/kg i.v.
Rat 8.3 60 9 95 n n
Rat 9.3 27 18 108 n n
Rat 10.3 20 12 100 n n
Rat 11.3 12 12 113 n n
Rat 13.3 60 12 0 n n
Mean 35.8 12.6 83.2
SD 22.7 3.3 47.0
Range 12–60 9–12 0–113 No twitching No twitching
Rat ID Induction time (min) Sleep time (min) Apnoea (sec) Twitch on induction (y/n) Twitch on recovery (y/n)
20 mg/kg IP
Rat 1 5 35 0 y n
Rat 2 2 58 0 y y
Rat 3 3 40 0 y y
Rat 4 4 35 0 n y
Rat 5 3 41 0 y n
Rat 6 4 45 0 y y
Rat 7 Not induced 0 0 y y
Rat 8 Not induced 0 0 n n
Rat 9 6 42 0 y y
Rat 10 Not induced 0 0 y y
Mean 3.9 29.6 0
SD 1.3 21.4 0
Range 3–6 0–58 0 8 of 10 twitched 7 of 10 twitched
© 2013 John Wiley & Sons Ltd
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were collected from each rat at 2, 4, 6, 10, 15, 20, 30, 45
and 60 min and immediately placed onto wet ice and then
centrifuged (4000 g, 10 min) within an hour of collection.
The minimum effective concentration (MEC) for immobilization
was empirically determined by interpolation between plasma
concentration before and after the time of recovery from immobi-
lization. Plasma samples were kept frozen at 80  10 °C
during storage and transport to the Jurox Chemistry Laboratory
until analysis. All plasma samples were analysed individually
(Ferre et al., 2006; Whittem et al., 2008; Pasloske et al., 2009).
ALFAXALONE ANALYSIS
Plasma samples underwent solid phase extraction (25–50 lL
sample volume), followed by liquid chromatography–mass
spectrometry (10 lL sample volume) over a 24-h period in the
same analytical run using previously described methods (Good-
win et al., 2012). A calibration curve was generated using a
standard sample set prepared by spiking known amounts of
11-hydroxyprogesterone as the internal standard and alfax-
alone (two linear standard curves covering 0.02–0.5 and 0.5–
5 mg/L, r2 > 0.99 for both segments) into extracted blank rat
plasma. Sample alfaxalone concentration was determined by
the alfaxalone/11-hydroxyprogesterone peak area ratio. The
assay lower limit of quantification (LLOQ) was 0.02 mg/L in
extracted plasma. The intra-assay coefficient of variation at
LLOQ was <18.5% and <11.0% for other concentration levels.
The limit of detection (LOD) was 0.002 mg/L. Sample extrac-
tion recoveries were >86% for all concentration levels. Both
accuracy and precision were acceptable if residual standard
deviation (RSD) was <20% at LLOQ and <15% for other
concentrations. Due to variations in the number of samples per
sample time collected from rats receiving IP injection, data
analysis was performed on pooled data for each time point fol-
lowing IP injection, while data from rats receiving i.v. injec-
tions were analysed for each animal individually (Ferre et al.,
2006; Whittem et al., 2008; Pasloske et al., 2009). Pharmaco-
kinetic analysis was carried out using noncompartmental
methods in Phoenix WinNonLin v 6.3 (Pharsight Products,
Sunnyvale, CA, USA) as previously described (Goodwin et al.,
2012). The area under the curve (AUC) from time of adminis-
tration to the last blood sample (AUC0–last) was calculated with
the linear trapezoidal rule (Gibaldi & Perrier, 1982). The termi-
nal slope of the curve (kz), estimated by linear regression of
3 data points using the best-fit function, was extrapolated to
calculate the total AUC from administration time to infinity
(AUC0–inf) as AUC0–last + the extrapolated AUC. The% AUC
extrapolated from the last sample time (AUCextrap%) was calcu-
lated as the extrapolated AUC  AUC0–inf 9 100%. The
plasma clearance (Clp), volume of distribution (VD) and elimi-
nation half-life (t1/2elim) were calculated using standard non-
compartmental formulae. For concentration parameters, a
best-fit approach was utilized where repeated nonlinear regres-
sions were used for a series of terminal points. For each regres-
sion, an adjusted R2 was computed with:
AdjustedR2 ¼ 1 ð1 R
2Þ  ðn 1Þ
ðn 2Þ
where n are the number of data points in the regression and R2 is
the square of the correlation coefficient. The relative bioavailability
(F%) for IP dosing compared to i.v. dosing was calculated with:
F% ¼ AUC (IP route)
AUC (i.v. route)
 Dose (i.v.)
Dose (IP)
 100
(Toutain & Bousquet-Melou, 2004a). All data are expressed as
mean  SD.
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Fig. 1. Plasma alfaxalone concentration over time in rats administered Alfaxan at 2 mg/kg i.v., 5 mg/kg i.v. and 20 mg/kg IP doses. Data are
mean  SD. As data for IP injection are derived from different subsets of animals at different sample times (number of animals contributing to each
sample time are indicated in parentheses next to the sample time), the symbols are not connected. The mean minimum effective concentration
(MEC) for each i.v. dose, defined as the mean minimum plasma alfaxalone concentration required to maintain immobilization, was calculated by
extrapolating the plasma concentrations at the time of recovery from immobilization from individual plasma concentrations and is presented as a
mean, indicated by the dashed lines on the graph.
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The level of anaesthesia achieved by alfaxalone was not
tested by evaluating reflex responses or making serial cardiore-
spiratory measurements. However, a brief description of the
immobilization achieved is useful, in particular, to note that
anaesthesia was sufficient to allow repeated blood sampling
from a tail tip cut, which involved manual massage of the tail
to expel blood from the wound. Apnoea, lasting 95–170 sec,
occurred in two of five rats at 2 mg/kg i.v. and four of five rats
at 5 mg/kg i.v. dosing, followed by recovery of spontaneous
breathing. The mean sleep times for rats given 2 and 5 mg/kg
i.v. were 10.4  6.6 and 12.6  3.3 min, respectively, which
were not significantly different (P = 0.52, unpaired two-tailed
t test). In contrast, after IP dosing, immobilization was not
induced in three of 10 rats, but no apnoea was observed
(Table 1). The mean sleep time for all rats given 20 mg/kg IP
was 29.6  21.4 min, which was not significantly longer than
for either i.v. dose (P > 0.05, unpaired two-tailed t test);
excluding rats in which no immobilization was induced, mean
sleep time was 42.3  7.8 min, which was significantly longer
than for either i.v. dose (P < 0.0001, unpaired two-tailed
t test). Animals that did not become immobilized had plasma
concentrations of alfaxalone in the lower end of the range
(0.58–0.78 mg/L) at 4 min after injection; animals that did
show immobilization had similar or higher plasma alfaxalone
levels at 4 min (range 0.47–3.78 mg/L). As all animals given
alfaxalone i.v. showed immobilization, we suggest that variable
absorption from the site of IP injection is the most likely cause
for lack of immobilization. The mean MEC for immobilization
of rats receiving 2 or 5 mg/kg i.v. was 1.5  0.8 and
2.1  0.4 mg/L, respectively, (Fig. 1) and was estimated from
pooled data to be 1.9 mg/L for IP dosing. IP injection caused
muscular twitching in eight rats during induction and seven
rats on recovery, with six rats twitching during both induction
and recovery. Mild facial twitching occurred in two rats with
2 mg/kg i.v. alfaxalone. Mean t1/2elim for 2 and 5 mg/kg i.v.
was similar (16.2  9.2 and 17.6  3.2 min, respectively) as
was the mean Clp (57.8  23.6 and 54.3  6.8 mL/min/kg,
respectively; Table 2). To facilitate comparison of Clp between
species, Clp was calculated at 24.5% and 23% of cardiac out-
put, respectively (Toutain & Bousquet-Melou, 2004b). The
mean Clp in rats following i.v. injection was similar to that
reported for the dog [53 and 59 mL/kg/min for 2 and 10 mg/
kg (Ferre et al., 2006)], but was larger than the mean Clp
reported for cats, horses and foals with 25, 37 and 20 mL/
min/kg, for 5, 1 and 3 mg/kg i.v., respectively, (Whittem et al.,
2008; Goodwin et al., 2011, 2012). In contrast to the high Clp
of alfaxalone following i.v. injection, sampling times of
60 min were not adequate to reliably determine alfaxalone
Clp following IP dosing (Fig. 1). We observed a Cmax of
2.99 mg/L at 10 min after IP administration, a value between
the Cmax of 2.2  0.9 and 5.2  1.3 mg/L for 2 and 5 mg/kg
i.v., respectively; by comparison, the Cmax seen in dogs follow-
ing 2 mg/kg i.v. was similar (Ferre et al., 2006). In contrast,
IP dosing led to sustained alfaxalone plasma levels, with an
AUC0–last of 96.2 min/mg/L, in comparison with AUC0–last of
36.9 and 86.7 for 2 and 5 mg/kg i.v., respectively. Sustained
plasma alfaxalone levels are the most likely cause of longer
sleep times following IP injection (Fink et al., 1982), compared
with i.v. administration. The relative bioavailability for 20 mg/
kg alfaxalone given IP was 26% and 28%, compared to the 2
and 5 mg/kg doses given i.v., respectively. This low bioavail-
ability via the IP route is consistent with high first-pass elimi-
nation of alfaxalone through hepatic metabolism (Child et al.,
1972; Novelli et al., 1975; Sear & McGivan, 1981) after IP
Table 2. Pharmacokinetic parameters for 10 adult Wistar rats after administration of a 60-sec ‘bolus’ injection of Alfaxan (Jurox Pty Ltd) at 2
and 5 mg/kg
Rat ID
t 1/2elim
(min)
Clp
(mL/min/kg)
VZ
(L/kg)
AUC0–last
(min mg/L)
AUC0–inf
(min mg/L)
AUC%
extrap
Cmax observed
(mg/L)
Cmax0 extrap
(mg/L)
2 mg/kg i.v.
Rat 4.3 10.4 68.8 1.0 28.2 29.1 3.0 2.491 3.148
Rat 5.3 11.9 38.9 0.7 50.1 51.4 2.5 2.562 2.676
Rat 6.3 14.6 90.3 1.9 20.2 22.1 8.8 1.402 2.236
Rat 7.3 32.5 59.2 2.8 25.2 33.8 25.3 1.216 1.342
Rat 12.3 11.8 31.7 0.5 60.9 63.1 3.4 3.366 3.679
Mean 16.2 57.8 1.4 36.9 39.9 8.6 2.207 2.616
SD 9.2 23.6 0.9 17.6 16.9 9.7 0.892 0.892
Range 10.4–32.5 31.7–90.3 0.5–2.8 20.2–60.9 22.1–63.1 2.5–25.3 1.2–3.4 1.3–3.7
5 mg/kg i.v.
Rat 8.3 17.8 53.9 1.4 86.3 92.8 7.0 5.578 6.940
Rat 9.3 15.0 48.8 1.1 98.3 102.5 4.2 6.607 7.380
Rat 10.3 15.8 47.2 1.1 100.9 105.9 4.7 6.224 5.730
Rat 11.3 16.7 63.9 1.5 72.9 78.3 6.9 4.207 5.404
Rat 13.3 23.0 57.6 1.9 75.3 86.8 13.2 3.528 3.427
Mean 17.6 54.3 1.4 86.7 93.3 7.2 5.229 5.776
SD 3.2 6.8 0.4 12.8 11.3 3.6 1.318 1.548
Range 15.0–23.0 47.2–63.9 1.1–1.9 72.9–100.9 78.3–105.9 4.2–13.2 3.5–6.6 3.4–7.4
20 mg/kg IP
Pooled NA NA NA 96.195 NA NA 2.99 NA
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injection, which predominantly enters the portal circulation
(Lukas et al., 1971). The t1/2elim of 16–17 min for the i.v. doses
in our study using adult female Wistar rats is longer than for
male Charles River rats (Child et al., 1972) or for male Wistar
rats (Visser et al., 2000) (7 min for 	 9 mg/kg alfaxalone as
Althesin i.v. and 13 min for 5 mg/kg alfaxalone in acetoni-
trile i.v., respectively). The longer t1/2elim observed in our study
is consistent with the lower Clp we observed, in comparison
with a Clp of 71 mL/min/kg (Visser et al., 2000). While sex
could account for differences in t1/2elim and Clp in our and
other pharmacokinetic studies in rat, and female Wistar rats
had a 64% higher Cmax than males after IP administration of
Althesin (Fink et al., 1982), the pharmacokinetics of alfax-
alone given i.v. are reported to be similar in male and female
dogs (Ferre et al., 2006) and cats (Whittem et al., 2008). Meth-
odological differences in analysis of plasma alfaxalone between
older (Child et al., 1972; Fink et al., 1982) and more recent
(Visser et al., 2000) studies could contribute to the differences
between our observations and previous reports; however, both
methodologies produce t1/2elim values lower than our observa-
tions. Variation in alfaxalone formulation is therefore the more
likely cause of differences in the pharmacokinetics of alfaxalone
in rats. Alfaxan given IP produced some attractive anaesthetic
qualities, including sustained plasma levels of alfaxalone,
absence of apnoea and longer sleep times, compared to i.v. dos-
ing. However, immobilization was not induced in 30% of rats
given Alfaxan IP, possibly related to the lower initial plasma
concentrations observed in these animals, and muscle twitch-
ing was frequently observed. A pharmacodynamic study of the
effects of combining IP injection of Alfaxan with other preme-
dication agents would be useful, to determine whether this
would reliably improve anaesthesia induction rates and reduce
muscle twitching, and thus provide an alternative anaesthetic
regimen for rats with a wide margin of safety.
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